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Abstract
Mycobacterium tuberculosis, the slow-growing bacteria responsible for 
the disease tuberculosis (TB) was thought to be effectively controlled in 
the developed world by antibiotics, discovered by the middle of the 
twentieth century and integrating a revolutionary treatment called DOTS 
where patients are closely monitored by health professionals that assure 
the completion of the long and demanding treatment.
Unfortunately, in poverty-stricken countries the disease never stopped 
being a plague and jointly with AIDS, decimated populations. The 
emergence of drug resistance draws even more attention to this disease 
which is considered a global epidemic and is responsible for one third of 
the World’s population being latently infected.
The need for new drugs able to shorten the length of the treatment, 
compatible with antiviral medication, effective against resistant Mtb 
strains and able to kill the latent form of the organism is now well 
recognised.
The electron transport chain (ETC) of M tuberculosis is a validated 
target for drug research due to its essentiality in the respiratory process. 
In mycobacterial membranes, type II NADH: menaquinone 
oxidoreductase (Ndh-2) is predicted to be an essential enzyme that 
catalyses the initial step in the respiratory chain. Phenothiazines target 
this type II NADH: menaquinone oxidoreductase and are already 
recognised as a new class of anti-tubercular compounds with potential 
inhibitory effects against latent mycobacteria, specifically inhibiting ndh 
activity.
In this thesis the hypoxic Wayne model and a simple colorimetric 
experiment, the microplate alamarBlue® assay (MABA) were used to test
iv
known electron transport chain inhibitors and phenothiazines, for their 
antitubercular activities. Throughout this thesis, different Mtb culture 
models were tried and optimised and finding the ideal conditions that 
could mimic the scenario of mycobacterial infection is one of the major 
challenges when working with this highly pathogenic organism. M. 
smegmatis was initially tested as an alternative, non-pathogenic model in 
humans for Mtb, but despite being useful for biochemical studies, results 
need to be treated cautiously due to significant differences between the 
electron transport chains of M. smegmatis and Mtb. For this reason, the 
model proved to be poor and drug susceptibility tests were performed 
only in Mtb. Phenothiazines were confirmed as effective against Mtb 
using different models, the results obtained being particularly interesting 
in anaerobic conditions. However, it is possible that not all 
phenothiazines have the same mode of action.
Additionally, an attempt was made to study in detail the protein encoded 
by the ndhA gene, a homologue of the ndh gene. This gene was cloned 
and transformed, however expression of ndhA proved challenging. A 
phylogenetic analysis of all hypothetical ndh homologues in 
Actinomycetales (the group that includes mycobacteria) was conducted. 
The analyses suggest that ndh and ndhA share a recent common ancestor. 
The ndh and ndhA genes, as well as the two hypothetical homologues 
display similar rates of non-synonymous to synonymous mutations. 
Suggesting they have been under strict purifying selection pressure which 
can be interpreted as meaning that they have been functional and 
important genes during the evolution of this organism.
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Chapter 1. General introduction
Tuberculosis (TB) is caused by the slow growing organism 
Mycobacterium tuberculosis (Mtb). Despite numerous efforts to control 
this human pathogen, TB remains the deadliest bacterial disease 
worldwide and it is recognised as one of the three greatest maladies of the 
developing countries, alongside malaria and the acquired immune 
deficiency syndrome (AIDS) (WHO 2009).
Anti-TB treatment is prolonged and demanding and it is not always 
strictly followed by the patient which leads to the emergence of drug 
resistant strains (Johnson et al. 2006). Multiple-drug resistant TB (MDR- 
TB) occurs when there is resistance to the two most effective first line TB 
drugs: rifampicin and isoniazid, while extensively drug resistant TB 
(XDR-TB) occurs when the bacteria are also resistant to one of the three 
classes of second-line drugs. Currently, there is no effective treatment 
against XDR-TB so it remains virtually without a cure (Gillespie 2002).
In the last few decades mainly due to co-infection with Human 
Immunodeficiency Virus (HIV) and the worrying appearance of resistant 
strains, it became obvious the need for the development of new 
treatments against TB. These new therapies should be able to target not 
only the growing bacteria responsible for the active disease, but also the 
sub-populations of resistant, slow-growing and persistent organisms that 
are responsible for the recalcitrance of the disease .
However, the organisms to kill are bacteria. Bacteria have great plasticity 
of behaviour, and this is one of the reasons why numerous compounds 
that were successfully tested in vitro failed to present positive results in 
vivo. Mycobacteria have various strategies to overcome adverse 
conditions, and this allows them to adapt and survive inside a hostile
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host. Also worth pointing out is the inefficacy of the current models used 
to mimic the complexity of the host environment during infection.
Despite all the interest in mycobacteria, these organisms and some of 
their basic behaviour and processes, remain unknown. A good 
understanding of the biology of mycobacteria is the first milestone in the 
journey towards an effective cure.
1.1. TB throughout history
Tuberculosis was a well-known disease in the nineteenth century and it 
was often associated with a romantic notion since many young artists 
died from it, like the English poet John Keats or the Scottish novelist 
Robert Louis Stevenson. TB affected everyone, from every social class, 
regardless of age or gender. People affected with TB, often called 
consumption, would become pale, lethargic, with a persistent cough, 
associated with blood in the later stages of the disease. The principle 
measure to fight TB was to isolate people in sanatoriums, preferably in 
cold areas and avoid contact with them, since it was known very early on 
that the disease affected the lungs and was highly contagious.
In 1882, Robert Koch discovered a staining technique capable of seeing 
Mtb but it was only 62 years later that the first active drug against TB 
appeared and revolutionized the treatments against the disease. 
Streptomycin was the first chemotherapeutic agent used against TB and it 
rendered the surgical procedures used at the time, obsolete and 
unnecessary. In the second half of the twentieth century, other drugs were 
discovered (e.g.: isoniazid, rifampicin, ethambutol and pyrazinamide) and 
the complete elimination of the disease was thought to be an achievable 
goal. Unfortunately, there were areas where TB cure was never on the 
horizon, namely the poor populations of Africa, where TB remained the
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number one cause of death among infectious diseases especially among 
HIV carriers (Granich et al. 2010).
In developed countries, TB cases decreased exponentially after the 
appearance of the new and effective antibiotics mentioned above (Zhang 
2005). In the 1980s the disease was pretty much limited to communities 
of immigrants, drug users and the homeless, however TB was still a 
major cause of death in third world countries, associated with famine and 
poor health and unhygienic conditions (WHO 2009). The scientific 
incentives for the study of Mtb were recognised but the wakeup call 
happened towards the end of the twentieth century when multidrug- 
resistant TB emerged (Gillespie 2002).
With the appearance of new multi-drug resistant phenotypes of the 
bacteria that cannot be cured with current first line chemotherapies, new 
strategies were adopted, namely the use of second line drugs, but in 
extreme cases, the patient benefits from the surgical removal of parts of 
the affected lungs (Takeda et al. 2005). This physically removes 
agglomerates of bacteria and increases the exposure of the remaining 
bacteria to drugs and to the host immune response.
In 1993, WHO (World Health Organisation) finally recognized TB as a 
global health emergency.
1.2. Impact of TB globally: facts and numbers
WHO declared TB as an epidemic in 1997. According to their last 
estimates, over 9 million people worldwide fall ill with TB every year 
(WHO 2009). Its effects are particularly devastating in developing 
countries, where poor health conditions and difficulties with access to 
basic medical care and medicines are major problems for the populations. 
It is estimated that 86% of TB cases are located in Africa and South-East
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Asia (WHO 2009), with South America and Northern Asia as additional 
areas of high prevalence of TB. A map showing the worldwide 
distribution of new TB cases per 100,000 individuals is displayed in Fig. 
1.1.
An estimated 15% of the population infected with TB (1.4 million 
people) are co-infected with HIV and each year the mortality rate ascends 
to more than 1.3 million deaths (WHO 2011).
To add to these scary figures, there were an estimated 0.5 million cases of 
multi-drug resistant TB (MDR-TB) in 2007 (WHO 2009). In MDR-TB 
the patient shows resistance to the two most effective first line drugs 
against TB: rifampicin and isoniazid, rendering the currently used 
treatment ineffective (Sharma and Mohan 2006).
Fig. 1.1.: Worldwide distribution of new TB cases per 100,000 people in 2010, 
according to WHO report, 2011 (WHO 2011).
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1.3. Mycobacterium tuberculosis: biology of infection 
Mtb usually enters the body through an aerosol route, when an actively 
infected individual coughs or sneezes, spreading small droplets that reach 
the new host’s respiratory routes. A scheme of the Mtb cycle is shown in 
Fig. 1.2.
In the normal phagocytic process bacteria that enter the host are 
internalised inside macrophages in a membrane-bound organelle called 
the phagosome. The phagosome will undergo a maturation process along 
the endocytic pathway leading to fusion with late endosomes and finally 
lysosomes, forming the phagolysosome where the ingested bacilli are 
degraded. Pathogenic mycobacteria survive inside the host macrophage 
by blocking the normal maturation of the phagosome (Vergne et al. 
2004). At this point, either they establish an episode of active disease, or 
the host immune system is able to induce a localized immune response, 
with recruitment of specific effector cells that results in the containment 
of the pathogen in granulomas. At this point, the latent-TB carrier is not 
contagious. Despite the fact that the Mtb bacilli are obligate aerobes, they 
are capable of surviving for long periods of time, even decades in 
microaerophilic or even anaerobic environments as long as they have 
time to adapt to these extreme conditions, entering a non-replicating state 
or latent form of the disease (Glickman and Jacobs Jr. 2001; Russell 
2001).
The risk of reactivation of the infection remains since the Mtb are not 
dead but only lying dormant, consequently a change in the immune 
system conditions of the host (e.g. as a result of HIV infection) may 
result in disease reactivation. When left untreated, due to bacteria 
multiplication, the lung tissue is destroyed and severe cough with bloody 
sputum and chest pain appear. At this point the TB carrier is highly 
contagious, allowing the cycle to re-start.
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Fig. 1.2.: Life cycle of Mycobacterium tuberculosis inside the human host: (A) The 
bacilli enter the human body through a respiratory route, through a cough or 
sneeze from an actively infected individual; (B) in the lung the bacteria are 
phagocysed by macrophages and (C) eventually contained inside granulomas; (D) 
at this point the host is considered to have latent TB; (E) however the bacteria are 
not dead and they remain capable of reactivating the infection if at some point 
there is a breach in the immune system of the individual; (F) re-initiating the cycle 
as active bacilli.
1.4. The granuloma
The characteristics of granuloma formation are still largely unknown, 
despite efforts to recreate models of in vitro granulomas and in vivo 
dissections. The use of animal models is often questioned due to the fact 
that they are not truly representative of the human scenario. It is known 
that granuloma formation occurs in the early stages of an infection 
episode, trying to ensure pathogen containment (Ulrichs and Kaufmann 
2006). The granuloma is described as having a central core of necrotic 
tissue that will be the source of nutrients to the contained mycobacteria 
and that augments along time, surrounded by dense layers of immune 
system cells, like macrophages and specialised leukocytes, epithelioid
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cells, dendritic cells, large multinucleated cells (Langhans giant cells) and 
lymphocytes. The development of the granulomas and recruitment of 
cells to control the invader organisms is due to the presence of cytokines 
and chemokines produced by local tissue cells and leucocytes (Ulrichs 
and Kaufmann 2006; Gupta et al. 2012). During latency, the 
granulomatous tissue will become fibrotic and will calcify, creating 
nodular lesions visible under X-ray, providing evidence of latent TB 
(Ehlers 2009).
According to Peyron and collaborators, the highly pathogenic 
mycobacteria stimulate the formation of foamy macrophages. These cells 
are granuloma-specific and have a high lipid content, that may be used as 
a nutritive reservoir for long-term persistence (Peyron et al. 2008).
Via and colleagues studied granulomas in various animal models, using 
pimonidazole (a hypoxyprobe which is an imaging agent indicative of 
hypoxic conditions) as well as metronidazole (a drug only effective 
against anaerobes) in order to better understand the nature of granulomas 
in these animals. In guinea pigs, rabbits and nonhuman primates caseous 
(necrotic) lesions are hypoxic, while solid cellular lesions have a reduced 
oxygen tension. In mice, despite being less oxygenated, TB lesions are 
not hypoxic. Metronidazole showed a profound effect on rabbits but 
proved ineffective when used in mice (Via et al. 2008), suggesting that 
mice are not a good model for the study of granulomas.
However, some research groups propose that the Mtb bacilli containment 
in granulomas can be replicated in vitro. Puissegur and colleagues 
developed a model to obtain mycobacteria-induced or mycobacterial 
antigen-induced granulomas. When peripheral blood mononuclear cells 
were isolated from a human blood sample from a Bacillus Calmette- 
Guerin (BCG)-vaccinated non-infected individual and then exposed to 
mycobacterial antigen-coated beads, or live-mycobacteria, they produced
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a cellular aggregation response, similar to the granuloma, with 
progressive recruitment and differentiation of cells (Puissegur et al. 
2004).
1.5. Pathogenic mycobacteria: reasons for success
There are a number of reasons why Mtb bacteria are as successful 
pathogens as they are. Some of the more obvious are the unique 
composition of its cell wall, its modular electron transport chain (ETC), 
and its capacity to persist through decades, remaining viable and able to 
resume growth as soon as a breach in the immune system of the host 
occurs (Bentrup and Russell 2001; Dick 2001; Wayne and . 2001).
1.5.1. The unique cell wall of Mtb
The mycobacterial cell wall is tripartite unlike other eubacteria and it 
consists of a membrane of trehalose dimycolates and glycopeptidolipids, 
also called mobile layer and then by three other covalently attached 
layers: a peptidoglycan layer, a layer of hydrophilic arabinogalactan and 
then a unique hydrophobic layer of mycolic acids. Mycolic acids are long 
chain branched |3 hydroxyl fatty acids (Fig. 1.3.). These layers constitute 
a barrier for both hydrophobic and hydrophilic compounds and as a 
consequence of this lipid- and glucolipid-rich membrane, the outer 
surface of the organism is extremely hydrophobic (Glickman and Jacobs 
Jr. 2001; Nguyen and Pieters 2009; Niederweis et al. 2010).
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Fig. 1.3.: Schematic representation of the cell wall of Mycobacterium tuberculosis.
1.6. Latency of Mtb
Mtb has the capacity to remain alive in the human host, without 
displaying symptoms of a primary active infection and with virulence 
mechanisms intact, enabling the organism, at some point during the host 
lifetime to reactivate and cause active disease in the host.
This phenomenon, where Mtb remain in a dormant state, is called 
latency. During this period, despite not showing clinical signs of 
infection, the individual infected will have strong immune response 
against Mtb antigens, detected through tuberculin skin testing (TST) 
(Ehlers 2009). Unfortunately this test is far from adequate due to the fact 
that it gives a high rate of false positives. The premise is that a person 
that was previously exposed to Mtb will have a strong reaction against
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Mtb proteins of tuberculin. But often the immune response is the result of 
a contact with Mtb proteins through vaccination or non-pathogenic 
mycobacteria, and are not indicative of the person being latently infected 
(Glickman and Jacobs Jr. 2001; Zumla et al. 2011) .
The reactivation of these dormant bacilli can occur at any time, even 
decades after the primary infection took place. Usually it occurs due to 
impairment of the immune system either caused by age, chronic illness or 
acquired immunodeficiency (Leung 1999). It is also not always easy to 
distinguish if an active TB infection in later life is due to reactivation or 
to a new episode of infection (Zumla et al. 2011). Verver and 
collaborators use bacterial DNA fingerprinting in order to identify if a 
subsequent infection was a reinfection or a new episode of TB infection 
(Verver et al. 2005). This characterisation is only possible if a study was 
performed during the first episode of infection, which is unlikely in a 
normal clinical scenario.
1.6.1. Non-, slow- or continuous- replication of Mtb during its latent 
state
Despite various in vivo and in vitro attempts to fully characterise the state 
of Mtb during latency, this issue is still controversial. There are two 
current hypotheses. The first hypothesis proposes that Mtb carry on living 
through decades, in a near-static state of non-replication or very slow 
replication that allows them to evade the host immune system and 
become insensitive to antibiotics (Ehlers 2009). The other hypothesis 
defends a dynamic state of continuous replication of the latent organisms 
being contained by the immune system. In both states the host and the 
bacteria live for decades in a precarious equilibrium which if disturbed,
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leads to reactivation of infection and active disease (Ehlers 2009)(Gomez 
and McKinney 2004).
Yang and colleagues, in an attempt to further classify the existence or not 
of replication during latency, used genomics and molecular epidemiology 
data, to study patients that after more than three decades of an initial 
episode of TB, showed signs of disease reactivation (Yang et al. 2011). 
They ruled out the possibility of individuals being infected by new strains 
of Mtb. Their research supports a scenario where Mtb does not replicate 
during latency. These inferences were obtained by comparing the 
frequency of insertion and deletions in 14 selected sets of 
mononucleotide simple sequence repeats (SSRs or microsatellites) in 
samples of Mtb from the initial infection with samples 30 years older, 
and finding no significant differences in their genomic profiles. However, 
the study has some limitations, namely the small number of cases studied, 
the very limited portion of the genome analysed and the fact that 
mutation rates of the SSRs in Mtb are unknown. In order to accept or 
refute their conclusion one would need to properly assess the mutation 
rate of the SSRs during normal replication by continuous culturing of the 
bacteria (Yang et al. 2011).
Gill and colleagues favour the second hypothesis, where Mtb bacilli are 
constantly replicating in the human host. In order to monitor Mtb 
replication, they used Mtb transformed with the plasmid pBPIO during 
mice infection. This plasmid is unstable and it is known that not all cells 
after replication will carry this plasmid. They used a mathematical model 
to assess bacterial growth, assuming a constant decay along time of the 
presence of the plasmid in each generation, independent of the replication 
rate of the cells. The loss of plasmid during chronic infection pointed to 
bacterial replication during this period, in contrast to what is commonly 
assumed in latency (Gill et al. 2009). Another argument in the defence of 
this continuous replication during latency is the fact that isoniazid, if
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given as a 9-month course of therapy is able to achieve complete 
sterilisation, avoiding TB reactivation. As this drug targets mycolic acid 
biosynthesis, to have an effect, it requires active replication. Hence if 
isoniazid is able to completely sterilize the host from bacteria, that 
suggests that at least part of the Mtb latent population is replicating 
(Ehlers 2009). The most recent research seems to support this idea 
(Zumla etal. 2011).
1.6.2. Models used in the study of Mtb latency
In order to study latency and the adaptive processes of Mtb that allow it 
to become latent and in a state of almost non-proliferation, two of the 
most utilised models are the Cornell mouse model, a drug induced model, 
and the Wayne hypoxia model. They are just two examples of how in the 
laboratory, it is possible to grow dormant Mtb populations, modulating 
some conditions that are known to reduce Mtb metabolism and induce the 
latent state. Considering that the focus of this thesis is in the ETC and 
metabolism, only a description of the main patterns of expression of 
genes involved in ETC and metabolism will be presented.
1.6.2.1. The Cornell model
The Cornell mouse model is an alternative dormancy model, first 
described in the 1950s by McCune, McDermott and colleagues at the 
Cornell University. According to this model, Mtb infected mice are 
treated with isoniazid and pyrazinamide for 12 weeks, before treatment is 
stopped. The mice do not present any evidence of active TB disease and 
no Mtb bacilli can be cultured from mouse spleens (McCune et al, 1956). 
After 12 weeks of not being treated with any antibiotic, one third of the 
mice have active and drug-sensitive Mtb. Therefore, these 12 weeks
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between disappearance and then reappearance of the infection are 
considered the latent period of the disease (Fig. 1.4.) (McCune and 
Tompsett 1956; Parrish et al. 1998). For this evidence of a period of Mtb 
"disappearance” with a “resuscitation” afterwards, the Cornell model is 
sometimes pointed out as the most convincing evidence of Mtb dormancy 
(Zhang 2004). Scanga and collaborators suggested some pertinent 
variations in the original Cornell mouse model, namely they suggested 
the antibiotic regimen should start 4 weeks after the initial infection and 
not immediately after Mtb incubation (Scanga et al. 1999). This is due to 
the fact that the original Cornell model did not take into account the role 
of the immune system in the establishment of the latent infection and 
Scanga and colleagues tried to address this in their study.
Latent disease
22^ 12 weeks 
INH ♦ PZA
B c 1
No disuse NO treatment Apparent ------- LP
sterile state -35% active TB
Fig. 1.4.: Schematic representation of the Cornell mouse model of dormancy. (A) A 
population of mice was infected with Mtb; (B) after a 12 weeks treatment with 
isoniazid (INH) and pyrazinamide (PZA), mice did not present any evidence of TB; 
(C) after no treatment for 4 weeks, mice remained healthy; (D) after 8 more weeks 
without treatment, 35% of the mice population was infected with active TB, i.e. by 
the end of 12 weeks of latent disease, reactivation occurred and the mice showed 
signs of active disease. Adapted from Parrish et al. 1998.
I.6.2.2. The Wayne model
In order to induce dormancy using this model, bacteria are submitted to a 
slow shift from aerobic to anaerobic conditions. The Mtb bacilli are 
grown in liquid media being constantly stirred in sealed tubes, with a 
precise proportion between air and liquid, with no disturbance on the 
surface of the liquid, leading to a gradual depletion of oxygen, occurring 
from the bottom of the vial to the top in a very progressive and controlled
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manner. Instead of dying, similar to what happens when there is an abrupt 
change of aeration in a culture, the bacilli are able to adapt successfully, 
entering a 2-phase state called non-replicating persistence (NRP) (Wayne 
1994; Wayne and Hayes 1996; Boshoff and Barry III 2005).
During the non-replicating phases of NRP-1 and NRP-2, there is no 
increase in the number of viable mycobacteria. During NRP-1, when 
oxygen saturation is approximately 1%, there is still a small increase in 
the turbidity of the culture, due to cell enlargement, however the number 
of viable bacteria and DNA synthesis are stationary (Wayne and 
Sohaskey 2001). Finally during NRP-2, when the oxygen saturation 
reaches 0.06%, the culture shifts to complete anaerobic conditions, a 
complete shutdown, or at least a significant reduction of metabolism 
occurs and morphological changes of bacteria also cease (Wayne and 
Hayes 1996; Wayne and Sohaskey 2001).
It is known that Mtb have their growth arrested at the same stage 
(phenomenon called synchronisation) (Wayne 1994). The shift from 
being active to the latent state of Mtb in terms of genetic expression 
profiles indicates the up-regulation of nitrate reductase and glycine 
dehydrogenase (Muttucumaru et al. 2004). Nitrate reductase is linked to 
nitrate reduction ensuring that the intake of energy during NRP and 
glycine dehydrogenase is linked to reductive amination of glyoxylate to 
glycine that leads to the oxidation of NADH, meaning a regeneration of 
NAD+ under hypoxia (Wayne and Sohaskey 2001).
The bacilli remain able to resume growth (Wayne 1994). In terms of drug 
susceptibility, dormant bacilli exhibit increased tolerance, but are 
nevertheless still susceptible to rifampicin and isoniazid and they become 
susceptible to metronidazole. This fact serves as evidence for the 
relevance of hypoxia in the phenomenon of latency, since metronidazole 
is only active against anaerobic or microaerophihc bacteria (Wayne and
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Hayes 1996).
In terms of patterns of gene expression, NRP stage 1 and NRP stage 2 
present different gene expression profiles (reviewed in detail by 
Muttucumaru et al. 2004). Many important regulatory genes are induced 
in both stages, namely acr, a gene encoding a heat-shock protein (a- 
crystallin) and the DosR regulon (see Section 1.16,). The activity of the 
enzymes isocitrate lyase, glycine dehydrogenase and nitrate reductase 
(encoded by narX and the narGHJI regulon) increase during the NRP-2 
stage of hypoxia (Sherman et al. 2001; Muttucumaru et al. 2004).
1.6.2.3. Other models used to recreate the dormancy phenomenon
Due to the recognition of the importance of the dormancy phenomenon in 
the pathology of TB disease, efforts were made in order to replicate this 
state in vitro. Besides the Wayne model of hypoxia, which is one of the 
best characterized models, and the Cornell mouse model, other attempts 
were made in order to induce the latent state of Mtb. Mtb bacilli were 
submitted to conditions that appear to be present in the macrophage, 
phagosome or granuloma environment or tuberculous lesions (Wayne 
and Sohaskey 2001), and some of those models are described in the 
sections below.
I.6.2.3.I. The nutrition starvation model
This model is based on evidence that points to the existence of severe 
limitations in terms of nutrients in TB lesions. Loebel and collaborators 
created this model in the 1930s (Loebel et al. 1933) which consists of the 
transfer of Mtb bacteria, after being grown in a typical nutrient rich 
media, to a phosphate buffered saline (PBS) solution, where the bacteria 
are forced to starve, but with no limitations on the degree of aeration. It
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was observed that bacilli remain viable but with impaired growth and a 
diminished respiratory rate. The bacteria also display tolerance to 
isoniazid, rifampicin and metronidazole (Betts et al. 2002; Gengenbacher 
et al. 2010).
In terms of patterns of gene expression, there is a general down- 
regulation of metabolic genes, apart from the enzyme isocitrate lyase 
(encoded by ict) (Betts et al. 2002). Regarding genes involved in the 
respiratory process, microarray analyses show a down-regulation of the 
genes involved in aerobic respiration (Teh et al. 2007). Type I NADH 
dehydrogenase (encoded by the genes nuoA-M) is the primary electron 
donor to the aerobic ETC, which catalyses the oxidation of NADH to 
NAD and leads to production of ATP, is down-regulated. However, 
alanine dehydrogenase (gene aid) is up-regulated suggesting a role for 
this enzyme in replenishing the NAD+ pool converting pyruvate to 
alanine (Betts et al. 2002; The et al. 2007). Also of note is the down- 
regulation of genes aipA-H that encode the ATP synthase complex and 
the significant up-regulation of pdhABC genes that encode the pyruvate 
dehydrogenase enzyme complex that converts pyruvate to acetyl 
coenzyme A (CoA) and CO2 and the up-regulation of JrdA that encodes 
fumarate reductase which is important in anaerobic respiration (Betts et 
al. 2002).
Gengenbacher and colleagues, comparing the oxygen deprived bacilli 
from the Wayne model, and the starved ones from Loebel, concluded that 
in terms of intracellular levels of ATP, the Loebel bacilli are less 
sensitive to ATP depletion, meaning that their metabolism is even more 
reduced than the dormant Wayne model bacilli, but both need F0Fi ATP 
synthase to maintain viability (Gengenbacher et al. 2010).
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1.6.2.3.2. Phosphate depletion
Rifat and colleagues mimicked the macrophage restrictive environment, 
limiting the phosphate in an Mtb culture. As a consequence, the bacilli 
presented restricted growth, morphological alterations such as bacterial 
elongation and altered acid fast characteristics, and exhibited phenotypic 
tolerance to isoniazid. Suggesting that phosphate starvation leads to a 
stress response similar to the one that occurs in dormancy (Rifat et al. 
2009).
I.6.2.3.3. The prolonged stationary-phase model
A number of groups have highlighted the similarities between persistence 
and bacteria continuously maintained in stationary phase (Hampshire et 
al. 2004; Voskuil et al. 2004). According to this model, after the 
exponential phase where the medium is depleted of nutrients and 
saturated with waste products and cell debris that result from cell 
metabolism and death, a percentage of bacteria survive by entering a non­
replicating state. In this model the bacteria are maintained in a 
continuously monitored chemostat (Hampshire et al. 2004)
In terms of expression of genes involved in metabolism in this aerobic 
nutrient-depletion adaptation model, the more significantly up-regulated 
genes are the ones involved in fatty acid degradation and in the 
glyoxylate shunt (this is indicative of the shift between carbohydrate 
sources of energy to fatty acids) and anaerobic respiration. There are 
similarities between this model and the nutrition starvation model. In 
terms of metabolism, the pattern of gene expression is similar, apart from 
isocitrate lyase which is up-regulated in this model contrary to what 
occurs in the nutrition starvation model (Betts et al. 2002). Perhaps the 
cause is that in the nutrition starvation model, the bacteria are
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immediately starved, not allowing for the gradual adaptation to starvation 
that occurs in this model (Hampshire et al. 2004).
I.6.2.3.4. The multiple-stress model
Recently, Deb and colleagues suggested a multiple-stress model for 
inducing dormancy in Mtb. According to this model, the bacteria are 
submitted to a combination of stresses (namely, low oxygen, high C02, 
low nutrient and acidic pH) as an alternative to the previous models 
where only a single factor of stress was induced. The reasoning for this 
model proposal is that in the human host, the bacteria are likely to be 
submitted to various stresses that limit their growth, so it is more realistic 
to induce dormancy by submitting the bacteria to more than one single 
stress factor. Applying this combination of stresses, a representative 
dormant state may be induced, where the bacteria stop replicating and 
acquire phenotypic antibiotic tolerance (Deb et al. 2009).
The advantage of these models is that since they generate bacilli that 
meet all the criteria of dormancy, they can be used in high-throughput 
screening for drugs targeting the persistent organisms.
1.6.3. Other mycobacteria and the dormancy phenomenon
There are a number of studies proving that M bovis BCG (an attenuated 
strain of M. bovis used as a live vaccine) is capable of a similar dormancy 
response when induced by oxygen deprivation to the one manifested by 
Mtb (Lim et al. 1999; Boon et al. 2001; Boon and Dick 2002).
M. bovis bacilli, submitted to the gradual depletion of oxygen enter the 
states of non-replicating persistence, with consequential induction of 
glycine dehydrogenase and induction of an a-crystallin-like small heat
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shock protein (whose up-regulation correlates with cell wall thickening of 
the bacilli). Apart from these two molecular markers, the bacilli acquired 
sensitivity to metronidazole (Lim et al. 1999).
Despite some studies defending the use of fast-growing, non-pathogenic 
strains, namely M. smegmatis to successfully recreate the phenomenon of 
persistence, the use of these models remain questionable since the results 
obtained with these models can differ from the ones obtained using slow 
growing pathogenic mycobacterial strains (Hutter and Dick 1998).
1.7. The difficulties of studying M tuberculosis
There are a number of reasons why Mtb research for new effective 
treatment against TB is complex.
The use of appropriate models remains controversial. The animal models 
are not representative. The pathology of the human disease is not similar 
to the one presented in animals, such as rodents, mainly due to the fact 
that TB does not occur naturally in them. The disease exception is the use 
of nonhuman primates, such as Macaca fctscicularis, commonly called 
cynomolgus macaques, that when infected with Mtb develop signs of TB 
disease, similar to the human species, namely presenting signs of 
granulomatous pathology (Lin et al. 2009).
In an attempt to study some of the most used animal models, namely 
mouse, guinea pig, rabbit and nonhuman primate and the conditions 
inside their granulomas, Via and colleagues used three major strategies in 
order to verify the existence of complete hypoxia inside these structures. 
They used a hypoxia marker called pimonidazole hydrochloride 
(hypoxyprobe), that forms adducts in hypoxic areas, that can be detected 
by immuno-histochemical staining. They measured the oxygen tension of 
the rabbit granulomas directly, using a surgical method and they also
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tested the drug metronidazole, in both rabbit and mice. This drug is 
known to be active only against bacteria kept in anaerobiosis. The 
conclusions pointed to the existence of truly hypoxic granulomas in 
guinea pigs, rabbits, and nonhuman primates. In the case of mice, their 
granulomas are not hypoxic (Via et al. 2008) and they do not become 
necrotic or calcified (Cosma et al. 2003). This conclusion was 
corroborated by further studies (Klinkenberg et al. 2008). Also, the 
disease does not evolve as per the human form; the bacterial burden can 
become extremely high and without being cleared at all (Cosma et al. 
2003) with the bacilli found mainly intracellularly (Hoff et al. 2011). A 
summary table of Mtb infection outcome characteristics in four different 
animal models is displayed in Table 1.1.
Table U.: Comparison of different animal models used to study Mtb and their 
limitations. Adapted from Rustad et al. 2009; Chao and Rubin 2010.
Model Primary
infection
Caseating and 
hypoxic 
granulomas
Latent
infection
Reactivation
Mouse Yes No No true latent 
state
No
Guinea Pig Yes Yes No true latent 
stage
No
Rabbit No Yes Not
demonstrated
Requires immune 
system repression
Monkey Yes Yes Yes Yes
The use of laboratory adapted strains of Mtb is also controversial due to 
the fact that the nutritive media used for the growth of the strains does not 
represent the human host environment. Clinical Mtb strains are 
heterogeneous and present differences in immunogenicity and 
pathogenicity (Dormans et al. 2004). There are also important differences 
at the level of whole genomes between clinical strains and laboratory
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adapted Mtb strains (Fleischmann et al. 2002). Another difficulty in 
studying Mtb in the lab environment is that in order to mimic the 
persistent phenotype, Mtb cells would be submitted to severe levels of 
stress and competition, where the bacilli will replicate and accumulate 
mutations at a much higher rate than in a normal infection episode 
(Gomez and McKinney 2004). Efforts are also aimed at the development 
of a new anti-TB vaccine. BCG, the current anti-TB vaccine, 
administered in children has variable efficacy, with reported success rates 
between 0 and 80% (Brandt et al. 2002). These different responses are 
attributed to different host susceptibilities and exposure to environmental 
mycobacteria, as well as loss in efficacy of BCG along the years (Brewer 
2000; Brandt et al. 2002). The development of a new vaccine, able to 
induce immunity in infants but also that could be administered at any 
time of life, inducing a total control and clearance of the infection, with 
an effect against latent forms of the disease (Castanon-Arreola and 
Lopez-Vidal 2004) is currently underway, but there are paradoxical ideas 
supporting vaccination (Parida and Kaufmann 2010).
There are strong beliefs that since the human body does not present a 
natural immunity when re-infected with mycobacteria, it may not be 
capable of establishing an effective immune response even when 
previously stimulated by vaccination (Barry 2001). One of the most 
difficult challenges in overcoming TB is the unpredictability, complexity 
and limited knowledge of the disease. TB is not easily categorised since it 
presents a whole spectrum of disease states, from complete sterilised 
scars, permanent disease, re-infections that occur decades after the first 
contact with the pathogen, immediate hyper-sensitivity to the bacilli, 
slowly developing disease or complete asymptomatic responses (Dheda 
et al. 2010; Achkar and Jenny-Avital 2011).
In the search for new anti-TB drugs, efforts are often concentrated on the 
identification of Mtb essential genes or Mtb virulence genes. The
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reduced genome of Mycobacterium leprae, exclusively adapted to grow 
on a human host, contrasting with the biggest genome of environmental 
non-pathogenic species as M. smegmatis suggests that many genes are 
possibly redundant and all those retained in Mycobacterium leprae are 
essential (Gomez-Valero et al. 2007). Another way of identifying 
essential genes is by causing random mutations in the mycobacterial 
genome and to observe how these mutations impair Mtb survival in 
different environmental settings (Sassetti et al. 2003; Sassetti and Rubin 
2003).
1.8. The current therapy: limitations
The first-line drug regimen currently in place is called DOTS (directly 
observed treatment, short-course) and it involves the direct monitoring of 
the patient by trained health-care professionals, to ensure that the regimen 
is strictly followed, in order to avoid the emergence of resistance and to 
assure complete sterilisation, it involves an initial phase of two months 
with a combination of the four first line drugs (isoniazid, rifampicin, 
ethambutol and pyrazinamide), followed by a second phase with four 
months duration of therapy with isoniazid and rifampicin alone (Bayer 
and Wilkinson 1995; Zhang 2005). The need for combinations of drugs is 
due, not only to the synergistic reaction of these drugs but also in an 
attempt to minimise the occurrence of resistance (Michel et al. 2008).
DOTS is an extremely demanding therapeutic option and can result in 
patient non-compliance. As soon as they start feeling better, they may 
abandon the treatment. Not only patient non-compliance but also wrong 
dosage and prescription of DOTS, as well as individual characteristics 
can lead to treatment failure (Gillespie 2002; Johnson et al. 2006).
The reason why DOTS duration cannot be shortened is often attributed to 
persistent organisms that exhibit phenotypic tolerance and evade the
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effect of antibiotics, due to their inactivity, since antibiotics usually target 
actively growing bacteria. These phenotypically tolerant organisms are in 
the stationary phase and are dormant bacteria(Zhang 2005), that have a 
reduced metabolism, but they are sensitive to the treatments since they do 
not have any genetic mutation and they are occasionally dividing, 
meaning that the prolonged exposure to DOTS will kill them (Mitchison 
and Coates 2004).
A more detailed characterisation of the drugs of the DOTS regimen is 
given below.
1.8.1. Isoniazid
Isoniazid (INH) (Fig. 1.5.) was discovered in 1952 by three different drug 
companies: Hoffman LaRoche, E. R. Squibb & Sons and Bayer, and it 
remains an important anti-TB drug, due to the fact that it is highly potent, 
well tolerated by the patient and inexpensive (Zhang 2005). Despite its 
importance, its mechanisms of action are not yet completely understood. 
There are still contradictory ideas in the field and new hypotheses of how 
INH works are regularly proposed in the literature.
H
NH-
Fig. 1.5.: Structure of isoniazid, C6H7N30.
INH is a pro-drug and it requires activation by Mtb catalase-peroxidase, 
encoded by the gene katG. This enzyme generates reactive oxygen 
species and reactive oxygen radicals toxic to Mtb. INH inhibits the
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synthesis of mycolic acids, important constituents of the cell wall of Mtb, 
inhibiting specifically the enoyl acyl carrier protein (ACP) reductase, 
encoded by InhA (Lei et al. 2000; Zhang 2005). In 1998 Mdludi and 
colleagues published a highly-cited study, and at the time highly 
controversial, attributing the inhibitory effect of isoniazid to be directed 
against the Mtb ketoacyl ACP synthase (Mdluli et al. 1998). The authors 
were criticised for over-simplifying a very complex process.
Resistance to the drug is caused either by mutations in KatG, the gene 
that encodes catalase-peroxidase which is involved in the activation of 
INH; mutations in the promoter regions of InhA (INH target) (Zhang 
2005; Handbook of anti-tuberculosis agents 2008; Zhang and Yew 2009) 
or by mutations in ndh that alters the NADH/NAD ratios along the 
electron transport chain. High levels of NADH either competitively 
inhibits the binding between the drug and the enzyme encoded by InhA or 
the activation of INH by the enzyme encoded by KatG (Miesel et al. 
1998; Lee et al. 2001; Vilcheze et al. 2005).
The success of INH is due to its specificity against TB and to the fact that 
it is cheap. However its side effects may include hepatitis and peripheral 
neuropathy (Thompson 1978).
1.8.2. Rifampicin
Rifampicin (RMP) (Fig. 1.6.) acts by binding and inhibiting DNA- 
dependent RNA polymerase in prokaryotic cells, i.e. inhibiting 
transcription. Resistance is caused by mutations in the rpoB gene that 
encodes the P-subunit of RNA polymerase. Rifampicin is active against 
on-growing organisms and also against non-multipliers and it is due to its 
action that chemotherapy against TB does not have an even longer 
duration (Zhang 2005; Zhang and Yew 2009). Prolonged use of
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rifampicin for at least 6 months and a careful identification of an 
optimum dosage is recommended for better outcomes, in terms of 
decreasing the risk of drug resistance and relapse rates (Menzies et al. 
2009).
Fig. 1.6.: Structure of rifampicin, C43H58N4Oi2.
1.8.3. Ethambutol
Ethambutol (EMB) (Fig. 1.7.) was discovered in 1956 by the Lederle 
Research Laboratories, after knowing that polyamines and diamines were 
active against Mtb (Thomas et al. 1961; Zhang 2005).
Fig. 1.7.: Structure of ethambutol, C1oH24N202.
EMB hampers the synthesis of arabinogalactan, a polymer of the Mtb cell 
wall, hence the specificity of EMB to mycobacterial cells. Resistance 
emerges due to mutations in embCAB operon, especially embB, the gene 
that encodes the enzyme involved in the synthesis of arabinogalactan 
(Zhang 2005; Handbook of anti-tuberculosis agents 2008; Zhang and 
Yew 2009). However, there are EMB-resistant Mtb strains that do not
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present mutations in embB, suggesting other determinants for resistance 
(Sreevatsan et al. 1997; Zhang and Yew 2009).
1.8.4. Pyrazinamide
Pyrazinamide (PZA) (Fig. 1.8.) was discovered in 1952 by the Lederle 
Research Laboratories, that based their studies in the same fact that led to 
the discovery of INH, the fact that nicotinamide had an inhibitory effect 
against Mtb (Malone et al. 1952; Zhang 2005). Nicotinamide is a 
structural analogue of PZA.
o
Fig. 1.8.: Structure of pyrazinamide, C5H5N3O.
PZA is a pro-drug that requires the activation by the enzyme 
PZase/nicotinamidase, encoded by the Mtb pncA gene, which converts it 
to its active form, pyrazinoic acid. One of the theories currently proposed 
for its mode of action is that PZA enters the mycobacterial cell, where it 
is converted to pyrazinoic acid, which leaves the cell. If the extracellular 
pH is acidic, protonated pyrazinoic acid will be formed and will re-enter 
the cell (Zimic et al. 2012), causing cellular damage, due to the defective 
efflux in Mtb. Hence PZA interferes with membrane energy metabolism 
(Zhang and Mitchison 2003; Zhang 2005; Handbook of anti-tuberculosis 
agents 2008). PZA is more active in anaerobic or microaerophilic 
conditions. In these conditions, the energy production by Mtb is reduced 
and PZA disrupts the already low energy cell metabolism (Zhang and 
Mitchison 2003; Wade and Zhang 2004). This drug is inactive at neutral
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pH so it is only active in acidic conditions and at low cell densities. This 
effect is important since after the initial infection, Mtb organisms are 
phagocysed and contained in acidic compartments inside the host 
macrophages (Salfinger and Heifets 1988).
The specific target of PZA was proposed to be FAS-I (fatty acid synthase 
I), although fatty acid synthesis either in vivo or in vitro is not inhibited 
by pyrazinoic acid suggesting that PZA has non-specific mechanisms of 
cell death (Boshoff et al. 2002).
Resistance to pyrazinamide is mainly due to mutations in the pncA Mtb 
gene (Zhang 2005; Handbook of anti-tuberculosis agents 2008; Zhang 
and Yew 2009).
1.8.5. Streptomycin
Streptomycin (Fig. 1.9.) was discovered in 1944 by Schatz and Waksman 
and it was the first effective drug against Mtb, representing the beginning 
of modem Mtb chemotherapy. It is an aminoglycoside antibiotic that 
inhibits bacterial protein synthesis. Resistance to this drug is associated 
with mutations in the genes that encode the small ribosomal subunit, 
namely rpsL and rrs (Zhang 2005; Handbook of anti-tuberculosis agents 
2008).
HO...
Fig. 1.9.: Structure of streptomycin, C21H39N7O12.
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1.9. Other anti-mycobacterial agents
Despite being considered one of the deadliest diseases of the 20th century, 
due to the introduction in the 1960s of rifampicin and ethambutol 
tuberculosis was considered for many years an easily controlled disease. 
This scenario changed due to the emergence of hyper-virulent and drug 
resistant strains and co-infection with HIV. So, when the regular regimen 
is not effective, due to resistance or unwanted side effects of the first line 
drugs, there are a number of second line drugs that can be used 
(capreomycin, cycloserine, streptomycin, clarithromycin and 
ciprofloxacin) (Mukherjee et al. 2004). These second line drugs are less 
effective, have less tolerable side effects and their costs are higher.
Many anti-TB drugs were discovered between 1950 and 1960 from the 
screening of antibiotics isolated from soil microbes that proved to have 
an effect against Mtb. That was the case of the second line anti-TB drugs 
such as cycloserine, kanamycin, amikacin, viomycin, capreomycin, 
rifamycins and rifampin. In the 1980s quinolone drugs were discovered 
(Zhang 2005).
1.9.1. Metronidazole, a drug against anaerobic bacteria
Metronidazole (Fig. 1.10.) is classified as a nitroimidazole, and it is a 
drug known to act against anaerobic or microaerophilic bacteria, hence its 
possible importance against latent Mtb. Metronidazole damages the 
pathogen DNA but it does not have an effect against active on-growing 
Mtb (Sacchettini et al. 2008). Metronidazole is often used as a control in 
the anaerobic TB studies since it is known to be active against dormant 
bacteria and it serves as an indicator of positive drug activity in anaerobic 
conditions. Also it does not have an antagonistic effect when used in 
conjunction with the first line anti-TB drugs (Wayne and Sramek 1994).
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Metronidazole shows low or no activity against the persistent bacilli in 
the Cornell mouse model, probably due to the non-establishment of 
complete hypoxia in this infection scenario (Dhillon et al. 1998).
Fig. 1.10.: Structure of metronidazole, C6H9N303.
A study sponsored by NIAID, the National Institute for Allergy and 
Infectious Diseases (www.niaid.nih.gov) is currently testing the effect of 
adding metronidazole to the treatment against multi-drug resistant TB, in 
patients from Masan, South Korea.
1.10. Resistance to antimycobacterial drugs
It was the discovery and development in the 1940s of effective anti­
bacterial drugs that led to an astonishing reduction in the mortality caused 
by bacterial infections. However, in parallel with these effective 
treatments against the pathogenic organisms, bacteria successfully 
developed their own strategies to counteract the effect of the drugs and 
this resulted in the emergence of resistant strains. Therefore, it is due to 
this phenomenon of resistance that TB, which was once controlled by a 
therapeutic regimen, is now one of the deadliest infections worldwide, 
with strains that are resistant to conventional forms of therapy (Gillespie 
2002; Mitchison 2005; WHO 2010).
The main cause for the emergence of resistant strains is the non- 
compliance of patients to an extremely demanding and prolonged 
therapeutic regimen often associated with lack of access to essential 
medical care (Gillespie 2002), this is called secondary resistance, also
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called acquired resistance. Apart from patient non-compliance, also to 
blame in the emergence of drug resistant Mtb strains are inaccurate 
prescribing patterns, often with a wrong selection of drugs as well as an 
incorrect dosage and treatment duration (Sharma and Mohan 2006).
TB primary resistance occurs when the person is infected with an already 
drug-resistant strain of Mtb. Drug resistance mutations occur either in the 
genes that encode the target or in the genes that encode the drug activator 
(Sacchettini et al. 2008).
For a long period there was very little interest from pharmaceuticals 
companies in investing resources into research for new anti-TB drugs. 
However, in the past few years the pressing need for novel compounds 
was finally recognised, due to the fact that the current therapy is 
ineffective against resistant strains and persistent organisms (Russell et 
al. 2010). All this led to considerable efforts that are now in place aimed 
at creating new and more effective ways of treatment (Gillespie 2002).
The dates of discovery of the current available anti-TB therapy are 
represented in Fig. 1.11, The time line shows the rise in resistant strains 
of TB as well as co-infection with HIV that represent the main worries 
for the TB eradication efforts.
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1st line TB drugs (Drug-sensitive TB)
Streptomycin (1944)
boniazkl (1952)
Pyrazinamide (1954)
Ethambutol (1941) 
Rifampin (1963)
Rifapentine (1965)
RHabutin (1975)
fiieo i*«o f
FQ-Ofloxadn (1980)
Amikidn (19/2)
Capreomydn (1963) 
Ethionamide (1961) 
Kanamydn (1957) 
Cydosarina (1955)
MS (1948)
2nd line TB drugs (Drug-resistant TB)
Fig. 1.11.: Time line of the discovery of the first and second line anti-TB drugs. 
Also represented is the emergence around the year 2000 of TB/HIV co-infection, 
multiple-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR- 
TB). Scheme adapted from TB Alliance Organization. In the figure, PAS 
represents para-aminosalicylic acid and FQ represents fluoroquinolone.
Multiple-drug resistant TB (MDR-TB) is defined as resistance to the two 
most effective first line TB drugs: rifampicin and isoniazid, while 
extensively drug resistant TB (XDR-TB) occurs when bacteria are also 
resistant to one of the three classes of second-line drugs, namely 
aminoglycosides, such as amikacin or kanamycin, cyclic polypeptides 
such as capreomycin and fluoroquinolones such as ciprofloxacin or 
levofloxacin (Barry III and Blanchard 2010). These resistant phenotypes 
are acquired by a sequence of cumulative mutations in the genes involved 
in individual drug resistance (Zhang and Yew 2009). A summary of the 
mechanisms of resistance involved in each of the first and second line 
drugs is displayed in Table 1.2.
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The WHO report of 2010 summarizes the latest estimates of the global 
epidemic of MDR-TB and XDR-TB and it includes an assessment of the 
progress that countries from all over the world are making in terms of 
diagnosis and treatment of these cases (WHO 2010). A map showing the 
worldwide distribution of XDR-TB cases is displayed in Fig. 1.12. A 
large part of Africa does not have reported XDR-TB cases but this is 
believed to be due to laboratory limitations in diagnosis (WHO 2010).
Fig. 1.12.: Worldwide distribution of countries reporting at least one case of XDR- 
TB (in red), according to WHO report, 2010 (WHO 2010).
1.10.1. Treatment of drug resistant TB
WHO published a guideline with recommendations for the treatment of 
drug resistant TB (WHO 2011). The success of the treatment depends on 
the early identification of the drug-resistance involved and in the 
establishment of a treatment focused on the particular individual and his 
background (Johnston et al. 2009).
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WHO recommendations are that in the intensive phase of the treatment, a 
regimen of at least four drugs should be implemented: a parenteral agent 
should be used (either kanamycin, amikacin or capreomycin, but often 
the first due to its lower cost), a fluoroquinolone, an oral bacteriostatic 
drug (either ethionamide or prothionamide) and pyrazinamide whose 
inclusion may represent a slight improvement in the outcome of the 
treatment (WHO 2011).
The duration of the MDR-TB treatment can last from 8 to 20 months, 
with increased risks of adverse reactions after 12 months (WHO 2011).
1.10.2. The future of anti-TB therapy
With the appearance of XDR Mtb strains by the end of the twentieth 
century that are virtually impossible to kill by the current chemotherapy, 
the need for new bactericidal compounds became urgent.
There are a number of ideal characteristics that a drug should have in 
order to improve the outcome of anti-TB therapy. Namely, the inhibitory 
compound should have great effectiveness, in order to reduce the 
duration of treatment and avoid patient noncompliance; should be active 
against drug-resistant strains of Mtb including the organisms in the latent 
state and it should be compatible with the current DOTS drugs (Cole and 
Alzari 2007).
Another feature to take into account is the affordability of new anti-TB 
compounds, since the new successful drugs need to be introduced into 
resource-poor countries so costs cannot be ignored (Dye and Floyd 2006; 
Young 2009).
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1.10.2.1. Organisations involved in the fight against TB
There are several worldwide associations that are placing an effort in the 
development of new drug therapies.
The Stop TB partnership was founded in 2001 with the objective of 
eliminating TB from the list of public health dangers and ultimately to 
eradicate TB worldwide. It comprises an international network containing 
public and private sectors fhttp://www.stoptb.org/T One of the seven 
Working Groups of the partnership, the Working Group on New Drugs 
(WGND) aims to accelerate the discovery, development and 
implementation of new drugs that are both effective and affordable in the 
fight against TB. The WGND is to act as a platform of communication 
and collaboration between the different partners involved.
The TB Alliance, the Global Alliance for TB Drug Development 
(www.tballiance.org) is another worldwide partnership, whose mission is 
to discover and develop better, faster acting and affordable drugs to fight 
tuberculosis.
Another relevant association in the fight against TB is the Bill & Melinda 
Gates foundation (www.gatesfoundation.org/tuberculosis). They focus 
their investments in innovation, aiming to find new drugs, diagnostics or 
a vaccine effective against TB and the accessibility and affordability of 
these new solutions across the World. They raise public awareness and 
advocate for funding.
1.10.2.2. Anti-TB drugs in the pipeline
In 2010 Barry and Blanchard reviewed the state of the art of compounds 
that were going into phase I and II clinical trials. These included the 
diarylquinoline R207910, the nitroimidazoles PA-824 and OPC67683, 
the diamine SQ109, the p-lactams clavulanate and carbapenems and
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oxazolidinones linezolid and PNU-100480 (Barry III and Blanchard
2010).
Some promising drugs have already moved to the final step, phase III, of 
clinical trials, which includes testing in more than 900 TB patients 
(http://www.newtbdrugs.org/pipeline.phpl. Gatifloxacin and 
moxifloxacin are fluoroquinolones and they have already shown great 
potential in decreasing the duration time of TB treatment.
The fluoroquinolones moxifloxacin (Fig. 1.13.B) and gatifloxacin (Fig. 
1.13A) also have an effect in many other infections, namely respiratory 
infections, such as pneumonia and hospital acquired infections caused by 
Staphylococcus aureus (Sacchettini et al. 2008). These two compounds 
have the highest in vitro activity against Mtb, but there are concerns 
regarding the emergence of resistant strains, since gyrA mutations are 
common (Rivers and Mancera 2008).
Fluoroquinolones interact with DNA gyrase and topoisomerase IV 
stopping the process of transcription, repair and replication of DNA, 
leading to the blocking of bacterial reproduction (Nguyen and Pieters 
2009). Rifapentine (Fig. 1.13.C) is a rifamycin. Rifapentine has some 
advantages compared to its analogue, rifampicin, specifically its serum 
half-life which is much longer than rifampicin hence requires less 
frequent dosing (Sacchettini et al. 2008).
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Fig. 1.13.: Structure of (A) gatifloxacin, C^H^FNaO^ (B) moxifloxacin, 
C21H24FN304 and (C) rifapentine, C47H64N4012.
1.11. High-throughput screening
High throughput screening is pivotal in the discovery of new drugs. 
Using informatics resources, a large amount of information can be 
compiled and analysed. This may include characterization of genes, 
structures of compounds, data generated in silico and cross-checking with 
the literature, which generates a large number of informatic hits. These 
hits may identify compounds with the desirable pharmacokinetic features. 
This high throughput screening allows the testing of a large number of 
these compounds (Sacchettini et al. 2008). Ananthan and colleagues 
described the testing of 3200 representative compounds from a set of 
13440 on Mtb H37Rv (Ananthan et al. 2009).
Inglese and colleagues proposed a series of directives to optimise and 
standardize the experiments and presentation of results in order to create 
comparable databases as well as to establish a quality control measure for 
the biochemical assays (Inglese et al. 2007; Inglese et al. 2007).
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The Tuberculosis Antimicrobial Acquisition and Coordinating Facility 
(TAACF) was established in 1994 by the USA National Institute of 
Allergy and Infectious Diseases with the purpose of concentrating 
commercial, academic and government efforts worldwide in identifying 
new anti-TB compounds and in their evaluation in vivo and in vitro. The 
TAACF experience ended in March 2010 but the outcome of their 
screening activities resulted in several promising anti-TB agents 
(http ://www.taacf.org/).
1.12. Persister organisms
The existence of persistent organism, able to evade not only the defences 
of the host immune system but also antibiotics used in anti-TB treatment, 
was always neglected. However, nowadays their importance and their 
lole in chronic infections are finally recognised. They impair drug 
effectiveness and extend the duration of treatment (Mitchison and Coates 
2004).
Persister cells are a very small fraction of cells of antibiotic sensitive 
strains of Mtb that despite being genotypically drug sensitive, are able to 
evade its effects (as well as the immune system of the host) due to 
phenotypic tolerance (Balaban et al. 2004). Despite not having genetic 
modifications, they present a distinct genetic expression profile: they 
have an impaired growth rate, and they divide very slowly compared to 
the remaining cells in the population (Mitchison and Coates 2004; Coates 
and Hu 2008). Despite this slow metabolism, persisters are dividing 
because INH and RMP, that exclusively target actively growing 
organisms, still have a bactericidal effect against these persisters, if taken 
over a long period (Mitchison and Coates 2004).
According to Mitchison and Coates, the heterogeneity in the growth of 
sub-populations inside the human host is the most important reason for
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slow Mtb sterilization. This fact is corroborated by an initial rapid 
clearance of active Mtb at the beginning of treatment, followed by this 
killing rate becoming increasingly slower as time goes by, which 
corresponds to the killing of the very slow growth persister organisms 
(Mitchison and Coates 2004).
The distinction between persister cells and mutants is depicted in Fig. 
1.14.. The latter ones have genetic alterations that confer drug resistance 
and these alteration will be vertically transmitted to their descendants, 
originating a drug resistant population (Fauvart et al. 2011).
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Fig. 1.14.: Difference between antibiotic resistance (A) and persistence (B). 
Population A is composed of drug-sensitive bacteria (blue bacilli) and a mutant 
resistant cell (blue bacilli with red dot). After antibiotic treatment, sensitive 
bacteria are killed and only the mutants survive, originating a population of 
resistant cells. If at T3 the cells were treated again with the same antibiotic, it will 
have no effect since they are resistant. Population B is composed of cells with no 
genetic alteration but this population contains a small percentage of persister cells 
that survive antibiotic treatment and are able to resume growth originating a drug- 
sensitive population that would be equally reduced if treated with the same 
antibiotic. Adapted from Fauvart et al. 2011.
It should also be pointed out that persister and non-multiplier organisms 
are two different things. Non-multipliers are all the dormant populations 
of bacteria that grow slowly and that include organisms in stationary 
phase, non-dividing or slow-dividers. Persisters are regularly referred to
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as a well-defined sub-population of these non-multiplying bacteria;, 
extremely antibiotic resistant, with a different gene profile (Coates and 
Hu 2008).
1.13. The Genomic Era in the study of Mtb
The complete sequencing of the Mtb H37Rv genome was published in 
1998 by Cole and collaborators (Cole et al. 1998).
TubercuList (http://tuberculist.epfl.ch/) is a publicly available database 
with the genome details of Mtb, created by the Institute Pasteur and it is a 
valuable genetic research tool. Detailed genetic information about the 
Mtb genome can be easily assessed and in this way a better understanding 
of the protein coding genes and genetic pathways of Mtb gained, 
allowing comparisons between pathogenic and non-pathogenic organisms 
which helps to clarify the mechanisms of virulence and drug resistance of 
Mtb.
The mapping of different strains of Mtb genomes is an on-going process, 
and is being constantly updated with further annotations. At present the 
Mtb H37Rv complete genome, as available in NCBI 
(http://www.ncbi.nlm.nih.gov/genome?Db=genome&Cmd=ShowDetailV 
iew&TermToSearch=l 35) has a length of 4,411,532 nucleotides 
sequenced and a GC content of 65%. Usually this GC content confers 
high stability of the DNA (G and C connect by 3 hydrogen bounds to the 
opposite DNA strand while A and T connect by two hydrogen bounds) 
and it is also characteristic of Gram positive Actinobacteria. 90% of the 
Mtb H37Rv genome is functional with a total of 4047 genes detected of 
which 3988 are protein coding genes.
In the Mtb genome there are more than 250 genes coding for enzymes 
involved in fatty acid metabolism. Approximately 9% of the genome
40
encodes glycine-rich proteins, the PE (novel glycine-alanine rich protein) 
and PPE (novel glycine-asparagine-rich protein) that could correspond to 
a source of antigenic variation, representing a pathogenic advantage 
(Domenech et al. 2001).
With the advent of complete genomes of Mtb, it became possible to 
develop microarrays that would target the complete transcriptome of the 
bacteria. This allowed researchers to develop probes (oligonucleotides) 
that are complementary to every single gene (in the case of whole 
genome microarrays) or of a specific set of genes of interest, and to study 
the patterns of gene expression under particular conditions (Debouck and 
Goodfellow 1999). Microarray results usually need further validation by 
other methods, typically quantitative real time PCR (RT-qPCR) whose 
data confirm the pattern of expression of a very limited number of genes 
(Butcher 2004).
Sassetti and colleagues analysed the complete Mtb genome and using 
transposon site hybridization (TraSH), identified 614 genes that were not 
mutating in growing bacteria which means that they are probably 
essential genes for the survival of the organism (Sassetti et al. 2003). 
Using the same methodology, Sassetti and Rubin, instead of just culturing 
Mtb in vitro, used the bacteria to infect mice and determined the Mtb 
genes that were essential to mycobacteria survival in vivo during 
infection. They were able to identify 194 genes (Sassetti and Rubin 
2003).
Nowadays bio informatics tools can be useful to identify new drug targets. 
Murphy and Brown compiled results from genome-wide DNA 
microarray experiments that determined gene expression patterns in the 
latent state of Mtb and combined them with gene essentiality data. This 
analysis allowed them to identify potential new drug targets for new 
therapeutic treatments (Murphy and Brown 2007). Also mathematical
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models allowed the study of the gene expression profiles of Mtb during 
latency using monitored experiments over time (Magombedze and 
Mulder 2012).
1.14. Peculiarities of M. tuberculosis metabolism
As reviewed in (Niederweis 2008), the main sources of energy necessary 
for Mtb to survive are carbohydrates or alternatively fatty acids. There is 
some evidence that points to the switch from carbohydrates to fatty acid 
metabolism during the passage from the acute to the chronic phase of 
Mtb infection (Boshoff and Barry III 2005; Munoz-Elias and McKinney 
2005). Titgemeyer and colleagues identified only 5 putative carbohydrate 
transporteis in pathogenic Mtb. Despite glycerol being the standard 
carbon source for Mtb growth, they did not identify any uptake system 
for it. This carbohydrate is directly diffused through the lipid membranes 
of the bacilli (Titgemeyer et al. 2007).
During infection Mtb switches its carbon sources of glycerol and glucose 
to fatty acids. A large portion of the Mtb genome refers to genes for lipid 
synthesis and degradation, biochemical activation and oxidation of fatty 
acids (Cole et al. 1998; Boshoff and Barry III 2005). During infection, 
the genes associated with fatty acid metabolism are up-regulated (Sassetti 
and Rubin 2003).
The fatty acid degradation involves the tricarboxylic acid (TCA) cycle 
and glyoxylate shunt (Fig. 1.15,). Isocitrate is converted to succinate and 
glyoxylate, by the enzyme isocitrate lyase encoded by two homologous 
genes {icll and icl2) (Cox and Cook 2007), and to a-ketoglutarate by 
isocitrate dehydrogenase in the TCA cycle. Deletion of both copies of the 
id gene, which encode isocitrate lyases 1 and 2 of the glyoxylate cycle 
completely impaired the in vitro bacterial growth on fatty acids but had 
little effect on the use of carbohydrates by the bacteria. In vivo, bacteria
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lacking icll and icl2 do not grow in mice and are rapidly eliminated, so 
this supports the idea that fatty acid metabolism is pivotal during 
infection and the glyoxylate cycle could be a good target for drug 
development (McKinney et al. 2000; Munoz-EHas and McKinney 2005). 
However, recognising the importance of fatty acid metabolism does not 
exclude the possibility of a parallel uptake of carbohydrates from the 
human host.
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Fig. 1.15.: Schematic representation of the glyoxylate shunt pathway. In the 
glyoxylate cycle, isocitrate is converted to succinate and glyoxylate, by the enzyme 
isocitrate lyase. In the tricarboxylic acid (TCA) cycle, isocitrate dehydrogenase 
converts isocitrate to a-ketoglutarate. Adapted from Russell 2001.
1.15. Electron transport chain
The electron transport chain (ETC) is a modular complex of enzymes 
within the bacterial membrane that is able to create a proton gradient 
across this membrane with the purpose of generating ATP. This ETC is 
considered to have two different sides: a menaquinone-reducing part.
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where a series of enzymes transfer electrons to menaquinone, reducing it 
to menaquinol; and a second part, the menaquinol-oxidizing part, where 
enzymes accept electrons from the reduced quinol, oxidizing it back to 
the quinone form and subsequently passing them to terminal electron 
acceptors (Kana et al 2009).
The first part includes the NADH: menaquinone oxidoreductases: one 
type I NADH dehydrogenase and two type II NADH dehydrogenases; a 
succinate: menaquinone oxidoreductase and flavoproteins that pass 
electrons to the quinone pool. In terms of the menaquinol-oxidizing part 
of the ETC, there is one electron acceptor which receives electrons 
directly from the menaquinol pool: the cytochrome bd oxidase, and an 
#<23-type cytochrome c oxidase that receives electrons from a 
menaquinol: cytochrome c oxidoreductase (the bcl complex). Finally, a 
multi-subunit ATP-synthase, generates ATP using the proton gradient 
created across the cytoplasmic membrane (Rao et al. 2001).
Hypoxia leads to a down-regulation of genes associated with aerobic 
respiration and an up-regulation to genes involved in fumarate and nitrate 
reduction (involving a fumarate and a nitrate reductase) and 
microaerophilic respiration. So there is a clear distinction between the 
ETC under normal aerobic conditions, where the energy production is at 
its maximum and the conditions that exist when the organism is 
submitted to an environment of very limited oxygen or completely 
depleted of oxygen (Boshoff and Barry III 2005).
A general scheme of ETC is shown in Fig. 1.16. but a much more 
detailed biochemical overview of the ETC processes and constituents can 
be found in Yagi and Matsuno-Yagi 2003, Brandt 2006 and Hosier et al. 
2006.
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1.15.1. Electron donors
1.15.1.1. The three NADH: nienaquinone oxidoreductases
The 14 subunits of the Type I NADH: menaquinone oxidoreductase 
(Ndh-1) are encoded by the genes nuoABCDEFGHIJKLMN, each one 
with similarities to homologous proteins in the mammalian 
mitochondrion (Yagi et al. 2001). In mitochondria, this enzyme 
(Complex I) is composed of 46 subunits, but it is quite similar to its 
bacterial homologue, in terms of sensitivity to the drugs rotenone and 
piericidin A (Yagi and Matsuno-Yagi 2003).
Type II NADH: menaquinone oxidoreductases are encoded by the gene 
ndh and its homologue ndhA. The type II NADH dehydrogenase (Ndh-2) 
single-subunit enzyme catalyses the transfer of electrons from NAD(P)H 
to the quinone pool without pumping protons across the membrane (Yagi 
and Matsuno-Yagi 2003). It is essential during hypoxia since it has a 
pivotal role in maintaining the NADH/NAD+ ratios within the Mtb cell 
(Vilcheze et al. 2005). Drug inhibition of the enzyme has been shown to 
lead to the non-replenishing of the NAD+ pool and consequent 
interruption of the electron transport cycle and cell death (Rao et al. 
2001; Kerscher et al. 2007).
Type I NADH dehydrogenase is not essential for mycobacterial growth in 
low oxygen conditions, therefore during hypoxia, Mtb is solely 
dependent on Ndh-2 (Rao et al. 2001). Contrary to type I NADH 
dehydrogenase, Ndh-2 does not have a human equivalent which makes it 
an even more desirable drug target (Weinstein et al. 2005). Ndh-2 is often 
the only type of NADH dehydrogenase present in many living 
prokaryotes (Melo et al. 2004).
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1.15.1.2. The succinate: menaquinone oxidoreductase
Mtb succinate: menaquinone oxidoreductase is a flavoprotein encoded by 
the genes sdhABCD and it is composed of two hydrophilic subunits and 
two hydrophobic subunits and it is an integral part of the tricarboxylic 
acid (TCA) cycle. The two hydrophilic subunits, encoded by the genes 
sdhAB accommodate a substrate binding site, FAD, and three iron-sulfur 
clusters (Bott and Niebisch 2003; Kana et al. 2009). The two 
hydrophobic subunits, encoded by sdhCD, contain two 6-type hemes and 
a quinone binding site. This enzyme does not pump protons and it is very 
similar to fiimarate reductase (see section 1.15.4.2). The enzymes differ 
in that they catalyse the same reaction but in different directions. 
Succinate reductase reduces quinone and catalyses the oxidation of 
succinate to fumarate. Fumarate reductase catalyses the oxidation of 
quinol and concomitant reduction of fumarate to succinate (Bott and 
Niebisch 2003; Kana et al. 2009).
1.15.1.3. Other electron donors
In its genome Mtb has other genes including dehydrogenases, namely L- 
lactase, glycerol-3-phosphate, malate and proline, but their functions are 
unknown (Kana et al. 2009).
1.15.2. Quinones in M. tuberculosis
Quinones are lipid-soluble molecules that transport electrons between the 
protein complexes in the electron transport chain. They transfer electrons 
between hydrogenases and cytochromes, functioning as reversible redox 
components of the electron transport chain (Farrand and Taber 1974). 
Quinones are an essential part in the respiratory chain (Brandt and 
Trumpower 1994). Ubiquinone is the quinone present in mammalian cells
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and most Gram positive and anaerobic bacteria contain menaquinone 
and/or demethylmenaquinones as their main quinone (Fig. 1.17.) 
(Bentley and Meganathan 1982). Mycobacteria have menaquinone, 
which has a lower redox potential than ubiquinone, meaning that it has 
less tendency to accept electrons and being reduced (Kana et al. 2009). In 
bacteria containing both ubiquinones and menaquinones, each quinone 
may have a specific and distinct electron-carrying role (Bentley and 
Meganathan 1982), although mycobacteria do not possess this plasticity.
The quinone structure consists of an isoprenoid unit which is 
hydrophobic and which allows the quinones to be soluble in the interior 
of membranes, where they can move freely (Roehm 2001), transferring 
electrons between the membrane-bound proteins.
o
Fig. 1.17.: Structures of (a) ubiquinone and (b) menaquinone
The biosynthesis of menaquinone has been studied in E. coli. In this 
organism, chorismate is converted into menaquinone by seven enzymes, 
encoded by the genes menA to menG (Hiratsuka et al. 2008). The 
biosynthesis of menaquinone in mycobacteria is schematized in Fig. 1.18. 
and it diverges from the ubiquinone biosynthesis pathway at the first step, 
with the conversion of chorismate to iso chorismate. The bacterial
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enzymes of this pathway, such as MenB, are potential targets for anti-TB 
drugs since they do not have human homologues (Truglio et al. 2003).
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Fig. 1.18.: Menaquinone biosynthesis pathway in mycobacteria, showing enzymes 
and intermediate products involved in the biosynthesis of chorismate to 
menaquinone. Green arrows refer to points where the pathway diverges into the 
production of ubiquinone and phylloquinone (neither present in mycobacteria). 
Light green letter genes (menF and menH) are present in other bacterial pathways 
but have not been identified in either Corynebacterium or Mycobacterium genus.
Mtb uses demethylmenaquinone-9 (DMK-9) as a lipid soluble 
electron/proton carrier in the quinone pool, encoded by menABCDEG 
(Teh et al. 2007/ However, accordingly to Weinstein and colleagues, this 
carrier is demethylmenaquinone-8 (DMK-8) (Weinstein et al. 2005).
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Genomic data support the notion that Mtb uses only menaquinone in the 
electron transport chain, since the Mtb genome contains homologues of 
most of the E. coli men genes, while homologues of the key ubiquinone 
biosynthesis genes are not present (Cole et al. 1998).
1.15.3. Electron acceptors
1.15.3.1. The menaquinol: cytochrome c oxidoreductase (bci 
complex)
The menaquinol; cytochrome c oxidoreductase or bej complex 
cytochrome c, is encoded by the qcrCAB operon. It is composed of 
cytochrome b and cytochrome cc. This enzyme transfers electrons from 
menaquinol to electron acceptors like cytochrome c and translocates 
protons across the membrane, in what is called the quinone cycle 
mechanism (Crofts 2004). The Mtb bej complex is associated with the 
aas-type cytochrome c oxidase forming a be]-acts super-complex, 
transferring electrons to this terminal oxidase (Kana et al. 2009). The 
disruption of this super-complex is not lethal in M. smegmettis, but it is 
lethal in Mtb (Matsoso et al. 2005).
1.15.3.2. The two terminal oxidases
The cytochrome bd oxidase is encoded by cydABCD and contains two 
structural subunits, encoded by cydA and cydB and three heme groups 
(two 6-type hemes and one heme d). The genes cydC and cydD encode a 
probable ATP-binding cassette (ABC)-type transporter (Cole et al. 1998). 
This enzyme catalyses the oxidation of menaquinol and it has high 
affinity for oxygen, hence its important role when bacteria are submitted 
to low oxygen conditions (Kana et al, 2009).
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In the other branch of the respiratory chain cytochrome c is fused to a 
third subunit of the bci complex, forming a super-complex terminating in 
an tffljrtype cytochrome c oxidase, encoded by the cluster of genes 
ctaBCDEF(see section 1.15.3.1.) (Weinstein et al. 2005).
1.15.4. The anaerobic respiratory enzymes of the ETC
The ETC of Mtb contains enzymes that are able to catalyse the oxidation 
of menaquinol and transfer electrons to a final acceptor that is nitrate 
rather than oxygen. They are denominated denitrification enzymes. The 
final electron acceptor can also be nitrite or fumarate, thus Mtb has a 
nitrite reductase, encoded by nirBD, and a fumarate reductase, encoded 
by JrdABCD that could be used for anaerobic fumarate respiration 
(Sohaskey; Sohaskey 2008).
1.15.4.1. Nitrate reductase
In the absence of oxygen, Mtb is capable of using nitrate as an alternative 
electron acceptor. The enzyme nitrate reductase, encoded by narGHJI, 
oxidises menaquinol and reduces nitrate to nitrite (Sohaskey 2005). In 
parallel with the over-expression of this cluster of genes, there is also an 
up-regulation of the navk2-narX operon, which encode the transporter 
NarK2 (nitrite-efflux system), and the inactive nitrate reductase NarX 
(Shi et al. 2005). With hypoxia, the reduction of nitrate to nitrite provides 
energy while bacteria adapt to anaerobiosis. There is evidence that nitrate 
respiration plays a role in persistence of Mtb in macrophages (Boshoff 
and Barry III 2005).
The expression of the operon narGHJI is not induced by hypoxia. It is 
nark2, the nitrate transporter, that is induced by the regulator DosR and
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so it is responsible for the up-regulation of nitrate reductase activity seen 
in non-replicating cultures (Park et al. 2003). Oxygen inhibits nitrate 
reduction and narK2, while hypoxia results in an inactive cytochrome 
oxidase and the increase of reduced components of the ETC, that may 
serve as a signal for narK2 activity (Sohaskey 2005).
1.15.4.2. Fumarate reductase
Fumarate reductase is encoded by frdABCD and it is structurally 
composed of 4 subunits, two hydrophilic subunits (encoded by frdAB 
containing one FAD and three iron-sulfur clusters) and two membrane 
anchor subunits (encoded by frdCD containing one heme b). Fumarate 
reductase is used as a terminal oxidase in some bacteria and parasites for 
fumarate respiration, but its role in Mtb is not yet clear (Watanabe et al. 
2011). It is probable that this enzyme is involved in the persistence 
phenomenon (Tian et al. 2005). This enzyme is similar to succinate and 
catalyses a similar reaction, but in the opposite direction (see section
1.15.1.2. ) (Kana et al. 2009).
1.15.4.3. Nitrite reductase
Nitrite reductase is a flavoprotein, encoded by nirBD, whose function in 
Mtb growth is unclear (Kana et al. 2009).
Fumarate, nitrite and nitrate reductase are less efficient in terms of energy 
output (Stouthamer et al. 1982). They do not use oxygen as the ultimate 
electron acceptor, resulting in a small ATP production and once again 
supporting the idea of low energy requirement during hypoxia (Boshoff 
and Barry III 2005).
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1.15.5. FiFo-ATP synthase
F1F0-ATP synthase is encoded by the atpABCDEFGH gene cluster and is 
responsible for the production of ATP by oxidative phosphorylation in 
aerobic conditions. It works as an ATPase, pumping protons through the 
membrane in anaerobic conditions (Tran and Cook 2005). The atpD gene 
that encodes the (3-subunit of FiFo-ATP synthase is an essential gene for 
Mtb (Sassetti et al. 2003; Tran and Cook 2005). Under hypoxia, the 
energy requirements are less, due to reduced metabolism, hence FiF0- 
ATP synthase is under-expressed (Berney and Cook 2010), but it remains 
essential (Rao et al. 2001).
1.15.6. Important drugs that target Mtb ETC
The drugs diarylquinolines and phenothiazines have in common the fact 
that both target oxidative phosphorylation in mycobacteria (Hurdle et al. 
2011). Phenothiazines target the initial step of the Mtb ETC, inhibiting 
type II NADH: menaquinone oxidoreductase and diarylquinolines are a 
class of drugs that target the subunit c, encoded by the gene atpE of the 
FiFo-ATP synthase enzyme in order to kill Mtb (Koul et al. 2007). As 
well as killing actively growing bacilli, diarylquinolines may have an 
even more active effect against dormant bacteria (Koul et al. 2008). This 
is indicative of the fact that since ATP synthase is under-expressed 
during latency, dormant bacteria still need residual activity of ATP 
synthase to survive and are more sensitive to alterations in ATP levels, 
than actively growing Mtb bacilli (Rao et al. 2001; Koul et al. 2008)
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X.16. DosR regulon
The electron transport chain is a dynamic modular complex that is 
capable of adjusting to environmental conditions, namely the availability 
of oxygen and nitric oxide (Brandt 2006). The changes in the respiratory 
chain of Mtb are often controlled by transcriptional regulators, such as 
the DosR regulon, that are known to change gene expression levels, in 
response to aerobic or anaerobic conditions (Boon and Dick 2002).
DosR is a two-component signalling system that is required for the Mtb 
response to hypoxia (Voskuil et al. 2004). Many of the genes up- 
regulated during hypoxia require DosR for their induction (Park et al. 
2003; Roberts et al. 2004; Voskuil et al 2004). Boon and Dick named 
Rv3133c gene as dosR (dormancy survival regulator) (Boon and Dick 
2002).
Apart from oxygen deprivation, which is typical of latency, nitric oxide 
(the product of activated macrophages in vivo) also modulates the 
expression of DosR (Voskuil et al. 2003; Kendall et al. 2004). DosR is 
often referred to as conferring a selective advantage in anaerobic 
conditions during infection (Reed et al. 2007).
Kendall and colleagues in an attempt to identify other stresses capable of 
up-regulating DosR regulon, observed that this regulon is induced in 
standing cultures, due to the settling of bacteria and the probable oxygen 
gradient and stress induced in the settled bacteria (Kendall et al. 2004).
Kumar and colleagues described in detail the two sensor kinase regulon, 
called DosS and DosT, controlled by the transcription factor DosR. They 
claimed that DosS is the redox sensor while DosT is an hypoxia sensor 
and carbon monoxide also induces the expression of the Mtb Dos regulon 
(Kumar et al. 2007), reinforcing the idea that the expression of DosR is 
mediated by environmental factors. More recently, Rustad and colleagues 
investigated the role of the 48-gene regulon in the hypoxic response.
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They argued that DosR regulon induction is transient and later a set of 
230 genes of an enduring hypoxic response (ERR) are induced (Rustad et 
al. 2008). EHR is independent of DosR since it occurs in a DosR mutant. 
The hypothesis proposed is that DosR may regulate the initial response in 
vitro and in vivo mice infections, but then to establish persistence and 
virulence, this regulon is dispensable. It is proposed that EHR is more 
stable and extensive than DosR response, being induced for a longer 
period (Rustad et al. 2008). This remains debatable.
In order to assess the role of this regulon in antibacterial drug tolerance, 
Bartek and colleagues, constructed a DosR mutant and showed that 
despite being needed for long-term survival in dormancy, this regulon is 
not required for in vivo or in vitro phenotypic drug tolerance (Bartek et al. 
2009).
In terms of genes induced by the DosR regulator, DosS/T and DosR 
regulate the expression of almost 50 genes (Kumar et al. 2007; Rustad et 
al. 2008), the majority of them still of unknown function. Within those 
that are already characterised, several are involved in adaptations to 
anaerobic conditions, namely the up-regulation of narX (nitrate 
reductase) and narK2 (nitrate transporter) and the repression of Type I 
menaquinone oxidoreductase (Ndh-1); the up-regulation of fdxA 
(ferredoxin), ctcr (a-crystallin protein) and nrdZ (dNTPs microaerophilic 
synthesis) and tgsl (triglyceride synthase) and others (Park et al. 2003; 
Rustad et al. 2008). Given its functional significance, DosR is often 
suggested as a possible drug target (Zhang 2005; Chao and Rubin 2010).
In 2004, Boshoff and colleagues using microarray profiling were able to 
characterise different patterns of gene expression, with the view to 
highlighting possible targets for better drug development. Organisms 
were submitted to different conditions of aeration and nutrition in the 
presence of nitric oxide or drugs. By analysing more than 400 different
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profiles of gene expression under these conditions, the authors identified 
150 clusters of co-regulated genes (Boshoff et al. 2004).
In terms of the respiratory chain, the study from Boshoff and colleagues 
recognised the importance of the phenothiazines in inhibiting oxygen 
consumption and in inhibiting two quinone reductases (type II NADH: 
menaquinone dehydrogenase and succinate dehydrogenase), which are 
associated with a rapid drop of ATP levels (Boshoff et al. 2004).
1.17. Phenothiazines
Phenothiazines (Fig. 1.19.) were never considered as potential anti- 
tubercular drugs, despite some anecdotal recognition of anti-TB effects 
observed in mental patients being treated with phenothiazines due to their 
psychiatric maladies (Amaral et al. 2004). Also, chronic administration of 
these tricyclic compounds is associated with severe side effects, making 
their use prohibitive to cure a long-lasting infection like TB that needs 
prolonged treatments (Amaral et al. 2001).
Chlorpromazine (CPZ) is a clear example that exhibits these two 
setbacks. It was the first compound of the phenothiazine class that was 
used in the 1950s in the psychiatric field and this period corresponds to 
the golden era of the discovery of antitubercular agents, so it was never 
considered as an anti-TB drug. Also early on, it was known that the 
prolonged used of this drug was associated with severe side effects, 
namely acute and chronic liver damage, cholestatic disease, 
agrunalocytosis and retinopathy, making its use prohibitive (Amaral et al. 
2001; Amaral et al. 2004).
Nowadays due to the emergence of resistance and the inefficacies of the 
current agents, scientific research aims to find new solutions or to 
(re)discover alternative and more effective anti-TB treatments. This led to
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the consideration of already discovered compounds that show anti­
microbial activity, despite having some contraindications. In this context, 
phenothiazines re-emerged as potential anti-TB agents (Amaral and 
Kristiansen 2000; Amaral et al. 2004; Amaral et al. 2008).
Early studies showed phenothiazines as having promising anti­
tuberculosis effects. One of the problems associated with phenothiazines 
used against TB were the non-achievable clinical doses of the drug 
needed to inhibit Mtb growth. However, studies showed that human 
macrophages concentrate phenothiazines increasing its concentration in 
the pulmonary tissue to 10-100 times its plasma concentration, killing the 
phagocysed mycobacteria, suggesting that the drug appears to be more 
effective in vivo than in vitro (Amaral et al. 2001; Amaral et al. 2004; 
Sacchettini et al. 2008).
Phenothiazines are responsible for enhancing the anti-tubercular effect of 
some of the drugs currently used for first-line anti-TB treatment, namely 
rifampicin and streptomycin (Amaral et al. 2008). Interestingly, 
phenothiazine treatment proved to be equally effective in normal or drug- 
resistant Mtb strains (Amaral et al. 2001; Viveiros and Amaral 2001; 
Amaral et al. 2008). For these reasons, Amaral and colleagues are 
amongst the advocates of the use of phenothiazines as adjuvants to four- 
or five-drug regimens against TB, defending the idea that the synergistic 
interaction between the agents will diminish the phenothiazine-associated 
severe side effects, since it will allow lower dosages of the drugs to be 
used, which may produce relatively milder side effects. Phenothiazines 
do not enhance the effect of isoniazid (Viveiros and Amaral 2001).
Experimental evidence demonstrates the complete inhibition of 
mycobacterial growth by trifluoperazine and suggests its use or similar 
calmodulin antagonists as anti-tubercular drugs (Amaral et al. 2004). 
They inhibit the transport of calcium by binding to the calcium-binding
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protein calmodulin or calmodulin-type proteins (Ratnakar and Murthy 
1992; Amaral et al. 2004) and they also inhibit the K+ transport from 
external to internal cellular compartments and between intracellular 
compartments (Amaral et al. 2007), compromising membrane integrity.
Phenothiazines are potent inhibitors of type II NADH menacjuinone 
dehydrogenase (Ndh-2) as well as succinate dehydrogenase. These drugs 
are able to block the NADH-dependent O2 consumption by the Mtb 
membrane, altering NADH/NAD and menaquinone/menaquinol ratios, 
altering cellular respiration and cell metabolism (Yano et al. 2006; 
Sacchettini et al. 2008; Dutta et al. 2010).
Thioridazine is the more promising phenothiazine in the TB research 
field. It can be used as a multi-target inhibitor (Dutta et al. 2010). It has 
broad-spectrum antibacterial activity against Mtb and it appears to be 
equally active against persistent organisms (Amaral et al. 1996; Amaral 
et al. 2010). Dutta and colleagues found that thioridazine treatment 
caused damage to the Mtb envelope and altered its energy metabolism. 
Using transmission electron microscopy (TEM) they demonstrated that 
thioridazine caused changes in the envelope morphology of tested cells, 
that increased with the exposure time to the drug (Dutta et al. 2010). 
Thioridazine enhanced the activity of rifampicin and streptomycin against 
TB, suggesting the potential for dosing reduction of these antibiotics 
(Amaral et al. 2001; Viveiros and Amaral 2001), and it proves to be 
extremely and equally potent against growing and resistant Mtb using a 
murine model (Soolingen et al. 2010).
In terms of side effects, cardio-toxicity is a concern with phenothiazines. 
This was verified during in vivo on studies with animals treated for a 
prolonged time and with high dosages of thioridazine, but no similar 
effects were observed in humans treated with low dosages. In terms of its 
psychiatric use, thioridazine proved over the years not to have the severe
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side effects associated with chlorpromazine so is considered a mild 
phenothiazine with only drowsiness associated with its use (Amaral et al. 
2001; Thanacoody 2007).
There are publications that report much more serious and frequent side 
effects, which are mediated as consequences of strong alpha-blocking 
activity (Handbook of anti-tuberculosis agents 2008). Due to the 
recognition of the potential of phenothiazines against Mtb, new 
phenothiazine derivatives are being biosynthesized, in an attempt to 
enhance their potency and selectivity (Bate et al. 2007; Madrid et al. 
2007; Martins et al. 2007).
Fig. 1.19.: Chemical structure of different compounds that belong to the class of 
phenothiazines. (A) Trifluoperazine, CziH^FaNsS; (B) flupenthixol, C23H25F3N2OS; 
(C) fluphenazine, C22H26F3N3OS; (D) chlorpromazine, C^H^Cl^S; (E)
promazine, CnHhoNjS; (F) perphenazine, C2iH26ClN3OS; (G) thioridazine, 
C21H26N2S2; (H) phenothiazine, C12H9NS and (I) promethazine, Q7H20N2S.
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1.18. Aims of the thesis
This thesis has four different objectives that interconnect in order to 
augment the knowledge of the ETC of Mtb. The main focus is in the 
importance of mycobacterial ETC components in persistence, namely the 
type II NADH: menaquinone oxidoreductase (Ndh-2) and in the 
confirmation of this enzyme as a potential drug target.
The main objectives are:
1. To validate the use of M smegmatis as a non-pathogenic model for the 
detailed study of the biochemical respiratory phenomenon of 
mycobacteria. If M smegmatis proves to be a good model it would enable 
objectives two and three to be more easily achieved since no containment 
level III would be required.
2. To set up and validate the Wayne model of hypoxia for the study of 
dormancy in mycobacteria. This consists of the use of different models of 
cell culture in order to replicate the in vivo conditions faced in the host by 
the bacteria and to establish a quantitative and reliable measure of the 
susceptibility of Mtb to different compounds. Drugs tested against Mtb 
were either the currently used therapy that worked as a validation for the 
method or compounds specifically targeting the ETC, namely the 
phenothiazines. Phenothiazines are inhibitors of the ETC enzyme Type II 
NADH: menaquinone oxidoreductase, encoded by the gene ndh.
3. To investigate the gene ndhA, homologue of ndh that encodes Ndh-2, 
and to investigate its functionality in the bacteria with the view to 
understanding if the presence of this ndh homologue confers some kind 
of evolutionary advantage to the Mtb organism. The gene was cloned, 
expressed and its activity and functionality were studied.
4. To contextualize under an evolutionary perspective the ndh genes 
present in Mtb within the overall Actinomycetales group that includes
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mycobacteria. The available genomes of this group were scrutinized for 
hypothetical ndh homologues and phylogenetic relationships analysed.
These aims together contribute to the overall goal of the work presented 
in this thesis; the identification and theoretical and experimental 
validation of an enzyme of the Mtb ETC as potential drug target.
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Chapter 2. Mycobacterium smegmatis, a non- 
pathogenic model for the study of M tuberculosis
2.1. Introduction
The complete genome of the M. smegmatis has been available at NCBI 
since 2006 (NC_008596) and this rapid-growing, saprophytic organism 
has been used as a model for the study of Mtb virulence and regulatory 
pathways at least for the last two decades (Waagmeester et al. 2005).
The major advantage of using M. smegmatis as a model organism for the 
study of Mtb is the fact that it is not pathogenic for humans and therefore 
it does not require containment level III facilities. The use of M. 
smegmatis in an initial phase of this study allowed the employment of all 
the resources of the general lab and made it possible to initiate the 
mycobacterial study while the category III areas were still being 
commissioned.
2.1.1. The ETC of M. smegmatis
Analysis of the M smegmatis genome and spectroscopic studies led to 
the conclusion that in terms of enzymes oxidizing menaquinol, this 
organism possesses a cytochrome bcj complex that is a cytochrome bcc 
associated with an o^-type cytochrome c oxidase and its second terminal 
oxidase is a cytochrome bd oxidase (Kana et al. 2001; Nantapong et al. 
2005; Megehee et al. 2006; Megehee and Lundrigan 2007).
The branch constituted by the super-complex bci-aa3 establishes a 
functional association (Megehee and Lundrigan 2007), where the 
cytochrome accepts electrons from a Rieske Fe-S cluster and passes them
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to the quinol cytochrome c reductase (Kana et al. 2001). This is 
particularly important for the growth of M. smegmatis in aerobic 
conditions. Mutants with this pathway disrupted survive using the 
alternative, less energy efficient pathway, through the branch of the ETC 
terminating in cytochrome bd oxidase that is highly over-expressed 
(Matsoso et al. 2005). Although growth is impaired, this branch is 
particularly important for the organism’s survival in environments with 
limited oxygen or when the other branch of the chain is impaired (Kana 
et al. 2001; Matsoso et al. 2005). Under these conditions of low oxygen, 
the cydAB gene expression increases and d-heme expression increases 
(Matsoso et al. 2005). Cytochrome bd does not pump protons through 
the membrane but it oxidizes menaquinol and has a very high affinity for 
oxygen (Megehee et al. 2006).
2.1.2. The use of M. smegmatis as a model to study Mtb
In the last few years, the use of M. smegmatis as a model to study Mtb 
has been challenged by some researchers. The arguments are that M. 
smegmatis is a saprophyte, fast growing and non-pathogenic organism. It 
has a higher resistance to high salt concentrations and exhibits 
remarkable differences in terms of oxidative stress response, virulence 
and drug susceptibility (Bloch 1977; Gray et al. 1982; Horsburgh Jr. 
1996). Barry claims that the differences between Mtb and M smegmatis 
are much more complex than just virulence and rate of growth (Barry III 
2001).
M. smegmatis proved to be more resistant to acidic pH than slow growing 
mycobacteria. Optimal growth of M. smegmatis occurs over a wide pH 
range (pH 5.0 to 7.4), and partial growth can be observed at a pH as low 
as 4.6. Even acid tolerance can be conferred to the bacilli if M smegmatis
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is previously exposed to a lower pH (e.g. pH 5.0) before being placed in a 
normally deadly pH of 3.0 (Rao et al. 2001).
Titgemeyer and colleagues studied in detail the mechanisms of carbon 
uptake systems of M smegmatis and Mtb which are particularly different. 
The plasticity of M. smegmatis and adaptation capabilities were notorious 
due to the fact that it has 28 different transporters of carbohydrates so it is 
able to grow using a great variety of sugars as energy sources, while Mtb 
is poorly equipped with only 5 (Titgemeyer et al. 2007). The porins in the 
M. smegmatis membrane, which increase the permeability of the bacilli 
represent a highly efficient nutrient exchange mechanism but limit the 
intracellular persistence of M smegmatis (Sharbati-Tehrani et al. 2005).
Smeulders and collaborators used M smegmatis as a model for the study 
of persistence under nutrition starvation and they concluded that bacilli 
were able to survive 650 days without carbon, nitrogen and phosphorus. 
Their results were contrary to the idea of M. smegmatis entering a 
dormant state, since during the apparent latency cells remained growing 
and dividing reinforcing the idea that M. smegmatis did not enter a true 
quiescent state. This study showed that the majority of the starved M. 
smegmatis population remains active, with a slower metabolism. 
However this study did not rule out the possibility of the existence of a 
very small sub-population of truly dormant bacilli (Smeulders et al. 
1999).
Some researchers argue that M smegmatis is able to exhibit dormancy 
behaviour induced by hypoxia, similar to Mtb (Dick et al. 1998; Anuchin 
et al. 2009). They argue that submitting M smegmatis to a gradual 
depletion of oxygen, instead of a sudden shift, leads to the survival of the 
bacteria, in a state of persistence. Under these conditions, the bacteria 
show sensitivity to metronidazole, resistance to antibiotics and 
synchronization of growth if reactivation occurs (Dick et al. 1998). These 
are typical hallmarks of latent Mtb but it is known that M. smegmatis
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lacks two typical genes directly related to dormancy in Mtb, the sigma 
factor sigF (DeMaio et al. 1996) and alpha-crystallin (Yuan et al. 1996). 
The up-regulation of alanine dehydrogenase was also reported in this 
“dormant” state of M. smegmatis, compared to cultures grown under no 
oxygen limitation (Hutter and Dick 1998), suggesting that this enzyme 
plays a role in dormancy. The oxidation of NADH in parallel with 
alanine generation maintains an NAD+ pool in conditions of limited 
oxygen (Hutter and Dick 1998). Glycine dehydrogenase activity that 
increased in the case of latent Mtb (Wayne and Hayes 1996) was not 
reported in M smegmatis.
Despite this controversy and non-acceptance by some researchers of M. 
smegmatis as a reliable model of Mtb study, this organism remains a 
widely used model for the study of its pathogenic relative Mtb, mainly 
due to the fact that it does not require level III containment. It serves as a 
useful tool to study Mtb but the results need further validation and must 
be interpreted with caution. The diarylquinoline TMC-207, an important 
anti-TB drug currently in the pipeline which inhibits Mtb ATP synthesis, 
was discovered using whole-cell screening against M. smegmatis 
(Andries et al. 2005). However, Altaf and colleagues argue that 50% of 
active anti-TB compounds would not be identified as active in a 
screening using M smegmatis due to the differences between organisms 
mentioned above (Altaf et al. 2010).
2.2. Methods
2.2.1. General considerations
Unless otherwise stated, all chemicals used were purchased from Sigma 
(Sigma-Aldrich, UK).
All cell culture work was carried out using standard aseptic techniques
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inside a Class II laminar flow cabinet.
Nutrient broths were prepared by diluting media powder in ddH20 
according to manufacturer’s instructions and autoclaved for lOmin at 
121°C.
Sterile, disposable plasticware was utilised throughout.
2.2.2. M smegmatis strain and growth media
M smegmatis strain me2155 was grown in tryptic soy broth (TSB) 
(Fluka, UK), supplemented with 0.1% (v/v) Tween® 80. Depending on 
the experiment performed it was also grown in Middlebrook 7H9 broth 
(BD Diagnostic, UK) enriched with 0.2% (v/v) of glycerol, 0.2% (v/v) 
glucose or 0.2% (v/v) succinate and 0.05% (v/v) Tween® 80.
2.2.2.I. Monitoring M. smegmatis growth
In order to assess the state of growth of cultures, optical density was 
monitored at 600 nm (ODgoo) using a Genesys 10UV Spectrophotometer 
(Thermo Scientific, UK).
To establish the zero point of the growth curve, the absorbance of 800 pi 
of sterile broth contained in a disposable cuvette (VWR International) 
was recorded. To monitor growth of inoculated flasks, aliquots of culture 
were removed at regular intervals and OD6oo recorded. When stationary 
phase (i.e. no further appreciable change in the turbidity of the culture) 
had been reached, plots of time versus ODsoo were generated to visualise 
the M. smegmatis growth curve.
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2.2.2.2. Storage of M. smegmatis stocks
Cells to be frozen were grown until mid-log phase, (i.e. OD6oo 0.6-0.9). 
An equal volume of storage medium was added to the cells prior to 
storage at -80°C. The storage medium consisted of 3 g TSB powder, 20 
ml 100% glycerol and 80 ml distilled water (ddEkO), autoclaved and 
stored at -4°C for up to 6 months.
2.2.2.3. M. smegmatis growth conditions
M. smegmatis was submitted to different oxygen conditions and nutrient 
availability during growth. 5 ml of TSB supplemented with 0.1% (v/v) 
Tween 80 was inoculated with 50 pi of M. smegmatis from a frozen 
stock and incubated overnight at 37°C in an Innova 4230 orbital shaking 
incubator (New Brunswick Scientific, USA) set to 200 rpm.
Assuring the same provenance of bacteria in the different conditions of 
this study, the suspension was then sub-cultured according to the methods 
stated below.
2.2.2.3.I. Aerobic growth of M smegmatis
For aerobic growth, an inoculum of 200 pi was added to 200 ml TSB in a 
500 ml Erlenmeyer flask (with a total capacity of 600 ml). To avoid 
culture contamination and permit maximal aeration, sterile tin foil was 
used to cover the culture flask opening. Cultures were incubated at 37°C 
and shaken at 200 rpm in an Innova 4230 orbital shaking incubator to 
allow rapid diffusion of oxygen between the headspace and the culture. 
At 4-5 hours intervals the ODeoo of the culture was measured as 
previously described (Section 2.2.2.1.).
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2.2.2.3.2. Anaerobic growth of M. smegmatis
To create a micro-aerophilic environment M. smegmatis was cultured in a 
500 ml Erlenmeyer flasks (600 ml of total capacity) containing 400 ml of 
TSB. In order to obtain persistent M. smegmatis bacilli in in vitro culture 
the hypoxia model proposed by Wayne and colleagues was used (Wayne 
and Hayes 1996). As such, a headspace (air): culture media ratio of 0.5 
(i.e. 200 ml air: 400 ml media) was used throughout.
400 ml of TSB was inoculated with 400 pi of M. smegmatis culture and a 
rubber skirted stopper (VWR International) was used to limit oxygen 
supply to the culture. To ensure anaerobic conditions the opening was 
further sealed with Parafllm (Pechiney Plastic Packaging Company, 
USA). The culture was incubated at 37°C and gently stirred on a 
magnetic stirrer, using a 50 mm stirring bar. At 4-5 hours intervals, and 
ensuring sterile conditions, the rubber stopper was pierced using a 40 
mm, 20 G needle (BD Diagnostic, UK) to remove and transfer an aliquot 
of bacterial culture to a disposable cuvette. The ODgoo was measured as 
previously described (Section 2.2.2.1.) and a curve of time versus the 
optical density plotted.
2.2.2.3.3. Nutrient-starved M, smegmatis culture 
To achieve nutrient-starvation conditions, after inoculating 200 ml of 
TSB with 200 pi of M. smegmatis culture, cells were allowed to grow for 
24 h or until OD6oo = 1.0. During this period, the cultures were shaken at 
200 rpm in an Innova 4230 orbital shaking incubator, at 37°C with 
unlimited oxygen supply.
Cells were then harvested by centrifugation at 3000 g for 5 min, washed 
twice using sterile phosphate buffered saline (PBS) pH 7.4 and re-
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suspended in 200 ml sterile PBS pH 7.4. Cultures were returned to the 
incubator and grown under the conditions described above.
ODeoo measurements were taken at 4-5 hours intervals until the turbidity 
of the culture stabilized (Section 2.2.2.1.) in order to plot a growth curve 
of time versus optical density.
2.2.2.3.4. Validation of viability of the organisms
At the end of the experiments and to verify that the turbidity observed in 
the cultures was the result of viable organisms in those different culture 
media, and not produced by cell debris or dead organisms that only grew 
in the first stages of the experiments, 200 pi of each M. smegmatis culture 
were incubated in aerobic conditions according to Section 2.2.2.3.1, for 
24 h. The growth was then monitored in order to confirm viability of the 
samples (see Section 2.2.2.1).
2.2.2.4. Preparation of membranes of M. smegmatis for spectral 
analysis and protein quantification
The preparation of M. smegmatis membranes was based in the protocol 
by Fisher et al. 2009. The M. smegmatis cells were grown until mid-log 
phase (ODeoo — 0.6-0.9) at 37°C with continuous shaking at 200 rpm in 
an Innova 4230 orbital shaking incubator. Cells were harvested by 
centrifugation at 4000 g for 20 minutes. The supernatant was discarded 
and the resultant pellet resuspended in 50 mM potassium phosphate 
buffer pH 7.4 (60 ml of buffer were added for every 1 L of cell culture) 
and centrifuged again at 4000 g for 20 minutes. Once again the 
supernatant was discarded and the pellet re-suspended in the same buffer 
(20 ml of buffer were added for every 1 L of cell culture). Cells were
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maintained on ice for 30 minutes following the addition of hen-egg 
lysozyme to a final concentration of 0.2 mg-ml'1.
A One Shot cell disruptor (Constant Systems Ltd, UK) was used to break 
the cells. Cells were maintained on ice to avoid denaturation of proteins 
due to generation of heat and submitted to 1 shot at 30,000psi. An anti­
foam cup was used in order to minimise foam production during the 
process and 6 ml of cell culture were used per shot. The high pressure 
forces the sample through a small fixed orifice in the cup to cause cell 
disruption.
The suspension was centrifuged at 10,000 g for 30 minutes at 4°C before 
the supernatant was collected and centrifuged at 39,000 rpm for 1 hour. 
The resultant pellet was homogenized in 2 ml of 50 mM potassium 
phosphate buffer, 2 mM ethylenediaminetetraacetic acid (EDTA) pH 7.4 
containing 20% (v/v) glycerol. The isolated membrane preparation was 
stored at -80°C until required.
2.2.2.5. Microplate Bradford assay method for protein quantification 
of M. smegmatis membranes
The total amount of protein in the crude membrane preparations was 
determined by the Bradford assay using bovine serum albumin (BSA) as 
the standard. The assay was performed in sterile 96-well microtitre flat 
bottom plates (NUNC, UK). A 1 mg-mf1 stock solution of BSA was 
serially diluted in ddHiO into three columns of the plate. The dilutions 
were prepared in triplicate. 20 pi of each M. smegmatis membrane 
preparation were plated and 200 pi of Bradford Dye reagent (Bio-Rad, 
UK) was added to each of the wells and mixed thoroughly. Following 
incubation at room temperature for 10 minutes a photometric reading of 
the plate was made at 575 nm using a Varioskan plate reader (Thermo
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Electron Corporation, UK). A calibration curve was generated for the 
protein standards (concentration of BSA was plotted versus absorbance) 
and this curve was used to determine the protein concentration in sample 
wells.
2.2.2.6. Spectral analysis of M. smegmatis membrane cytochromes 
Spectra were recorded at room temperature using a Cary-UV 4000 UV- 
VIS spectrophotometer (Varian, UK). Aliquots of the membrane 
preparation (typically 1-2 pi) were mixed with 700 pi of 50 mM 
potassium phosphate, 2 mM EDTA, pH 7.4. Oxidised membrane spectra 
were recorded following the addition of a single crystal of potassium 
ferricyanide (K3Fe(CN)6) whilst a few grains of sodium dithionite were 
added to generate the reduced spectra. Five spectra were recorded for 
each oxidation state and averages calculated prior to creating a difference 
spectrum by subtracting the average oxidised spectrum from the average 
reduced spectrum. To ensure complete oxidation/reduction of samples 
spectra were re-recorded following further addition of sodium 
dithionite/potassium cyanide. If no further spectral changes were 
observed complete oxidation/reduction was assumed.
2.2.3. Testing drug toxicity against M smegmatis using the 
microplate alamarBlue® assay (MABA)
MABA is used for measuring cell proliferation and viability by monitoring 
the oxidation-reduction state of the environment of cellular growth. 
AlamarBlue® (AbD Serotec, UK) is a soluble, non-toxic oxidation- 
reduction (redox) dye stable in culture medium. It incorporates an 
oxidation-reduction indicator that changes colour in response to the
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chemical reduction of the medium, i.e. the dye changes from blue to pink 
upon reduction due to cell growth..
The drugs to test were solubilised either in ethanol or distilled H20, 
according to Table 2.1. lOmM stock solutions were sterilised through a 
0.22pm pore filter and stored at -20°C.
1 in 3 serial dilutions of the initial lOmM stocks were prepared using 
TSB supplemented with 0.1% (v/v) Tween® 80. For each compound eight 
serial dilutions were made. All dilutions were prepared at double the 
required final well concentration to allow for further dilution in the test 
wells with TSB.
Table 2.1.: Details of compounds tested against M. smegmatis strain mc2155 using 
an in vitro microplate alamarBlue® assay (MABA). The table presents the name, 
molecular weight and solvents used to dilute each respective drug used in the 
MABA bioassay.
Compound Molecular Weight Solvent
Ethambutol dihydrochloride 277.23 dH20
Isoniazid 137.14 dH2Q
Pyrazinamide 123.11 dH20
Rifampicin 822.94 Ethanol
Streptomycin sulphate salt 728.69 dH20
MABA was performed in sterile 96-well microtitre flat bottom plates 
(NUNC, UK). 50pl of broth were plated in row C (2 to 11) and in 
columns 6 and 11 (D, E and F). 50pl of each pre-prepared drug dilution 
were added into columns 2, 3, 4, 5, 7, 8, 9 and 10. The concentration of 
drug decreased from left to right, Column 2 containing the highest drug 
concentration and column 10 the lowest drug concentration. Finally, 
50pl of M smegmatis inoculum was added in rows D, E and F (2 to 11).
Wells in columns 6 and 11 (D, E, F) were free-drug controls containing
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50^1 of broth and 50^1 of bacteria inoculum. Wells in row C (2 to 11) 
were M smegmatis^rez wells, acting as blanks containing 50|al of broth 
and 50fxl of the respective drug dilution. The other wells were test wells 
with bacteria and varying concentrations of the test compounds (See Fig. 
2.1, for plate format).
After 16 hours incubation at 37°C, 20pl of alamarBlue® were added per 
well and the plates were returned to the incubator. After 4 hours, plates 
were read using an Opsys MR™ Microplate Reader (Dynex 
Technologies, USA) at an absorbance of 570nm.
4 5 6 7 s 9 10 11 12
0OOOOO0OOOOOO 
'OOOOOOOOOO0O-oooooooooooo
G
H
Fig. 2.1.: Representative 96 well microplate format for screening drug 
susceptibility of M. smegmatis to various compounds using MABA. • represents 
blank wells, <D corresponds to wells containing 50pl broth and 50pl drug dilution, 
<2> contained lOOpl of broth, <3> were wells containing 50pl broth and 50pl M. 
smegmatis inoculums and O were wells containing 50pl drug dilutions and 50pl of 
M. smegmatis cells.
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2.2.4. Data analysis
Graphs were generated plotting the concentration of drug against the 
percentage of growth of the bacteria in the test wells. The bioassay was 
normalised for the 100% growth in the control wells (drug-free wells), 
with M. smegmatis grown without inhibitor. All the test wells were 
compared to this value in order to obtain a percentage of growth.
The IC5o (half maximal inhibitory concentration) refers to the 
concentration of drug which causes 50% inhibition of growth. The IC90 
(90% inhibitory concentration) refers to the concentration of drug which 
causes inhibition of 90% of microbial growth. All the ICs are presented 
in pM with their respective standard deviations (SD).
A data report was generated using the Revelation QuickLink™ 1.0 
software (Dynex Technologies, USA), from the data obtained with the 
plate reader. A concentration versus response graph was plotted using 
GraphPad Prism version 5.00 for Windows (GraphPad Software, USA). 
The software allowed the inference of both IC50 and IC90 from a 
generated log-concentration response sigmoid curve that was constrained 
between 0 and 100%. Results were given as the mean of two independent 
experiments.
2.3. Results
The aim of this chapter was to classify the effectiveness of M smegmatis 
as an Mtb model and if successful to employ this model for further work 
in this thesis. The focus was to look at its electron transport chain and 
patterns of growth. If M smegmatis presents similarities with Mtb, this 
organism could be used to test potential inhibitors to Mtb, without 
requiring Containment Level 3 facilities.
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M. smegmatis bacilli grown from the same batch were submitted to 
different growth conditions and their growth monitored, as a turbidity 
change of the liquid media, in an optical density meter.
As expected, M. smegmatis grows optimally in conditions of unlimited 
aeration. There is an initial lag phase with a slow increase of the number 
of bacteria, shown by an increase in OD60o that lasts 10 to 14 hours. This 
was followed by a phase of exponential growth. When the medium is 
saturated, with cell debris and products of cell metabolism, at around 40 
hours after the start of the experiment the curve reaches a plateau 
(stationary phase), were the number of bacteria remains constant (Fig. 
2.2.- red line).
Submitting the cultures to anaerobiosis created an environment with 
severe hypoxia resulted in limited growth of the cultures. The cultures 
never grew exponentially and reached a plateau at 8-fold lower than in 
the aerobic cultures 24 hours after the beginning of the experiment (Fig. 
2.2.- blue line vs red line).
In the case where an initial culture of M. smegmatis with an ODgoo of 1 
was cultured in a minimal medium without any source of nutrients, there 
was an abrupt decrease in the number of organisms, followed by a small 
increase in numbers which was not sustained. The culture reached a 
plateau 10 hours after the beginning of the experiment (Fig. 2.2.- green 
line).
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Fig. 2.2.: Growth curves of Mycobacterium smegmatis cultures under different 
conditions. (_, red line) corresponds to cultures grown under conditions of 
unlimited oxygen supply, (_, blue line) represents the cultures grown under 
limited aeration conditions and in ( _, green line) the bacterial cells were deprived 
of a carbon source of energy. The experiment was monitored over 80 hours. The 
data shown are the averages from two independent experiments performed in
duplicate.
In order to assess any quantitative differences between the proteins 
expressed in the membranes of the organisms grown under distinct 
conditions, the total amount of proteins in the crude membranes of M. 
smegmatis preparations grown in aerobiosis and anaerobiosis were 
determined by the Bradford assay. A calibration curve was generated for 
protein standards and this curve was used to determine the protein 
concentration in test samples (Fig. 2.3.).
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Fig. 2.3.: Linear correlation between the absorbance at 575nm and the 
concentration of protein. BSA was used as the standard. The graph represents the 
range when the relation between the concentration of BSA and the respective 
absorbance showed linearity. The obtained linear relationship infers that 
concentration of protein (mg-ml-1)=[Absorbance at 575nm - (0.3586 ± 0.02124)| / 
0.1266 ± 0.008229), r2=0.9875. Results were based on 4 independent replicates.
The total amount of protein was higher in the cultures grown under 
severe hypoxia, compared to the ones submitted to unlimited aeration, 
unfortunately, as there were no discrimination of the kind of proteins no 
conclusions can be drawn about what causes this phenomenon (Table 
2.2.). Also, considering the uncertainty of the results, this difference is 
most certainly non-significant. The 95% confidence intervals are large 
and they overlap at about 85% of their range.
Table 2.2.: Total protein concentration of the prepared membrane fractions, using 
BSA as the protein standard based on two independent replicates. Values between 
brackets indicate the 95% confidence interval.
Growth conditions Protein concentration (mg/ml)
Aerobic culture 0.716 [0.515; 0.945]
Anaerobic culture 0.780 [0.575; 1.014]
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Spectral analyses were performed on the M. smegmatis membranes in 
order to investigate the peak profiles of the cytochromes under different 
growth conditions (Fig. 2.4.). Based on previously defined cytochrome 
profiles (Vrij et al. 1987), it is assumed that a peak at 552nm corresponds 
to cytochrome c, a peak at 563nm relates to cytochrome b and a peak at 
600nm belongs to cytochrome a. A peak at 630nm corresponds to 
cytochrome bd. A peak around 530nm shows a summation of all the 
hemes of the cytochromes present.
0.006
cyt aa3
0.004- cyt bd
summation of 
all cyt hemes
0.002-
0.000
Wavelength (nm)
Fig. 2.4.: Reduced minus oxidised spectra of Mycobacterium smegmatis membranes 
grown under ( _, green line) aerobic and ( _, orange line) anaerobic conditions.
To further characterise the spectra, ratios were calculated in order to 
quantify the differences between the cytochromes in the membranes 
when grown under conditions of different aeration and nutrition (Table 
2.3.).
The use of ratios was required since the values of absorbance variation 
obtained in each spectrum are not normalised and interest focuses on the 
relative peaks within each run. Thus, the peak height of a given 
cytochrome is divided by the peak height of a second cytochrome from
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the same spectrum. Comparing different spectra it is possible to evaluate 
if a given cytochrome is preferred in relation to another, depending on the 
growth conditions.
Table 2.3.: Ratios between the different signals corresponding to the different 
cytochromes present in the Mycobacterium smegmatis membranes from cultures 
grown under different conditions. Ratios were calculated from difference spectra 
peaks.
Growth
conditions
Cyt
c:b
Cyt
c:aa3
Cyt
c:bd
Cyt
b:aa3
Cyt
b:bd
Cyt
aa3ibd
Early aerobic 1.04 1.76 8.5 1.69 8.17 4.83
Late aerobic 1.11 2.49 3.46 2.25 3.13 1.39
Hypoxia 1.01 4.03 2.69 4.00 2.67 0.67
Starvation 1.00 1.64 1.76 1.64 1.76 1.07
The ratios for cytochromes b, c and aas in relation to cytochrome bd are 
substantially higher in early aerobiosis, with late aerobiosis having the 
second highest value. The ratio between b and acts is higher in hypoxia 
and it is also higher between c and acts. The ratio between c and b is very 
similar between the four growth conditions and always approximately 1.
The following graphs (Fig. 2.5., A-H)) are the spectral analyses of the 
membranes obtained from M smegmatis cultured under different 
conditions. They show some of the variability that can exist between 
spectra, although there are some trends, described below.
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Fig. 2.5.: UV-visible difference spectra of membrane fractions isolated from 
Mycobacterium smegmatis grown under different conditions. Difference spectra 
were generated by subtracting potassium ferricyanide-oxidised spectra from 
sodium dithionite-reduced spectra: A-B correspond to cultures in an initial phase 
of growth under aerobic conditions; C-D correspond to cultures with 40h growth 
under aerobic conditions; E-F correspond to cells that were grown under severe 
hypoxia; G cells were submitted to nutrient starvation; H cells grew with unlimited 
oxygen but the carbon source was succinate instead of glycerol.
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Cytochrome aa$ is the preferred cytochrome when the cultures are grown 
aerobically, with a small peak related to cytochrome bd, at 630nm (Fig. 
2.5., A-B). After 40 hours of aerobic growth, the spectra show the 
probable oxygen limitation in the culture medium due to high density of 
individuals which resulted in a higher peak at 630nm that corresponds to 
cytochrome bd (Fig. 2.5., C-D).
Cytochrome b (at 563nm) and c (at 552nm) can exhibit two different 
peaks (as in Fig. 2.5., C) but they can also appear as one single peak (as 
in Fig. 2.5., G). Usually the membranes have similar quantities of these 
two cytochromes, although when the carbon source of the cells was 
succinate, instead of glycerol, an apparent reduction of cytochrome b 
occurred, compared to cytochrome c (Fig. 2.5., FI). There is an increase 
in cytochrome bd (at 630nm) when in conditions of anaerobiosis and a 
less pronounced increase of this cytochrome in conditions of late 
aerobiosis (Fig. 2.5., E-F), consistent with the table of ratios (Table 2.3.).
In the case of nutrient starvation (Fig, 2.5., G), despite no oxygen 
limitation, the pattern of cytochromes is similar to the one presented in 
anaerobiosis or late aerobiosis, this reflecting the high amount of stress 
and low metabolism of the analysed cultures (as observed through their 
limited growth).
Drug susceptibility tests were performed in the M. smegtnatis organisms. 
The current DOTS chemotherapeutic agents were tested against this non- 
pathogenic organism. The results are shown in Table 2.4. and the 
respective IC5o curves are displayed in Fig, 2.6. to 2.10. Only 
streptomycin and rifampicin were effective against M, smegtnatis, 
enabling an IC5o calculation (Fig. 2.6. and Fig. 2.8.). Ethambutol (Fig. 
2.7.) and isoniazid (Fig. 2.9.) had some inhibitory effect at the highest 
concentration tested (lOOpM), meaning that the IC5o would be greater 
than 100 pM and could not be calculated.
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Table 2.4.: Bactericidal IC5o and IC9o values of the inhibitor compounds tested 
against M. smegmatis. The results are presented with the respective standard 
errors and were obtained by calculating an average of two independent replicate 
experiments.
Drug tested IC5o (pM) SE (pM) ICh, (pM) SE (pM)
Streptomycin 0.98 0.226 25.56 13.497
Ethambutol >100 - >100 -
Rifampicin 4.35 0.751 92.08 63.405
Isoniazid >100 - >100 -
Pyrazinamide >100 - >100 _
(Streptomycin) pM
Fig. 2.6.: Curve of M. smegmatis growth inhibition when exposed to different 
concentrations of streptomycin. Percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor. Error bars were 
calculated from two independent experiments.
(Ethambutol) pM
Fig. 2.7.: Curve of M. smegmatis growth inhibition when exposed to different 
concentrations of ethambutol. Percentages of growth were estimated assuming that 
100% growth occurred in the absence of the inhibitor. Error bars were calculated 
from two independent experiments.
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Fig. 2.8.: Curve of M. smegmatis growth inhibition when exposed to different 
concentrations of rifampicin. Percentages of growth were estimated assuming that 
100% growth occurred in the absence of the inhibitor. Error bars were calculated 
from two independent experiments.
(Isoniazid) pM
Fig. 2.9.: Curve of M. smegmatis growth inhibition when exposed to different 
concentrations of isoniazid. Percentages of growth were estimated assuming that 
100% growth occurred in the absence of the inhibitor. Error bars were calculated 
from two independent experiments.
[Pyrazinamide] pM
Fig. 2.10.: Curve of M. smegmatis growth inhibition when exposed to different 
concentrations of pyrazinamide. Percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor. Error bars were 
calculated from two independent experiments.
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2.4. Discussion
The motivation for the use of the M. smegmatis membranes in this study 
was due to the fact that they could serve as models for the cytochromes 
present in the mycobacteria membranes and the handling of this organism 
does not involve the safety restrictions that severely limit the Mtb study. 
During the beginning of this work, the containment level III facilities at 
the Liverpool School of Tropical Medicine (LSTM) were still being 
commissioned and this impaired the work with Mycobacterium 
tuberculosis. In this context, the use of M. smegmatis also allowed 
establishing microbiology techniques that would be required for the study 
of Mtb.
The major disadvantage of using M smegmatis is related to the fact that 
there are differences in its ETC compared with Mtb ETC, namely the 
existence of a second cytochrome bd and the presence of a super complex 
cytochrome bcc in the non-pathogenic organism (Kana et al. 2001), need 
to be taken into account if drugs against Mtb ETC were tested against M. 
smegmatis.
The spectral analysis of M smegmatis showed that cytochrome 
expression in the M smegmatis membranes is dependent on growth 
conditions and submitting the bacteria to different models of growth 
correlates directly with the spectra displayed. Mycobacterial electron 
transport chain is branched, meaning that the flow of electrons after 
menaquinone oxidation will occur either through the branch with a 
terminal cytochrome bcj-aas oxidase or through the branch terminating in 
the alternative cytochrome bd oxidase.
Cytochrome aai is mainly associated with aerobic growth (Matsoso et al. 
2005). The ratios between cytochrome b and aa^ and between c and aa$ 
are substantially higher in hypoxia, reflecting the lower expression of the 
denominator cytochrome aas in the absence of oxygen. The ratio between
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cytochrome acts and bd is lower in hypoxia and it is much higher in early 
aerobiosis (Table 2.3.). These results are in agreement with previous 
work from Matsoso et al. 2005 and Kana et al. 2001, that reported an 
association between cytochrome aa3 and growth under aerobic 
conditions.
On the other hand, cytochrome bd is mainly associated with hypoxia. The 
ratios between c, b or aa3 and bd are consistently higher in early 
aerobiosis, they decrease in late aerobiosis were there is already some 
oxygen limitation due to the overgrowth of the organisms and they are 
lower in hypoxia (Table 2.3.). These results are consistent with the 
literature (Kana et al. 2001) that reports the association between 
cytochrome bd and anaerobic sis or low oxygen conditions.
Under unlimited aeration, where oxygen acts as the final electron 
acceptor, cytochrome c (including <3#j-type cytochrome c) is the main 
cytochrome utilized, with the less energy efficient cytochrome bd being 
under-expressed (Kana et al. 2001; Niebisch and Bott 2003). This was 
what was observed analysing the data regarding early aerobiosis, where 
cultures are growing without any stress (related to oxygen limitation or 
media nutrients limitation). Thus the ratios where cytochrome bd is the 
denominator are higher due to the lower expression of bd (Table 2.3.).
In the case of M smegmatis grown under nutrient starvation, the results 
presented do not show a clear trend towards any of the two pathways, 
meaning no cytochrome is preferred. Berney and Cook determined that in 
starvation conditions, both cytochrome aa3 and bd are under-expressed 
(Berney and Cook 2010). The data presented here (Fig. 2.5, G) do not 
allow inferences as to whether the cytochromes aa3 and bd are being 
under-expressed, but are in agreement with the work of Berney and 
Cook since no preference in expression of these two cytochromes was 
observed.
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A similar spectral analysis was performed with M, smegmatis by Kana 
and colleagues (Kana et al. 2001) and later on, the same principles 
(Weinstein et al. 2005) and whose conclusions are coincident with the 
data presented here.
Once the containment level III facilities became available, a similar 
spectral analysis work was considered. However, to study Mtb 
membranes in the spectrophotometer located in the general lab the cells 
would need to be previously killed, potentially damaging the proteins to 
be monitored. A possible way of doing it would be as Weinstein and 
colleagues by exposing Mtb to gamma radiation (Weinstein et al. 2005), 
something that could not be done due to technical difficulties. An attempt 
was made trying to kill Mtb using different concentrations of 
paraformaldehyde, but paraformaldehyde altered irreversibly the obtained 
spectra.
Drug susceptibility tests were performed on M. smegmatis using the five 
first line drugs currently used against TB: streptomycin, ethambutol, 
rifampicin, isoniazid and pyrazinamide using the MABA assay.
Some of these drugs are specific against all mycobacteria so a 
comparable result between Mtb and M. smegmatis could be expected. 
However, M smegmatis shows much lower sensitivity to the drugs than 
Mtb (Collins and Franzblau 1997), a statement that can be supported by 
the IC5o values obtained against Mtb in Chapter 3.
Altaf and colleagues assessed the efficacy of M, smegmatis as an in vitro 
model for the detection of possible inhibitory compounds against Mtb. 
Screening with a library of anti-mycobacterial compounds demonstrated 
that half of the compounds that were detected as active against Mtb were 
not detected using M smegmatis (Altaf et al. 2010).
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These arguments question the use of M smegmatis as a model for Mtb 
drug susceptibility testing. However the obtained results also differ from 
other published studies using the same strain of M smegmatis. While 
there are not many published IC50 results to compare with the ones 
obtained (Table 2.4.), they have been compiled in Table 2.5.
Table 2.5.: IC5o values of compounds tested against M. smegmatis me2 155 with 
their respective standard errors.
Compound ICsoOiM) SE (pM) References
Ethambutol 3.66 0.10 (Miller et al. 2009)
Rifampicin 4.36 0.49 (Miller et al. 2009)
Streptomycin 0.50 0.09 (Miller et al. 2009)
Isoniazid 7.80 0.60 (Delaine et al. 2010)
Although the assay could have been further replicated and optimized, by 
then the containment level III laboratories were already available at 
LSTM, M smegmatis was abandoned and the assay was carried out with 
just Mtb.
However, it is unlikely that the discrepancies between the published 
results and the ones obtained in this study are only due to assay 
limitations, since for two of the compounds (streptomycin and 
rifampicin) the results obtained are very similar to the ones in the 
literature (Miller et al. 2009). For ethambutol and isoniazid, the results 
obtained here (Fig. 2.6. and 2.9.) suggest that M smegmatis could be 
highly tolerant to these compounds, while the published M smegmatis 
drug susceptibility profile suggest drug sensitivity with both IC50 values 
less than 10 pM (Table 2.5.). The most probable explanation is that the 
culture of M. smegmatis could be composed of some highly tolerant
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individuals to both ethambutol and isoniazid. The existence of sub­
populations of bacilli that display different susceptibility to drugs in M. 
smegmatis cultures is known (Islam et al. 2012). In Mtb simultaneous 
resistance to these two compounds is often reported (Parsons et al. 2005),
In this chapter, a spectroscopic characterization of cytochrome 
components of M smegmatis was successfully established. The next step 
would be to test ETC inhibitors against the crude membranes, in order to 
compare the alterations in the spectra, as done in Kana et al. 2001 and 
Weinstein et al. 2005. The analyses of the spectra using different 
inhibitors could show differences in relation to the expected cytochrome 
patterns, which would be indicative of the target and mode of action of 
the inhibitors under different growth conditions (Weinstein et al. 2005).
In summary, these data indicate that M smegmatis is a convenient model 
to study the effect of inhibitors on ETC components due to the ease in 
which difference spectra can be obtained. However, the significant 
difference in the sensitivity of M smegmatis to first line drugs renders 
this model unsuitable for whole-cell sensitivity testing in either 
replicating or slow-growing models.
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Chapter 3. Drug susceptibility of Mycobacterium 
tuberculosis, using the MABA
3.1. Introduction
In this section, different compounds currently used in TB treatment and 
some promising new drug candidates, specifically targeting the ETC, 
namely phenothiazines will be tested, using the Microplate AlamarBlue® 
assay (MABA). As outlined in the general introduction, inhibitors of the 
mycobacterial electron transport chain could be a promising new class of 
anti-tuberculosis drugs.
3.1.1. Brief description of different drug susceptibility tests used for 
M. tuberculosis
One of the biggest problems in terms of the study of Mtb is the lack of 
truly standardised procedures and the lack of directives as to how to 
present data (Simons and Soolingen 2011). Even when similar 
methodologies are used, the results are not always comparable.
Below is a brief overview of the most common used methods to study 
Mtb drug susceptibility. Throughout the work presented in this thesis, the 
MABA assay was used.
3.I.I.I. Microdilution and proportion methods
The microdilution and proportion methods serve as the basic reference 
for all the current susceptibility tests (Canetti et al. 1963). They consist of 
incubating either in liquid (microdilution) or solid (proportion) media, a 
constant volume of Mtb inoculum, with different concentrations of a
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compound to test. At the time necessary to quantify visible bacterial 
growth, a comparison is made between bacterial number in the presence 
of different concentrations of drug and the controls (where bacteria grow 
in identical medium without addition of the inhibitory compound). This 
assessment of the numbers is made directly, either by colony counting (in 
the case of solid media growth) or by simple fluorimetric absorbance 
measurements.
The advantages of the use of these methods are that they are reliable, they 
allow multiple-drug testing at different concentrations and they can be 
used with a variety of conditions. The disadvantages are the long duration 
of the experimentation required to assess visible growth in Mtb cultures. 
In addition, the number of plates needed to generate conclusions and to 
perform drug combination testing is prohibitive (Wallace Jr. et al. 1986).
3.1.1.2. Microplate AlamarBlue® assay (MABA)
AlamarBlue®, the commercial name for resazurin is a soluble, non-toxic, 
blue and non-fluorescent dye that is reduced to resorufin turning pink and 
fluorescent. Cell growth leads to the reduction of growth medium and this 
colour change can be assessed by direct visualisation or using 
fluorometer or spectrophotometer readers (O'Brien et al. 2000). MABA is 
a simple, rapid and reliable method. A number of studies confirm the 
efficacy of this method over the ones obtained using proportion methods 
(Yajko et al. 1995; Collins and Franzblau 1997; Franzblau et al. 1998; 
Palomino and Portaels 1999). MABA can be used not only to test drugs 
against mycobacteria grown in a nutrient medium, but can also assess the 
effects of these drugs in mycobacteria-infected cells (Hartkoorn et al. 
2007). As it is fairly inexpensive and does not need complex detector 
devices, it can be performed in developing countries (Franzblau et al. 
1998).
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A major criticism of the method is that data generated from it are often 
irreproducible (Leonard et al. 2008). The assay results need to be 
carefully analysed and extensively repeated in order to obtain valid 
conclusions.
3.I.I.3. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) assay
The MTT assay is a low-cost method used to check cytotoxicity. MTT is 
a yellow tetrazolium salt that is converted into blue formazan by 
succinate dehydrogenase of a live cell (Mossman 1983; Abate et al. 
2004). The assumption made is that the quantity of formazan is directly 
proportional to the number of living cells in the media. The formazan 
precipitate is then dissolved by the detergent sodium dodecyl sulphate 
(SDS) and the absorbance is read in a fluorimetric detector. The 
advantages of this colorimetric method are its simplicity and affordability 
to be used for routine cytotoxicity diagnosis in resource-limited countries. 
MTT is particularly useful as a diagnostic tool for detection of Mtb and 
even subpopulations of resistant strains. It can be used as a simple assay 
to evaluate the activity of antimicrobial compounds. However, it is 
difficult to standardise the method for all drugs. For example, isoniazid is 
known to interfere with the normal reduction of MTT, resulting in 
misleading results (Abate et al. 1998).
3.1.1.4. BACTEC radiometric method
The BACTEC radiometric method was introduced in 1977 and 
revolutionised the conventional methods of Mtb detection (Roberts et al. 
1983). The average detection time for Mtb positive cultures was reduced 
from 25-30 days to 4-10 days.
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The BACTEC tubes contain Middlebrook 7H12 broth containing a 14C- 
radio-labeled substrate, palmitate. The viable bacteria use this carbon 
source, releasing 14C02 that is detected by an ionic sensor of the 
BACTEC instrument (Roberts et al. 1983). Drug susceptibility testing 
can be done comparing the radioactive counts in the test tubes with the 
ones in control tubes with no added drugs.
The major benefit of the use of this radiometric method is that it reduces 
the duration of the experiment. Compared to the conventional plating 
methods, besides being rapid, this method is easily standardized and it is 
reproducible between different research groups. It can also be easily 
adapted to study latent Mtb (Kharatmal et al. 2009).The major 
disadvantage of BACTEC is the fact that the researcher will be dealing 
with radioactivity with all the handling and radioisotope disposal charges 
that it carries (Collins and Franzblau 1997).
3.1.1.5. Nitrate reductase assay
The nitrate reductase assay (NRA) uses the ability of live Mtb to reduce 
nitrate to nitrite. The Mtb cells are incubated in a medium with potassium 
nitrate (KN03) and the drugs to test (Angeby et al. 2002; Lemus et al. 
2006). After incubation the presence of nitrite can be detected when there 
was growth of the colonies, using a mixture of 50% concentrated 
hydrochloric acid, 0.2% sulphanilamide and 0.1% «-(l-
naphtyl)ethylenediamide dihydrochloride, due to colour change of the 
media. This method is inexpensive and it allows faster results than the 
direct visualization of growing colonies. However, nitrite can be further 
reduced to nitrite oxide, and this compound is not detected in the NRA, 
causing false negative results (Angeby et al. 2002).
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3.1.1.6. Low-Oxygen-Recovery assay
The Low-Oxygen-Recovery assay (LORA) is used in studies of drug 
tolerance using bacilli in the non-replicating persistent state (Cho et al. 
2007). The cells are cultured for extended periods of time under 
controlled conditions of limited aeration and then allowed to "recover" 
for 28 hours under aerobic conditions, before being either counted by 
direct plate counting or the absorbance of the culture suspensions 
assessed using a spectrophotometer (Cho et al. 2007). The aerobic 
recovery time is determined by the amount of time necessary to detect 
growth in drug-free control cultures.
3.1.1.7, MB/BacT
The MB/BacT method was developed by Organon Teknica corp. and it is 
considered accurate, rapid and does not require the use of radioactivity. 
MB/BacT bottles contain a non-selective growth media and after 
incubation with Mtb, the C02 released by growing bacteria is detected 
through a colorimetric sensor. The MB/BacT detection system recognises 
positive growth when there is a change in this colorimetric indicator 
(Piersimoni et al. 2001).
The method is fully automated, reducing the need for constant monitoring 
and making it ideal to process a large amount of cases (Dfaz-Infantes et 
al. 2000). It allows the study of drug susceptible Mtb but also resistant 
Mtb (Dfaz-Infantes et al. 2000; Piersimoni et al. 2006). Despite being a 
rapid and easy method, MB/BacT requires heavy investments in 
equipment and running costs (Mueller et al. 2008).
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3.I.I.8. Mycobacterium Growth Indicator Tube method (MGIT)
The MGIT is a rapid and non-radiometric system of culture, detection 
and recovery of Mtb and in parallel with MB/BacT system, represented a 
step forward in the isolation of mycobacteria from clinical samples. The 
MGIT consists of a tube filled with an enriched media with a fluorescent 
indicator at the bottom. This indicator is quenched in the presence of the 
medium with oxygen. By using a transluminator with UV light, the tubes 
that have viable organisms can be identified due to the consumption of 
oxygen by live organisms, allowing the fluorescence to be detected. Drug 
susceptibility testing can be performed comparing the fluorescence in the 
test tubes with the fluorescence of control tubes with no added drugs 
(Walters and Hanna 1996).
3.2. Methods
3.2.1. General considerations regarding Mtb culturing
Mtb is classed as hazard group 3 by the Advisory Committee on 
Dangerous Pathogens (ACDP) and therefore all work involving 
manipulation of specimens and culture material was carried out within a 
Nuaire Labguard Class II biological safety cabinet (Nuaire, USA) within 
a Containment Level 3 laboratory.
All media and reagents were sterilised by autoclaving or filtration 
through a 0.22pm pore syringe filter (Gelman Sciences, UK).
Inside the incubator and during transport from the incubator to the safety 
cabinet, Mtb cultures were safely contained inside a Bio Transport™ 
Carrier box (Nalgene®, USA).
5% (v/v) Surfanios (Anios lab, France) was used throughout as 
disinfectant due to its superior ability to sterilise mycobacteria. All waste
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generated was autoclaved and liquid waste was immersed in a solution of 
5% (v/v) of Surfanios prior to being autoclaved.
Some of the standard procedures used throughout the lab work involving 
Mtb were adapted from a compilation of Mtb protocols (Parish and 
Stoker 2001).
3.2.2. Mtb strain and growth media
Mtb strain H37Rv (ATCC#25618) was grown in Middlebrook 7H9 
Broth (BD Diagnostic, UK) enriched with 0.2% (v/v) glycerol, 0.05% 
(v/v) Tween® 80 and 10% (v/v) OADC, in Middlebrook 7H11 Agar 
plates supplemented with 0.2% (v/v) glycerol and 10% (v/v) OADC and 
Lbwenstein-Jensen slopes (BD Diagnostic, UK) depending on the 
experiment. OADC is an enrichment supplement composed of oleic acid, 
albumin, dextrose and catalase, which are essential for mycobacterial 
growth.
3.2.3. Storage of Mtb stocks
The continuous sub-culture of Mtb in solid or liquid medium was avoided 
since during prolonged in vitro culture mutations occur frequently (David 
1970). In addition cultures were kept as a backup measure in the case of 
contamination of the initial stock. The storage medium consisted of 0.47g 
Middlebrook 7H9 Broth powder supplemented with 10ml OADC, 20ml 
glycerol and 70ml ddHaO. This solution was sterilized through a 0.22|um 
pore filter and stored at 4°C for up to 4 months.
The Mtb suspension to be frozen was grown until it reached the turbidity 
of a McFarland standard number 2, that corresponds to 6xl08 CFU/ml
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(see Section 3.2.5.). 250j.il aliquots of cell culture were added to an equal 
volume of storage medium and stored immediately at -20°C.
3.2.4. Culturing Mtb from frozen stocks
A vial containing 500jd of frozen Mtb was retrieved from the -20°C 
freezer, and allowed to defrost at room temperature. 50pl of the Mtb 
stock was inoculated directly into 10ml of Middlebrook 7H9 Broth and 
incubated at 37°C in a 5% C02 HERACell 150 C02 incubator (Thermo 
Scientific, UK).
From the same vial, a pre-warmed Lowenstein-Jensen slope was 
inoculated using a lOpl disposable loop (NUNC, UK).
After 2-3 weeks growth, using a 10pi disposable loop an isolated Mtb 
colony was transferred from the slope to a 50ml Falcon tube containing 
10ml of Middlebrook 7H9 Broth. The culture was vortexed and 
subsequently incubated for a minimum of 2 weeks before use. Slopes 
were incubated for up to 4 months, functioning as a cell reservoir and the 
visual verification that cell stocks were not contaminated.
Any cells remaining in the defrosted vial were not returned to storage but 
were instead discarded in 5% (v/v) Surfanios.
3.2.5. Quantification of viable Mtb in liquid culture using McFarland 
Equivalence Turbidity Standards
The McFarland standards are commercially available from Pro-Lab (Pro- 
Lab Diagnostics, UK). Standards can be prepared using different 
combinations of barium chloride (BaCl2) and sulphuric acid (H2S04) but 
a mixture of water and latex beads which is commercially available is
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more stable and reliable (Zamora and Perez-Gracia 2012). When the 
turbidity of an unknown sample is adjusted to match the turbidity of the 
McFarland standard, it produces predictable bacterial counts (McFarland 
1907).
The number of bacteria in a suspension was estimated from the standard 
curve obtained from a plot of the ODgoo of the McFarland standard 
against the number of bacteria equivalent to that standard.
3.2.6. Confirmation of the number of viable Mtb by colony counting
To confirm the validity of the McFarland Equivalence Turbidity 
Standards as a method to assess bacterial numbers, direct counting of 
visible colonies in Petri dishes was performed.
An 800pl aliquot of Mtb culture was placed in a disposable cuvette and 
the ODeoo measured and recorded as previously described (Section 
2.2.2.1.). A second aliquot of 200pl from the same culture was placed in 
a sterile Eppendorf and serially diluted with sterile lOmM PBS, pH 7.2 in 
a range between 1 to 103 and 1 to 109. The dilutions were thoroughly 
mixed by vortexing to ensure homogeneity, followed by the spread of 
lOOpl of each of these cultures onto Petri dishes containing 20ml of 
Middlebrook 7H10 Agar, supplemented with 10% (v/v) OADC, 0.05% 
(v/v) and 0.2% (v/v) glycerol.
Plates were bagged, boxed and incubated at 37°C, 5% C02 for 3 weeks, 
until visible colonies appeared. Plates presenting 50-100 organisms were 
selected and counted.
The number of bacteria in the original sample corresponds to the number 
of bacteria counted in the plate multiplied by the dilution factor used. 
Finally, this value was compared to the number of bacteria predicted
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using the McFarland spectrophotometer procedure described above (see 
Section 3.2.5.) to confirm the validity of the assay.
3.2.7. Mtb growth curves and generation time
In order to plot growth curves for Mtb cultures, the culture turbidity was 
monitored twice weekly at 600nm using a WPA CO 8000 Biowave cell 
density meter (Biochrom, UK).
The generation time, defined as the time for Mtb cells to double in 
number, was assessed by plotting a curve of time versus calculated 
colony forming units (CFU), obtained from the OD6oo of the culture (see 
Section 3.2.5.). CFU were expressed as the number of viable cells/ml.
3.2.7.I. pH dependent growth of Mtb
In order to identify the optimal pH for the growth of Mtb and to 
characterise Mtb growth under different pH ranges, the growth medium 
(Middlebrook 7H9 Broth enriched with 0.2% (v/v) glycerol, 0.05% (v/v) 
Tween® 80 and 10% (v/v) OADC) was modified, adding KOH and KC1 
to adjust the solution to a range of pH: 4.5; 5.6; 6.5; 7.4 and 8.3.
Mtb curves were plotted against time, according to section 3.2.7..
3.2.8. Sterilisation of Mtb cells
To ensure the safety of the assays performed and that the sterilisation 
methods used to kill Mtb were effective, cultures were diluted to a 
McFarland standard number 1 (see Section 3.2.5.) in Middlebrook 7H9 
Broth and incubated with lOOpl paraformaldehyde at 8 different
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concentrations (0%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 5%, and 10% (v/v) 
paraformaldehyde diluted in ddH20). After 2h incubation at 37°C lOOpl 
of the cell suspension were plated on Middlebrook 7H11 Agar plates. 
The plates were incubated for 4 weeks at 37°C before scoring the colony 
growth as culture positive or negative.
3.2.9. Mtb growth conditions
Assuring the same provenance of bacteria, a 2 week culture of Mtb at 
OD6oo~0.9 was selected and used throughout this experiment, being sub­
cultured according to one of the methods stated in Section 3.2.9.1-4, 
depending on the endpoint being investigated.
3.2.9.I. Preparation of Mtb aerobic cultures
50pl of Mtb inoculum were transferred to a 50ml Falcon tube containing 
10ml of Middlebrook 7H9 sterile Broth, supplemented with 0.2% (v/v) 
glycerol, 0.05% (v/v) Tween® 80 and 10% (v/v) OADC. The culture was 
vortexed and incubated for a minimum of 2 weeks at 37°C in a 5% C02 
incubator before use. The turbidity of the culture was monitored until it 
stabilized (see Section 3.2.7.) and discarded when 3 months old.
3.2.9.2. Hypoxia model of growth: cultures grown in limited oxygen 
conditions
The model used for Mtb growth was an adaptation of the Wayne model 
of growth (Wayne and Hayes 1996).
For growth under limited aeration which results in the creation of a 
microaerophilic environment, 3 75pi of the log-exponential phase Mtb
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were cultured in 50ml Falcon tubes containing 37.5ml of Middlebrook 
7H9 Broth. Each tube contained a Polytetrafluoroethylene-coated (PTFE- 
coated) magnetic stirring bar (VWR International, UK) with 8 x 5mm 
dimensions that were autoclaved before use.
Two 50ml flasks were used to monitor the growth of the culture. Rubber 
skirted stoppers (VWR International, UK) were used to limit oxygen 
supply to the cultures. To ensure anaerobic conditions the opening was 
further sealed with Parafilm® (Pechiney Plastic Packaging Company, 
USA). At selected times, the syringe was inserted into the sealed flasks 
through the rubber stopper and an aliquot of culture was collected and its 
turbidity determined in the portable WPA CO 8000 Biowave cell density 
meter (Biochrom, UK).
Thereafter, 20pl of this suspension were diluted 1:1 xlO5 and TUIO7 in 
sterile broth and inoculated in Lowenstein-Jensen slopes to assess the 
time when the number of viable bacteria stabilised.
In one 50ml flask, a stock sterile solution of methylene blue (500pg/ml 
solubilised in ddlUO) was added to a final concentration of 1.5pg/ml. 
The reduction-associated decolonization of this dye was used as a visual 
indicator of oxygen depletion (Wayne and Hayes 1996). Cultures were 
incubated in a 5% C02 incubator at 37°C, stirring at 160rpm on a Biostir 
4 magnetic stirrer (Wheaton Industries Inc, USA).
3.2.9.3. Preparation of Mtb cultures grown in fatty acid rich media
50jj,l of Mtb inoculum were transferred to a 50ml Falcon tube containing 
10ml of fatty acid rich media.
The preparation of the fatty acid rich medium was adapted from 
Schnappinger and colleagues (Schnappinger et al. 2003) and consisted of 
minimal media supplemented with a saturated fatty acid. Media was
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prepared by adding 0.5g asparagine, Ig KH2PO4, 2.5g Na2P04, lOmg 
MgS04-7H205 50mg ferric ammonium citrate, 0.5mg CaCl2, O.lmg 
ZnS04 and 0.5ml Tween® 80. 0.2% (w/v) sodium palmitate was 
dissolved in ddf^O at 50°C and added to the media at a final 
concentration of 0.05mM. The final volume was adjusted to 1 litre using 
ddH^O. The solution was filtered through a 0.22pm pore syringe filter 
and the pH adjusted to 6.6.
The culture was mixed by vortexing and incubated at 37°C in a 5% C02 
incubator. The turbidity of the culture was monitored up to 3 months and 
after this time, the culture was discarded.
3.2.9.4. Preparation of Mtb cultures grown under nutrient starvation
50pl of Mtb inoculum were transferred to a 50ml Falcon tube containing 
10ml of sterile PBS pH 6.5. The culture was vortexed and incubated at 
37°C in a 5% C02 incubator for 3 months. The preparation of Mtb 
starved cultures was based on the method described by Betts et al. 2002.
3.2.10. In vitro Mtb drug sensitivity assays using the microplate 
alamarBlue® assay (MABA)
The MABA involved the addition of alamarBlue® solution to a 96-well 
microplate containing varying concentrations of test compounds and 
cultures of Mtb, strain H37Rv. After the incubation period the growth of 
Mtb was observed as a change in the colouration of the alamarBlue® 
solution. The methodology was previously described for M smegmatis in 
Section 2.2.3 but it is described here in more detail with reference to Mtb.
The setting of the plate (see Section 3.2.10.4. and Fig. 3.1.) included 
drug-free controls, representing the undisturbed growth of the Mtb cells.
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The control wells will have 100% growth and all the test wells were 
compared to this value in order to obtain a percentage of growth.
The setting of the plate also included Mtb-free controls which allowed 
the correction of the final results, subtracting the absorbance of the 
background (drug, media, alamarBlue® and paraformaldehyde) against 
the test wells, in order to obtain just the absorbance related to the Mtb 
growth.
3.2.10.1. Determination of the optimum cell density for the sensitivity 
of the assay
To identify the optimal cell concentration to use for the determination of 
the IC5o values, cells were serially diluted in complete nutrient broth and 
incubated overnight at 37°C with 20pl alamarBlue®. The reaction was 
terminated by addition of 100pi of 10% (v/v) paraformaldehyde to every 
well followed by an incubation period of 2h. The sterilised plates were 
read using a plate reader at 570nm. The concentration of cells was plotted 
versus the absorbance signal to identify the range of optimal cell density 
to use in the assay, corresponding to the linearity of the correlation.
3.2.10.2. Preparation of Mtb inoculums used in MABA
A constant bacterial density was used throughout all experiments. An 
Mtb culture, either grown under aerobic or anaerobic conditions (as 
described in Section 3.2.9.I. and 3.2.9.2.), was diluted to the turbidity of 
a McFarland Standard number 1 (i.e. corresponding to a bacterial 
concentration of 3xl08 CFU/ml). This solution was further diluted 1:30, 
to obtain a final concentration of 1 x 107 CFU/ml. Dilutions were made 
using complete Middlebrook 7H9 Broth.
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3.2.10.3. Preparation of drug dilutions used in MABA
All compounds tested were dissolved either in DMSO, ethanol, methanol, 
or ddtkO (Table 3.1.). DMSO, ethanol and methanol were of analytical 
grade (>99.5% purity), were not further diluted and are commercially 
available (Sigma, USA). lOmM stock solutions were prepared and 
sterilised through a 0.22jLim pore filter and stored at -20°C.
1 in 3 serial dilutions of the initial lOmM stocks were prepared using 
Middlebrook 7H9 Broth enriched with 0.2% (v/v) glycerol, 0.05% (v/v) 
Tween 80 and 10% (v/v) OADC. For each compound eight serial 
dilutions were made. All dilutions were freshly prepared at double the 
required final well concentration to allow for further dilution in the test 
wells with Middlebrook 7H9 Broth and to ensure compound degradation 
was not a factor affecting data.
Table 3.1.: Details of compounds tested against Mtb strain H37Rv using an in vitro 
microplate alamarBlue assay (MABA). The table presents the name, molecular 
weight and solvents used to dissolve each drug used in the MABA bioassay.
Compound Molecular Weight Solvent
Chlorpromazine hydrochloride 355.33 DMSO
cw-(z)-Flupenthixol dihydrochloride 507.44 DMSO
Ethambutol dihydrochloride 277.23 dH20
Fluphenazine dihydrochloride 510.44 DMSO
Isoniazid 137.14 dH20
Metronidazole 171.15 DMSO
Perphenazine 403.97 DMSO
Phenothiazine 199.27 DMSO
Promazine hydrochloride 320.88 DMSO
Promethazine hydrochloride 320.88 DMSO
Pyrazinamide 123.11 dH20
Rifampicin 822.94 Ethanol
Streptomycin sulphate salt 728.69 dH20
Thioridazine hydrochloride 407.04 Methanol
Trifluoperazine dihydrochloride 480.42 Methanol
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3.2.10.4. Preparation of the 96-well microplate for the Mtb MABA
The assay was performed in sterile 96-well microtitre flat bottom plates 
(NUNC, UK). 200|nl of ddHaO were added to the wells at the perimeter 
of the microplate in order to minimize evaporation of medium in test 
wells during incubation (see Fig. 3.1. for plate format).
50pl of broth were plated in row C (columns 2 to 11) and in columns 6 
and 11 (rows D, E and F). 50j.il of each pre-prepared drug dilution were 
added into columns 2, 3, 4, 5, 7, 8, 9 and 10. The concentration of drug 
decreased from left to right, with column 2 containing the highest drug 
concentration and column 10 the lowest drug concentration. Finally, 
50|xl of Mtb inoculum was added in rows D, E and F (2 to 11).
Wells in columns 6 and 11 (rows D, E and F) were free-drug controls 
containing 50pl of broth and 50j.il of bacteria inoculum. Wells in row C 
(2 to 11) were Mtb -free wells, acting as blanks containing 50pl of broth 
and 50|il of the respective drug dilution. The other wells were test wells 
with bacteria and varying concentrations of the test compounds.
Each plate was then bagged, placed inside a sealed protective box and 
transferred to a 5% CO2 incubator.
3.2.10.5. Addition of alamarBlue® to MABA
After 7 days incubation at 37°C, 20j.il of alamarBlue® was added to each 
well and the plates returned to the incubator.
After 24h, plates were sterilised by adding lOOjal of 10% (v/v) 
paraformaldehyde to each well. The solution of 10% (v/v) was freshly 
prepared on the day of the experiment, from a commercially available 
37% (v/v) stock solution from Sigma. 27ml of the stock solution were
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diluted in 73ml ddH20) and filtered through a 0.22fj.m pore filter to 
eliminate particles that could affect the photometric reading of the plate.
After a minimum of 2h, plates were wiped thoroughly with 5% (v/v) 
Surfanios and read using an Opsys MR™ Microplate Reader (Dynex 
Technologies, USA) at an absorbance of 570nm.
1 2 3 4 5 6 7 8 9 10 11 12
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Fig. 3.1.: Representative 96 well microplate format for screening drug 
susceptibility of Mtb to various compounds using MABA. • represents wells 
containing 200pl of ddH20, ® corresponds to wells containing 50pl broth and 50pl 
drug dilution, <Z> contained lOOpl of broth, (3) were wells containing 50pl broth and 
50pl Mtb inoculums and O were wells containing 50pl drug dilutions and 50pl of 
Mtb cells.
3.2.10.6. Time-dependent effects of test compounds on Mtb growth
In order to assess if the exposure time to the drug affected its ability to 
inhibit the growth of Mtb, the bioassay included some modifications. 
Here, three 96-well plates were set up. After the usual 7 days of 
incubation, alamarBlue^ was added to each well of one of the plates and 
the plate returned to the incubator and the assay processed as described in 
Section 3.2.10.5. To the second of the plates, alamarBlue^ was added
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after 14 days of incubation and to the third plate, alamarBlue® was added 
after 21 days of incubation with the test compounds.
3,2.10.7. Modification of MABA in order to test the susceptibility of 
Mtb growing under micro-aerophillic conditions
In order to test the drug susceptibility of Mtb grown under micro- 
aerophillic conditions, the bioassay used included some modifications. 
The format of the 96-well plate was maintained, but after plate 
preparation, it was placed inside an anaerobic bag with an Aerocult IS 
sachet (Merck, Germany) that was humidified with 8ml ddH20 in order 
to produce the necessary anaerobic environment. The bag, part of the 
Aerocult IS kit was sealed with a thermal sealer and incubated in a 5% 
CO2 incubator at 37°C.
After 7 days, the plate was removed from the anaerobic conditions and 
placed inside a zipped bag and returned to the incubator.
After further 7 days incubation, the assay was terminated as described in 
Section 3.2.10.5.
3.2.10.8. Data analysis of drug susceptibility testing
The results of drug susceptibility testing were presented in terms of the 
efficacy of each drug in inhibiting the growth of Mtb.
Graphs were generated plotting the concentration of drug against the 
percentage of growth of the bacteria in the test wells. This percentage 
was calculated assuming 100% growth in control wells without any 
inhibitor.
106
The IC50 (half maximal inhibitory concentration) refers to the 
concentration of drug which causes 50% inhibition of growth. The IC90 
(90% inhibitory concentration) refers to the concentration of drug which 
causes inhibition of 90% of microbial growth.
A data report was generated using the Revelation QuickLink™ 1.0 
software (Dynex Technologies, USA), from the data obtained with the 
plate reader, A dose versus response graph was plotted using GraphPad 
Prism version 5.00 for Windows (GraphPad Software, USA), with the 
respective number of replicates. The software allowed the inference of 
both IC50 and IC90 from a generated log-dose response sigmoid curve that 
was constrained between 0 and 100% and the standard errors associated 
with this inference.
3.2.11. Drug combination assay
In order to assess the effect of some of the drugs used in combination, a 
modification of the method of Berenbaum (Berenbaum 1978) was used.
The IC50 values of each drug to be tested in combination were determined 
alone and these values were used to prepare two individual working drug 
solutions with a concentration sixteen times the IC50 of the drug being 
tested.
Thereafter, these prepared drug solutions were combined in fixed ratio 
combinations of 10:0, 9:1, 7:3, 5:5, 3:7, 1:9 and 0:10. Each combination 
was then serially diluted 8 times before being tested against Mtb as 
described above.
With the data from the plate reader the IC50 for each drug combination 
was determined and used to calculate the 50% fractional inhibitory
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concentration (FIC) for each compound, at each of the ratios, according 
to the formulae below.
FICdrug a = (IC50 of drug A in combination/ICso of drug A alone)
FICdmgB = (IC50 of drug B in combination/ICso of drug B alone)
Using these interaction coefficients it was possible to draw an 
isobologram of FICdmgA versus FICdrugb (Fig. 3.2.).
The sum of FICdrug a and FICdrug b determines whether the combined 
bacteriostatic effect of the two drugs tested was synergistic, additive or 
antagonistic. When the sum equals 1.0 the isobologram represents an 
additive effect, when the sum is less than 1.0 the isobologram represents 
a trend toward a synergistic effect and when the sum is higher than 1.0 it 
represents a trend towards an antagonistic effect (Fig. 3.2.).
Antagonistic 
*__effect
Additive 
v effect
^ 0.5-
Synergistic 
V effect
drug A
Fig. 3.2.: Classical isobologram and chemical interaction between compounds A 
and B. Adapted from Tallarida 2006.
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3.2.12. Specimen collection and preparation of slides for Mtb staining
Mtb strain H37Rv grown under unlimited aeration or microaerophillic 
conditions (Section 3.2.9.1. and 3.2.9.2.) were harvested by 
centrifugation at 3000g’ for 10 minutes. The supernatant was discarded 
and the pellet resuspended in sterile PBS, pH 7.4. Thin and uniform 
smears were prepared on clean black oval slides with CELL-BOND 
coating (Alpha-Tec systems, USA) using lOpl of the resuspended cells. 
Slides were fixed by heating at 65-70°C for 10 minutes on a heat block 
placed inside an appropriate biological safety cabinet. Slides were 
allowed to cool before being transferred to a staining rack.
3.2.12.1. Dyes and reagents used for staining Mtb
Auramine phenol and potassium permanganate are commercially 
available from ProLab (Pro-Lab Diagnostics, USA) and were prepared 
according to the manufacturer instructions. Briefly, the reagents were 
diluted 1 in 10 in ddH20 and stored at room temperature in the dark.
Nile Red was dissolved in absolute ethanol to create a stock 
concentration of 0.5mg/ml. It was stored at -20°C and further diluted 
1:50 in ethanol to obtain a working solution of 0.1 pg/ml as required.
Differentiator solution consisted of 1% (v/v) hydrochloric acid and 75% 
(v/v) absolute ethanol in ddH20.
3.2.12.2. Staining procedure
For auramine phenol staining of Mtb, slides were flooded with the 
fluorescent stain, left to stand for 10 minutes and then rinsed with ddH20. 
Slides were then flooded with differentiator solution (1% hydrochloric 
acid: methanol: dH20) for 10 minutes, rinsed a second time with ddH2D,
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flooded with 0.1% (w/v) potassium permanganate for 45 seconds and 
finally rinsed again with ddH^O before being air dried.
The Nile Red staining method included an extra step compared to the 
Auramine phenol method. Briefly, slides were flooded with auramine 
phenol and left to stand for 10 minutes before the stain was rinsed with 
ddH20. Slides were then flooded with differentiator solution for 10 
minutes, rinsed with ddH2Oand flooded with freshly prepared Nile Red 
solution for 10 minutes. The slides were then rinsed with ddH20, flooded 
with 0.1% (w/v) potassium permanganate for 45 seconds and rinsed again 
with ddH20 before being air dried.
Air dried slides were mounted in 100pl of sterile PBS, a coverslip was 
placed on top of the smears and the slides sealed using nail polish. Slides 
were kept in darkness and examined immediately by fluorescence oil 
immersion microscopy using a wide blue (> 525 nm) long-pass filter at 
an amplification of lOOx. Images were captured using a camera fitted to 
the fluorescence microscope.
3.3. Results
3.3.1. Patterns of Mtb growth when submitted to different conditions
Mtb bacilli grown from the same batch were submitted to different 
growth conditions and their growth monitored by a change in turbidity of 
the liquid media, in an optical density meter.
As expected, Mtb grows optimally in conditions of unlimited aeration 
(Fig. 3.3.- blue line). Around day 5, there is exponential growth of 
bacteria. Around day 23 there is a stabilisation of the numbers, the 
bacteria reach a stationaiy phase.
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Submitting the cultures to severe hypoxia, mimicking the environment 
that exists inside the granuloma involves the gradual depletion of oxygen 
from the culture. The bacteria present a distinctive three-stage optical 
curve of growth (Fig. 3.3.- red line). In Fig. 3.4. this curve is presented in 
detail. For the first 8-9 days, there is sufficient oxygen in the media to 
support exponential growth. Then for 10-11 days there is a shift into 
microaerobic NRP-1 stage, where there is a continuous slow rise in OD 
due to cell enlargement, but not cell number (this was expected and 
confirmed by plating Mtb at day 15, 18 and 20 and obtaining a similar 
number of bacteria despite the increase in OD) (Wayne and Sohaskey 
2001). From day 20 the bacteria shift to NRP-2, the culture becomes 
anaerobic and there is no further cell enlargement (Fig. 3.4.). This curve 
pattern is characteristic of the slow stirring model of Mtb hypoxic growth 
(Wayne and Sohaskey 2001). Cell enlargement of Mtb cells grown 
anaerobically is shown in Fig. 3.58.B and Fig. 3.59.A-D.
The cells grown in a fatty acid rich media had a small exponential growth 
phase followed by the stabilisation of the number of mycobacteria (Fig. 
3.3.- green line). Mycobacterium has fatty acid as its major nutrient 
source of energy inside granulomas in vivo, so instead of glucose and 
glycerol they use exclusively fatty acids as carbon sources of energy 
(McKinney et al. 2000; Schnappinger et al. 2003; Niederweis 2008). Mtb 
cells were able to subsist in the fatty acid rich medium but their growth 
was very limited.
The cells grown in a minimal medium (Fig. 3.3.- pink line), without 
carbon sources of energy showed very limited growth.
To confirm that viable bacteria remained in all the differently grown 
batches, bacteria were subcultured in Ldwenstein-Jensen slopes and their 
viability confirmed visually after 3 weeks.
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Fig. 3.3.: Typical growth curves of Mtb cultures grown under different conditions. 
( _, blue line) corresponds to cultures grown under conditions of unlimited oxygen 
supply, (_, red line) represents the cultures grown under limited aeration 
conditions, in ( _, green line) the bacterial cells were grown in a fatty acid rich 
media and in (_, pink line) the cells were deprived of a carbon source of energy. 
The data shown are the averages and standard deviations of 6 replicates. Cross- 
section indicates the anaerobic growth region to be analysed in detail in Fig. 3.4..
NRP-2
NRP-1
Exponential
growth
Time (days)
Fig. 3.4.: Detail of the growth curve of Mtb grown anaerobically, red line from Fig. 
3.3.. There was a gradual depletion of oxygen from the culture and the bacteria 
present a distinctive three-stage optical curve of growth. An initial exponential 
growth phase followed by two phases of non-replicative persistence (NRP), where 
there is no increase in the numbers of bacteria, just a small increase in the optical 
densities and then the stabilisation of the numbers. The data shown are the 
averages and standard deviations of 6 replicates.
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3.3.1.1. pH dependence of growth of Mtb
In terms of acidity/alkalinity of the medium, Mtb bacilli grow optimally 
at a strict pH range. The ideal pH is 6.5. (Fig. 3.5.- green line) if the pH 
was a little higher (pH7.4) the growth is impaired but possible (Fig. 3.5.- 
pink line). At alkaline pH of 8.3 (Fig. 3.5.- black line) or acidic pH of 4.5 
(Fig. 3.5.- red line) or 5.6 (Fig. 3.5.- blue line), the growth is reduced to a 
minimum.
Time (days)
Fig. 3.5.: Typical growth curves of Mtb cultures grown under different pH 
conditions. ( _, red line) corresponds to cultures grown at the acidic pH of 4.5, (_, 
blue line) represents the cultures grown at pH 5.6, in ( _, green line) the pH was 
6.5 and this correspond to the pH of Middlebrook broth, in (_, pink line) the 
cultures were grown at pH 7.4 and (_, black line) represents the cultures grown at 
alkaline pH of 8.3. The data shown are the averages and standard deviations of 6 
replicates.
3.3.2. Quantification of bacterial numbers and sterilisation of Mtb
In order to quantify the number of bacteria in a suspension and to 
standardize the quantity of bacteria used per experiment, McFarland 
standards were used. Fig. 3.6. shows the standard curve of Mtb using the 
McFarland standards, which allows for the estimation of the number of 
bacteria in a given bacterial suspension.
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Bacterial concentration (Million CFU/ml)
Fig. 3.6.: Linear correlation between the OD60oand the bacterial concentration of a 
sample. The right side Y-axis indicates the number of the McFarland standard 
used to obtain this calibration curve. The obtained linear relation was bacterial 
concentration (MCFU/ml) = OD60o /(0.0009410 ± 0.00001962). Each datapoint was 
obtained from three different bacterial suspensions.
To assess the bactericidal power of the decontamination agent, 
paraformaldehyde, a simple assay was performed and Fig. 3.7. shows the 
data obtained. Paraformaldehyde caused a concentration dependent 
decrease in the viability of Mtb, with 1% (v/v) causing total loss of 
viability.
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Fig. 3.7.: M. tuberculosis strain H37Rv viability after 2h exposure to different 
concentrations of paraformaldehyde.
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3.3.3. Drug testing of various compounds against Mtb under no 
aeration limitations
The following graphs display the results obtained for the drug 
susceptibility tests of various compounds tested under unlimited aeration. 
In the first five assays (Fig. 3.8. to 3.12.), Mtb were grown in the 
presence of the first line anti-TB agents: streptomycin (Fig. 3.8.), 
ethambutol (Fig. 3.9.), rifampicin (Fig. 3.10.), isoniazid (Fig. 3.11.) and 
pyrazinamide (Fig. 3.12.).
The first line anti-TB agents were all effective against Mtb strain H37Rv, 
apart from pyrazinamide that did not have any effect on Mtb growth. 
Pyrazinamide is reported to be effective only in acidic pFl, being 
completely inactive at a neutral pH (Zhang and Mitchison 2003). Due to 
severe limitations in culture growth when submitted to acidic pH 
conditions, the assay could not be adapted to test pyrazinamide.
100-'
o.ooi
(Streptomycin) pM
Fig. 3.8.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of streptomycin. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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Fig. 3.9.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of ethambutol. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
100-1
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Fig. 3.10.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of rifampicin. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
0.001
Fig. 3.11.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of isoniazid. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
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Fig. 3.12.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of pyrazinamide. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
Metronidazole (Fig. 3.13.) did not have a significant inhibitory effect 
against aerobic Mtb showing just a small decrease in mycobacterial 
growth when submitted to high concentrations of the drug.
[Metronidazole| |iM
Fig. 3.13.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of metronidazole. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
The following graphs (Fig. 3.14. to 3.22.) show the inhibitory effects of 
nine phenothiazine compounds tested against aerobic Mtb FI37Rv. All the 
compounds had an inhibitory effect against Mtb and an order of potency
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can be established: trifluoperazine (Fig. 3.15.) > thioridazine (Fig. 3.14.) 
> flupenthixol (Fig. 3.21.) > fluphenazine (Fig. 3.20.) > perphenazine 
(Fig. 3.19.) > chlorpromazine (Fig. 3.22.) > promethazine (Fig. 3.17.) > 
promazine (Fig. 3.16.) > phenothiazine (Fig. 3.18.). Phenothiazine was 
the only agent that did not present an IC50 for the studied concentrations.
100-
|Thioridazine| |iM
Fig. 3.14.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of thioridazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
ITrifluoperazine) |iM
Fig. 3.15.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of trifluoperazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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100
(Promazine) |tM
Fig. 3.16.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of promazine. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
loo-i
|Promethazine) )lM
Fig. 3.17.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of promethazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
100- i-
(Phenothiazine) jiM
Fig. 3.18.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of phenothiazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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(Perphenazine) pM
Fig. 3.19.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of perphenazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
100-
(Fluphenazine) pM
Fig. 3.20.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of fluphenazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
(Flupenthixol) pM
Fig. 3.21.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of flupenthixol. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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[Chlorpromazine] pM
Fig. 3.22.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of chlorpromazine. The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
Mefloquine (Fig. 3.23.) is a synthetic analogue of quinine, a drug used in 
malaria treatment that had previously been reported as having a strong 
inhibitory effect against Mtb (Mao et al. 2007 ).
100-
| Mefloquine | pM
Fig. 3.23.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of mefloquine. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
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Piericidin A (Fig. 3.24.) is a specific inhibitor of complex I NADH 
dehydrogenase and despite the fact that it does not present a clinically 
relevant IC50, was able to completely inhibit the growth of Mtb at 
concentrations higher than lOOOfiM.
100-
|Piericidin A) |iM
Fig. 3.24.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of piericidin A. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
Atovaquone (Fig. 3.25.), a ubiquinone analogue that blocks 
mitochondrial electron transport (Srivastava et al. 1997) does not inhibit 
significantly Mtb H37Rv growth. This is the expected result considering 
that menaquinone is the electron acceptor of Mtb, and not ubiquinone.
Fig. 3.25.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of atovaquone. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
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Rotenone (Fig. 3.26.), which inhibits the oxidation of NADH to NAD 
does not have a significant effect against Mtb H37Rv, since Mtb possess 
Ndh-2, an alternative NADH dehydrogenase insensitive to rotenone 
(Yagi and Matsuno-Yagi 2003).
100-
(Rotenone) |lM
Fig. 3.26.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of rotenone. The percentages of growth were estimated assuming 
that 100% growth occurred in the absence of the inhibitor.
1 -hydroxy-2-dodecyl-4( 1 //)quinolone (HDQ) (Fig. 3.27.), a quinolone- 
like compound that has high affinity for alternative NADH 
dehydrogenases, did not have a significant effect against aerobic Mtb 
H37Rv (Saleh et al. 2007) probably due to the existence of type I NADH 
dehydrogenases able to donate electrons to the ETC.
100-
(HDQ| nM
Fig. 3.27.: Curve of the Mtb inhibition of growth when exposed to different 
concentrations of l-hydroxy-2-dodecyl-4(lff)quinolone (HDQ). The percentages of 
growth were estimated assuming that 100% growth occurred in the absence of the 
inhibitor.
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Table 3.2. displays the IC50 and IC90 values and the respective standard 
errors of the compounds tested against Mtb under conditions of unlimited 
aeration. The number of replicates used in that determination is also 
indicated. The variation in the level of replication for each drug tested is 
explained by quality control performed on the results of the assays and 
not by an initial different number of replications of the procedure. Plates 
presenting anomalous or missing reads for a given test wells were 
entirely rejected. These IC50 and IC90 values are the summing up of the 
graphs described above (Fig. 3.8. to Fig. 3.27.).
Table 3.2.: Summary table of the IC5o and IC90 values of the inhibitor compounds 
tested against Mtb strain H37Rv using a MABA assay. The results are presented 
with the respective standard errors, n indicates the number of replicates.
Compound
tested IC50 (pM) SE (pM) IC90 (pM) SE (pM) n
Streptomycin 0.19 0.020 0.59 0.146 4
Ethambutol 2.16 0.330 10.33 3.564 6
Rifampicin 1.38X10'3 2.069xl0'4 6.70X10-3 2.192xl0‘3 7
Isoniazid 0.19 0.019 0.97 0.213 7
Metronidazole >2000 - >2000 - 5
Thioridazine 13.43 1.078 47.37 8.245 5
Trifluoperazine 11.23 1.208 61.40 14.430 7
Promazine 59.45 2.331 126.90 11.820 4
Promethazine 52.16 3.841 194.90 30.840 4
Phenothiazine >100 - >100 - 4
Perphenazine 19.85 2.453 71.22 18.540 4
Fluphenazine 15.99 1.214 42.04 6.168 5
Flupenthixol 13.64 0.711 29.35 3.173 4
Chlorpromazine 23.83 3.554 166.70 55.200 4
Mefloquine 7.31 0.340 15.71 1.158 8
Piericidin A 141.20 12.560 670.30 125.300 4
Atovaquone >100 - >100 - 3
Rotenone >100 - >100 - 4
HDQ >100 - >100 - 3
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3.3.4. Drug testing of thioridazine and trifluoperazine when used in 
combination with 4 DOTS drugs under no aeration limitations
The following graphs (Fig. 3.28.A - O) present the results obtained upon 
testing two compounds in combination against Mtb in aerobic conditions. 
Two of the more effective phenothiazines (thioridazine and 
trifluoperazine) were tested in combination with four of the current anti- 
TB compounds (ethambutol, isoniazid, rifampicin and streptomycin).
The isobologram representing the combination of thioridazine and 
trifluoperazine (Fig. 3.28.-A) shows a curve significantly concave, with 
FIC values less than 1.0 suggesting a synergistic effect between these two 
compounds (Berenbaum 1978; Tallarida 2006). A synergistic effect 
means that both drugs used in combination will have a stronger effect 
than when used separately.
Streptomycin, when used in combination with trifluoperazine (Fig. 3.28.- 
B) or thioridazine (Fig. 3.8.-C) shows a slight subadditivity effect and the 
same happens with rifampicin when used in combination with 
trifluoperazine (Fig. 3.8.-D), thioridazine (Fig. 3.8.-E) or streptomycin 
(Fig. 3.8.-F). The isoboles remain close to the additive line meaning that 
the slight antagonistic effect is not significant according to the convention 
of Berenbaum (Berenbaum 1978).
The isobolograms representing the combination of isoniazid and 
trifluoperazine (Fig. 3.28.-G) or thioridazine (Fig. 3.28.-H) show 
convexity with FIC values higher than 2, indicating antagonism 
(Tallarida 2006). An antagonistic effect means that both drugs used in 
combination will be less effective than when used separately.
The effect of isoniazid against Mtb H37Rv when used in combination 
with streptomycin (Fig. 3.28.-I) or rifampicin (Fig. 3.28.-J) is additive.
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Ethambutol when titrated against trifluoperazine (Fig. 3.28.-K) or 
thioridazine (Fig. 3.28.-L) showed slightly more convexity than either 
streptomycin or rifampicin when tested in combination with the 
phenothiazines, suggesting a subadditivity effect. The same occurs when 
ethambutol is tested in combination with rifampicin (Fig. 3.28.-N) or 
isoniazid (Fig. 3.28.-0). A completely additive effect was obtained when 
ethambutol was tested in combination with streptomycin (Fig. 3.28.-M).
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FIC of Trifluoperazine FIC of Streptomycin
FIC of Streptomycin FIC of Rifampicin
FIC of Rifampicin
FIC of Isoniazid
FIC of Rifampicin
FIC of Isoniazid
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Fig. 3.28.: Typical isobolograms representing 
the interaction between trifluoperazine and
thioridazine (A), streptomycin and 
trifluoperazine (B), streptomycin and
thioridazine (C), rifampicin and trifluoperazine 
(D), rifampicin and thioridazine (E), rifampicin 
and streptomycin (F), isoniazid and 
trifluoperazine (G), isoniazid and thioridazine 
(H), isoniazid and streptomycin (I), isoniazid 
and rifampicin (j), ethambutol and 
trifluoperazine (K), ethambutol and
thioridazine (L), ethambutol and streptomycin 
(M), ethambutol and rifampicin (N) and
ethambutol and isoniazid (O).
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3.3.5. Drug testing of various compounds against Mtb with variation 
in the length of exposure to the drug and in the aeration conditions
Fig. 3.29. to 3.57. and Tables 3.3. to 3.16. show the results of the drug 
susceptibility tests with variation of different conditions, including length 
of exposure to the drug (that varies between 7, 14 and 21 days) in 
aerobiosis. Data are also presented comparing the activity of the agents in 
cultures grown in aerobic and anaerobic conditions. The anaerobic assay 
had 7 days duration with severe hypoxia where Mtb was in contact with 
the drug followed by 7 days under normal aerobic conditions, to enable 
the detection of growth.
3.3.5.1. Streptomycin
Streptomycin, a first line anti-TB agent was effective against Mtb H37Rv 
in aerobiosis, with very low IC50 after 7 and 14 days exposure. The IC50 
increased in the assay over 21 days (Fig. 3.29. and Table 3.3.) The 
inhibitory effect in the anaerobic assay was also low, with an IC50 of 0.10 
pM (Fig. 3.30. and Table 3.3.).
100--t
[Streptomycin] pM
Fig. 3.29.: Curves of Mtb susceptibility to different concentrations of streptomycin. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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0.001
[Streptomycin] pM
Fig. 3.30.: Curves of Mtb susceptibility to streptomycin. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.3.: IC5o and lC9o values of streptomycin against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
IC90
OiM)
SE
(pM)
n
Aerobiosis 7 days 0.19 0.020 0.59 0.146 4
Streptomycin Aerobiosis 14 days 0.11 0.009 0.25 0.034 4
Aerobiosis 21 days 0.50 0.051 1.30 0.314 3
Hypoxia 14 days 0.10 0.017 0.66 0.232 4
3.3.S.2. Ethambutol
Ethambutol, another first line anti-TB drug was almost equally effective 
against Mtb H37Rv independent of the length of exposure to the drug 
(Fig. 3.31. and Table 3.4.) or the aeration conditions of the assay (Fig. 
3.32. and Table 3.4.).
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Fig. 3.31.: Curves of Mtb susceptibility to different concentrations of ethambutol. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
(Ethambutol] (iM
Fig. 3.32.: Curves of Mtb susceptibility to ethambutol. Cultures were grown under 
conditions of unlimited aeration ( _, pink line) and under severe hypoxia (_, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
Table 3.4.: IC50 and IC90 values of ethambutol against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
ICx,
(pM)
SE
(hM)
n
Aerobiosis 7 days 2.16 0.330 10.33 3.564 6
Ethambutol Aerobiosis 14 days 2.37 0.611 14.78 8.338 4
Aerobiosis 21 days 2.64 0.317 7.05 1.663 4
Hypoxia 14 days 2.71 0.380 13.46 4.107 6
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3.3.S.3. Rifampicin
Rifampicin, the most effective anti-TB drug tested, had a stronger anti- 
TB effect in conditions of aerobiosis with 7 days exposure to the drug, 
decreasing its effect after 14 days duration of the assay and even more at 
21 days (Fig. 3.33. and Table 3.5.). Rifampicin was less effective in the 
anaerobic assay (Fig. 3.34. and Table 3.5.).
i—H
0.0001 0.001 0.01 
[Rifampicin] pM
Fig. 3.33.: Curves of Mtb susceptibility to different concentrations of rifampicin. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
0.0001 0.001 0.01 c
[Rifampicin] pM
Fig. 3.34.: Curves of Mtb susceptibility to rifampicin. Cultures were grown under 
conditions of unlimited aeration ( _, pink line) and under severe hypoxia ( _, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
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Table 3.5.: IC50 and IC9o values of rifampicin against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(HM)
IC9o
(mM)
SE
OiM)
n
Aerobiosis 7 days 1.38xl03 2.069x10“* 6.70X10'3 2.192X10*3 7
Rifampicin Aerobiosis 14 days 3.07X10'3 1.771x10“* 6.63xl03 8.000x10“* 7
Aerobiosis 21 days 7.40X10'3 4.833x10“* 4.17X10'2 5.923x10'3 6
Hypoxia 14 days 3.25X10'2 2.046X10'3 2.55x10-' 3.510X10-2 7
3.3.S.4. Isoniazid
Isoniazid, another first line anti-TB drug, displayed a pattern of inhibition 
similar to rifampicin. This drug had a stronger anti-TB effect in 
aerobiosis with 7 days exposure to the drug, decreasing its effect after 14 
days duration of the assay and even more at 21 days (Fig. 3.35. and Table 
3.6.). Isoniazid was less effective in the anaerobic assay (Fig. 3.36. and 
Table 3.6.).
o.ooi
[Isoniazid) (iM
Fig. 3.35.: Curves of Mtb susceptibility to different concentrations of isoniazid. The 
exposure period of Mtb to the drug was 7 days ( _, green line), 14 days ( _, blue 
line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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Fig. 3.36.: Curves of Mtb susceptibility to isoniazid. Cultures were grown under 
conditions of unlimited aeration (_, pink line) and under severe hypoxia (_, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
Table 3.6.: ICjo and IG*) values of isoniazid against Mtb strain H37Rv. The results 
are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
ic90
(pM)
SE
(pM)
n
Aerobiosis 7 days 0.19 0.019 0.97 0.213 7
Isoniazid Aerobiosis 14 days 0.34 0.018 1.061 0.117 5
Aerobiosis 21 days 1.19 0.098 4.74 0.852 5
Hypoxia 14 days 1.55 0.080 9.23 1.042 5
3.3.S.5. Pyrazinamide
Pyrazinamide, the last first line anti-TB drug tested did not have an effect 
in either assay (Fig. 3.37. and Fig. 3.38.). The experiments were 
performed as a control but since no optimisation for the peculiarities of 
the action of this drug were done, no effect was expected.
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[Pyrazinamide] jiM
Fig. 3.37.: Curves of Mtb susceptibility to different concentrations of 
pyrazinamide. The exposure period of Mtb to the drug was 7 days ( _, green line), 
14 days (_, blue line) and 21 days ( _, red line). The percentages of growth were 
estimated assuming that 100% growth occurred in the absence of the inhibitor.
|Pyrazinamide] nM
Fig. 3.38.: Curves of Mtb susceptibility to pyrazinamide. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
3.3.5.6. Metronidazole
Metronidazole was effective against anaerobic organisms, serving as a 
control for the growth conditions of the expeiments. It did not show 
significant inhibitory effect against aerobic Mtb (Fig. 3.39. and Table 
3.7.).
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(Metronidazole) }tM
Fig. 3.39.: Curves of Mtb susceptibility to metronidazole. Cultures were grown 
under conditions of unlimited aeration ( _, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.7.: ICso and IC90 values of metronidazole against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number 
of replicates.
Compound
tested
Growth
conditions
Exposure
time
IC5o
(pM)
SE
(pM)
IC90
(PM)
SE
(pM)
n
Aerobiosis 7 days >2000 - >2000 - 5
Metronidazole Hypoxia 14 days 55.13 8.856 627.10 225.900 4
3.3.5.7. Phenothiazine compounds
In the following graphs (Fig. 3.40. to Fig. 3.57.) the inhibitory effects of 
nine phenothiazine compounds are presented. All the phenothiazines 
tested had a higher inhibitory effect against anaerobic organisms, 
comparing with aerobic Mtb.
3.3.5.7.I. Thioridazine
Thioridazine was one of the more effective phenothiazines in aerobiosis 
and the most effective in anaerobiosis. This drug had an IC50 of 13.43 pM 
against Mtb in aerobiosis with 7 days exposure to the drug, decreasing its
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effect after 14 days duration of the assay and even more at 21 days (Fig. 
3.40. and Table 3.8.). Thioridazine had an IC50 of 3.64 fiM against Mtb in 
anaerobiosis (Fig. 3.41. and Table 3.8.).
(Thioridazine|
Fig. 3.40.: Curves of Mtb susceptibility to different concentrations of thioridazine. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
(Thioridazine) 11M
Fig. 3.41.: Curves of Mtb susceptibility to thioridazine. Cultures were grown under 
conditions of unlimited aeration ( _, pink line) and under severe hypoxia ( _, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
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Table 3.8.: IC5o and IC9o values of thioridazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(mM)
SE
(pM)
IC90
(pM)
SE
(pM)
n
Aerobiosis 7 days 13.43 1.078 47.37 8.245 5
Thioridazine Aerobiosis 14 days 21.67 1.063 72.84 7.698 4
Aerobiosis 21 days 27.98 1.662 73.07 11.15 4
Hypoxia 14 days 3.64 0.231 16.52 2.420 4
3.3.5.7.2. Trifluoperazine
Trifluoperazine was the most effective phenothiazine in aerobiosis and 
one of the more effectives in anaerobiosis. This drug had a stronger 
inhibitory effect in the 7 days aerobic assay, followed by the 14 and 21 
days assays (Fig. 3.42. and Table 3.9.). Trifluoperazine was much more 
effective under anaerobiosis (Fig. 3.43. and Table 3.9.).
|Tkifluoperazine| pM
Fig. 3.42.: Curves of Mtb susceptibility to different concentrations of 
trifluoperazine. The exposure period of Mtb to the drug was 7 days ( _, green line), 
14 days (_, blue line) and 21 days ( _, red line). The percentages of growth were 
estimated assuming that 100% growth occurred in the absence of the inhibitor.
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ITrifluoperazinej jiM
Fig. 3.43.: Curves of Mtb susceptibility to trifluoperazine. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.9.: IC50 and IC90 values of trifluoperazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
IC50
(pM)
SE
(pM)
IC*,
(pM)
SE
(pM)
n
Aerobiosis 7 days 11.23 1.208 61.04 14.430 7
Trifluoperazine Aerobiosis 14 days 17.77 1.697 85.28 17.690 6
Aerobiosis 21 days 18.47 1.993 74.85 17.370 6
Hypoxia 14 days 4.22 0.306 16.34 2.592 6
3.3.5.7.3. Promazine
Promazine was one of the less effective phenothiazine tested. In 
aerobiosis it seemed to be more effective when the exposure time to the 
drug was 14 days, followed by the 7 and 21 days assays (Fig. 3.44. and 
Table 3.10.). Promazine was much more effective under anaerobiosis 
with an IC50 of 12.19 pM (Fig. 3.45. and Table 3.10.).
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(Promazine]
Fig. 3.44.: Curves of Mtb susceptibility to different concentrations of promazine. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
too-*:
Fig. 3.45.: Curves of Mtb susceptibility to promazine. Cultures were grown under 
conditions of unlimited aeration (_ , pink line) and under severe hypoxia ( _, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
Table 3.10.: IC50 and IC9o values of promazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(hM)
IC90
(PM)
SE
(pM)
n
Aerobiosis 7 days 59.45 2.331 126.90 11.820 4
Promazine Aerobiosis 14 days 48.99 2.237 115.70 11.840 4
Aerobiosis 21 days 63.68 2.375 136.70 12.420 4
Hypoxia 14 days 12.19 1.315 65.28 15.390 4
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3.3.S.7.4. Promethazine
Promethazine was one of the less effective phenothiazine tested. In 
aerobiosis it seemed to be more effective when the exposure time to the 
drug was 7 days, followed by the 14 days assay but its effect strongly 
decreases in the assay after 21 days (Fig. 3.46. and Table 3.11.). 
Promethazine was more effective under anaerobiosis with an IC5o of 
21.02 pM (Fig. 3.47. and Table 3.11.).
|Promethazine)
Fig. 3.46.: Curves of Mtb susceptibility to different concentrations of 
promethazine. The exposure period of Mtb to the drug was 7 days ( _ , green line), 
14 days (_, blue line) and 21 days ( _, red line). The percentages of growth were 
estimated assuming that 100% growth occurred in the absence of the inhibitor.
(Promethazine) jiM
Fig. 3.47.: Curves of Mtb susceptibility to promethazine. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
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Table 3.11.: ICso and IC.*, values of promethazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
IC90
(pM)
SE
(pM)
n
Aerobiosis 7 days 52.16 3.841 194.90 30.840 4
Promethazine Aerobiosis 14 days 59.68 8.282 238.00 72.590 4
Aerobiosis 21 days 126.80 6.552 351.10 39.100 4
Hypoxia 14 days 21.02 1.533 91.16 14.460 4
3.3.5.7.5. Phenothiazine
Phenothiazine was the least effective drug of the phenothiazine group 
tested. No significant effect that allowed the calculation of ICSO was 
obtained with the variation in the length of the experiment done under 
aerobiosis (Fig. 3.48. and Table 3.12.). Despite an apparent stronger 
effect against anaerobic Mtb bacilli, no IC5o could be calculated (Fig. 
3.49. and Table 3.12.).
(Phenothiazine) jiM
Fig. 3.48.: Curves of Mtb susceptibility to different concentrations of 
phenothiazine. The exposure period of Mtb to the drug was 7 days ( _, green line), 
14 days (_, blue line) and 21 days (_, red line). The percentages of growth were 
estimated assuming that 100% growth occurred in the absence of the inhibitor.
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[Phenothiazine]
Fig. 3.49.: Curves of Mtb susceptibility to phenothiazine. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.12.: IC5o and IC90 values of phenothiazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number 
of replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
IQo
(pM)
SE
(pM)
n
Aerobiosis 7 days >100 - >100 - 4
Phenothiazine Aerobiosis 14 days >100 - >100 - 3
Aerobiosis 21 days >100 - >100 - 3
Hypoxia 14 days >100 - >100 - 4
3.3.5.7.6. Perphenazine
Perphenazine in aerobiosis was more effective when the exposure time to 
the drug was 14 days, followed by the 7 and 21 days assays (Fig. 3.50. 
and Table 3.13.). Perphenazine was much more effective under 
anaerobiosis with an IC50 of 7.90 pM (Fig. 3.51. and Table 3.13.).
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(Perphenazine) pM
Fig. 3.50.: Curves of Mtb susceptibility to different concentrations of perphenazine. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
(Perphenazine) pM
Fig. 3.51.. Curves of Mtb susceptibility to perphenazine. Cultures were grown 
under conditions of unlimited aeration ( _, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.13.: IC5o and IC90 values of perphenazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
ic90
(pM)
SE
(pM)
n
Aerobiosis 7 days 19.85 2.453 71.22 18.540 4
Perphenazine Aerobiosis 14 days 15.35 0.955 40.49 4.957 4
Aerobiosis 21 days 37.66 4.588 189.10 51.060 4
Hypoxia 14 days 7.90 0.909 22.20 5.135 4
144
3.3.5.7.T. Fluphenazine
Fluphenazine in aerobiosis was more effective when the exposure time to 
the drug was 14 days, followed by the 7 and 21 days assays (Fig. 3.52. 
and Table 3.14.). Fluphenazine was much more effective under 
anaerobiosis with one of the lower IC50 of the phenothiazines tested (Fig. 
3.53. and Table 3.14.).
|Fluphenazine| pM
Fig. 3.52.: Curves of Mtb susceptibility to different concentrations of fluphenazine. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_, 
blue line) and 21 days (_, red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
(Fluphenazine) pM
Fig. 3.53.: Curves of Mtb susceptibility to fluphenazine. Cultures were grown 
under conditions of unlimited aeration (_, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
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Table 3.14.: IC5o and IC90 values of fluphenazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
IC50
(pM)
SE
(pM)
IC90
(pM)
SE
(pM)
n
Aerobiosis 7 days 15.99 1.214 42.04 6.168 5
Fluphenazine Aerobiosis 14 days 14.55 1.692 59.60 14.98 5
Aerobiosis 21 days 20.46 1.900 98.79 20000 4
Hypoxia 14 days 3.92 0.414 13.20 3.303 4
3.3.5.7.8. Flupenthixol
Flupenthixol in aerobiosis was more effective when the exposure time to 
the drug was 14 days, with an IC50 of 10.61 pM followed by the 7 and 21 
days assays (Fig. 3.54. and Table 3.15.). Flupenthixol was more effective 
under anaerobiosis with an IC50 of 10.45 pM (Fig. 3.55. and Table 3.15.), 
but this potency increase is not as significant as other phenothiazine 
compounds.
[Flupenthixol] pM
Fig. 3.54.: Curves of Mtb susceptibility to different concentrations of flupenthixol. 
The exposure period of Mtb to the drug was 7 days (_, green line), 14 days (_,
)ue lin°) and 21 days (-■> red line). The percentages of growth were estimated 
assuming that 100% growth occurred in the absence of the inhibitor.
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[Flupenthixol] (iM
Fig. 3.55.: Curves of Mtb susceptibility to flupenthixol. Cultures were grown under 
conditions of unlimited aeration (_, pink line) and under severe hypoxia ( _, blue 
line).The percentages of growth were estimated assuming that 100% growth 
occurred in the absence of the inhibitor.
Table 3.15.: IC50 and IC9o values of flupenthixol against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
ic50
(pM)
SE
(pM)
IC90
(pM)
SE
(pM)
n
Aerobiosis 7 days 13.64 0.711 29.35 3.173 4
Flupenthixol Aerobiosis 14 days 10.61 0.620 28.46 4.141 4
Aerobiosis 21 days 17.19 1.839 51.89 11.690 4
Hypoxia 14 days 10.45 0.314 22.41 1.932 4
3.3.5.7.9. Chlorpromazine
Chlorpromazine in aerobiosis was more effective when the exposure time 
to the drug was 14 days, followed by the 7 and 21 days assays (Fig. 3.56. 
and Table 3.16.) however the IC5o values are all similar, especially 
considering the standard errors associated with the IC5o curve inference. 
Chlorpromazine was more effective under anaerobiosis similar to the 
other phenothiazines (Fig. 3.57. and Table 3.16.).
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too- r
(Chlorpromazine|
Fig. 3.56.: Curves of Mtb susceptibility to different concentrations of 
chlorpromazine. The exposure period of Mtb to the drug was 7 days ( , green
line), 14 days ( _ , blue line) and 21 days (_, red line). The percentages of growth 
were estimated assuming that 100% growth occurred in the absence of the 
inhibitor.
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[Chlorpromazine| pM
Fig. 3.57.: Curves of Mtb susceptibility to chlorpromazine. Cultures were grown 
under conditions of unlimited aeration ( _, pink line) and under severe hypoxia 
(_, blue line).The percentages of growth were estimated assuming that 100% 
growth occurred in the absence of the inhibitor.
Table 3.16.: IC50 and IC90 values of chlorpromazine against Mtb strain H37Rv. The 
results are presented with the respective standard errors, n indicates the number of 
replicates.
Compound
tested
Growth
conditions
Exposure
time
IC50
(pM)
SE
(pM)
IC90
(pM)
SE
(pM)
n
Aerobiosis 7 days 23.83 3.554 166.70 55.200 4
Chlorpromazine Aerobiosis 14 days 22.11 1.509 69.59 10.240 4
Aerobiosis 21 days 25.39 5.722 146.50 72.870 4
Hypoxia 14 days 14.37 0.975 88.03 13.030 4
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3.3.6. Microscopy observation of Mtb grown under different aeration 
conditions
Microscopic images were obtained from Mtb cultures in order to identify 
any possible morphological differences between the cultures grown under 
no oxygen limitation (Fig. 3.58.A and Fig. 3.59.E) and those grown under 
severe hypoxia (Fig. 3.58.B and Fig. 3.59.A-D), using the Wayne model.
The anaerobic cultures (Fig. 3.58.B and Fig. 3.59.A-D) present a great 
amount of debris (blue arrow-heads) that results from cell death. The 
viable anaerobic bacteria appeared longer and with a thicker cell wall 
(pink arrow-heads). The aerobic Mtb (Fig. 3.58.A and Fig. 3.59.E, red 
arrow-heads) appeared as slender bacilli.
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3.4. Discussion
In this chapter the Wayne model of growth was optimised and an assay to 
test drug susceptibility of Mtb either in aerobic or anaerobic conditions 
was developed. Also, two of the more effective phenothiazines 
(thioridazine and trifluoperazine) were tested in combination with four of 
the current anti-TB compounds (ethambutol, isoniazid, rifampicin and 
streptomycin).
The purpose of the testing of streptomycin, ethambutol, isoniazid, 
pyrazinamide and rifampicin (DOTS drugs) was to use them as quality 
control of the method, a number of studies reported Mtb H37Rv drug 
susceptibility for these compounds, using different assays.
Table 3.17. provides an overview of some relevant literature data 
regarding the DOTS drugs. One striking feature is the heterogeneity of 
the indices used, which makes the comparison between studies extremely 
difficult or even impossible. Given this, any comparison between the 
results reported here and the literature will only be possible if an IC50 
value was reported for the given compound. The only directly 
comparable value is isoniazid whose published IC50 value of less than 0.3 
\xM (Table 3.17.) is consistent with the 0.19 juM value reported here 
(Table 3.2.).
In this study a static model of drug testing was used. Mtb bacilli were 
submitted to a drug and the drug effect was measured at defined time 
points. One should point out that this way, bacterial growth is limited not 
only by the drug but also by nutrient limitation, space, aeration and 
accumulation of toxic metabolites in the culture (Vaddady et al. 2010).
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In aerobic conditions, DOTS drugs were effective. Rifampicin being the 
most effective of all the drugs tested. Pyrazinamide, a pro-drug that only 
works in vivo under acidic conditions (Zhang and Mitchison 2003), did 
not show any effect either in aerobiosis or in anaerobiosis. This drug was 
used only as control since no positive results were expected. The assay 
could have been modified but further optimisation would be needed since 
pyrazinamide acid requirements would compromise Mtb growth (See 
Fig. 3.5. for optimal pH for Mtb growth).
Bacilli were also exposed to the drug at different lengths of time: 7 days 
was the duration of the normal assay. The drug was added at day 0 and 
after 7, 14 and 21 days the growth was assessed (See Tables 3.3. to 3.6 
and Tables 3.8 to 3.16.). Considering the DOTS compounds, the IC50 at 
day 7 and day 14 were very similar, and the IC50 greatly increased at day 
21 except for ethambutol whose IC50S remained nearly constant.
Isoniazid and streptomycin are reported to be rapid and concentration 
dependent bactericidal drugs (Turnidge 2003; Steenwinkel et al. 2010), 
so that hypothetically the drugs would act quickly on the first days of the 
assay, killing a great proportion of the population. It is known that in one 
population there are a certain number of individuals with phenotypic 
tolerance that will evade the action of these drugs (Balaban et al. 2004; 
Mitchison and Coates 2004), elevating the IC50S, observable after 21 
days, probably due to regrowth of sub-populations. Rifampicin according 
to Vaddady and colleagues is a concentration-dependent bactericidal drug 
(Vaddady et al. 2010) so the expected outcome is a similar pattern of IC50 
to the one obtained for isoniazid and streptomycin, as was observed. 
Gangadharam and collaborators also obtained a decrease in the effect of 
both rifampicin and isoniazid after 6 days which they attributed to the 
development of drug-resistant mutants (Gangadharam et al. 1990). This 
could be a possible explanation for the increase of the IC5o values after
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the initial 7 days of culture but it is more likely to be due to the existence 
of highly tolerant organisms during the initial 7 days.
EthambutoPs major role is to prevent emergence of resistance to other 
anti-mycobacterial drugs and its effect is mainly bacteriostatic, only 
inhibiting mycobacterial growth (Rastogi et al. 1996; Steenwinkel et al. 
2010). However at high concentrations, ethambutol has also been pointed 
out as being bactericidal (Gangadharam et al. 1990; Bakker-Woudenberg 
et al. 2005). The IC50S remained nearly constant along the 21 days, 
however with a small increase in the 21 days (Table 3.4.). One of the 
reasons why the effect of ethambutol seems constant throughout the 21 
duration of the assay is the fact that ethambutol has a bacteriostatic action 
which led to the inhibition of the growth at a steady rate during the time 
of the experiment impairing the occurrence of an initial exponential phase 
of growth (Fig. 3.31.). Also, ethambutol has been pointed out as a time- 
dependent bactericidal drug whose effects increased with time of 
exposure (Bakker-Woudenberg et al. 2005).
Regarding the results of the DOTS drugs tested under severe hypoxia, 
rifampicin and isoniazid showed higher IC5o (3.25xlO'2|uM and 1.55pM 
respectively) than those obtained under aerobic conditions (1.38><10'3pM 
and 0.19pM respectively). Streptomycin and ethambutol, drugs that 
typically target growing organisms and that should present much higher 
concentrations needed to inhibit mycobacterial growth showed 
unexpected results. Streptomycin decreased its IC50 by almost half 
(0.19pM in aerobiosis and O.lOpM in hypoxia) and ethambutol IC50 was 
similar to the one obtained in aerobiosis only slightly higher (2.16pM in 
aerobiosis and 2.71 pM in hypoxia).
The result obtained for ethambutol (Fig. 3.32.) is explained by the assay 
design, where after the period of exposure to the drug and due to the need 
for the recognition of growth, Mtb is transferred to aerobiosis and after 7
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days the growth in the wells is assessed. The bacteriostatic effect of this 
drug will mainly happen in the aerobic growth, showing a value close to 
(but higher than) the one obtained in the aerobic assay, since the growth 
under anaerobiosis conditions is minimal. Ethambutol targets the 
biosynthesis of a polysaccharide of the mycobacterial cell wall 
(arabinogalactan) (Takayama and Kilburn 1989).
The result obtained for streptomycin is not theoretically expected since 
streptomycin is a bactericidal drug that targets protein synthesis (Zhang 
2005) so a higher IC50 under anaerobic conditions was expected. 
However, streptomycin was previously reported to be either active (Li 
and Franzblau 1999; Cho et al. 2007) or inactive (Heifets et al. 2005) in 
the Wayne hypoxia model. The reasons for this are unknown.
A possible explanation may be the existence of sub-populations of 
bacteria still actively growing, along with the hypoxia adapted ones that 
showed sensitivity to metronidazole and more susceptibility to 
phenothiazines. Due to the possibility of existence of heterogeneous 
subpopulations with different metabolic rates, the IC50S and even IC90S 
may provide uncertain results specially when comparing the results 
between different assays.
In the studied case, the IC50 may correspond mainly to the inhibition of 
growing organisms and one could require a measure that considered a 
much larger percentage of inhibition in order to be certain that that 
measure is accounting for action in the slow- and non-growing 
organisms.
The phenothiazine data showed that they have different modes of action 
and that these drugs are much more effective under anaerobic conditions. 
The IC50 were still in a range unlikely to be able to be achieved in vivo, 
but they are a promising group of drugs that could be used as starting 
point for new drug development. There are several studies involving
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phenothiazines but none until now performed chemical validation of this 
group. In this work, not only a couple of phenothiazines were proven to 
have an inhibitory effect against Mtb but the entire group (a wide range 
of phenothiazines picked carefully due to their chemical structures) was 
tested and important differences in terms of their particular behaviour 
were identified through the different drug susceptibility profiles (Fig.
3.28. and Fig. 3.40. to 3.55. and Tables 3.8. to 3.16.). Also a structure- 
activity study could be made of the different phenothiazines to establish 
the reasons for the differences in the observed inhibitory effects and thus 
determine the ideal scaffold compound for the synthesis of new anti-TB 
compounds.
The isobologram data showed additive effects for the combination of 
rifampicin and streptomycin with the two phenothiazines tested (Fig.
3.28. -B,-C,-D,-E). The combination of ethambutol and trifluoperazine 
(Fig. 3.28.-K) or thioridazine (Fig. 3.28.-L) showed a slight sub-additive 
effect. These results are not consistent with the studies by Amaral and 
colleagues that reported synergistic effects between phenothiazines and 
the current used anti-TB drugs (Amaral and Kristiansen 2000; Amaral et 
al. 2004). It is not possible to explain discrepancies between the data 
presented here and the work by Amaral and colleagues, however, 
considering the modes of actions for these compounds, the expected 
results would be a lack of synergism or antagonism with the respiratory 
chain inhibiting phenothiazines as reported here.
Trifluoperazine and thioridazine were shown to be significantly 
antagonistic with isoniazid (Fig. 3.28.-G,-H). This result is consistent 
with the mode of action of this drug and with the observation that 
mutations in ndh are seen in INH-resistant Mtb isolates (Viveiros and 
Amaral 2001). Isoniazid targets the enzyme InhA, a key enyme in the 
fatty acid biosynthesis pathway (Lei et al. 2000). However the inhibitory 
effect of isoniazid is only possible after the compound has formed an
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adduct with NAD+ catalysed by the catalase peroxidise KatG. This way 
the inhibitory effect of isoniazid will decrease with a higher ratio of 
intracellular NADH/NAD+. Such a change in the ratio can be caused by 
mutation in ndht where the mutations in this gene were revealed to cause 
isoniazid resistance in Mtb (Lee et al. 2001) and in M smegmatis and M 
bovis (Miesel et al. 1998; Vilcheze et al. 2005). NADH might compete 
with the isoniazid-NAD+ adduct at the active site of InhA or, since 
NADH is a peroxidase substrate, might compete with the adduct 
formation (Miesel et al. 1998; Lee et al. 2001; Rawat et al. 2003; Argyrou 
et al. 2007). Phenothiazines are known to act by inhibiting type II NADH 
dehydrogenases mimicking the effect of the afore-mentioned mutations in 
ndh and leading to an increase in the intracellular NADHZNAD+ ratios 
(Yano et al. 2006). This antagonism between isoniazid and 
phenothiazines is confirmed by the isobole data (Fig. 3.28.-G,-H). In 
terms of therapeutic use this suggests the contraindication of both 
isoniazid and a phenothiazine since this could result in a sub-optimal 
response.
Thioridazine and trifluoperazine combined (Fig. 3.28.-A) showed a 
synergistic effect, suggesting a complementary mode of action between 
these two phenothiazines with a similar mode of action. Jia and 
colleagues describe this as one particular case of synergism (Jia et al. 
2009).
The metronidazole data (Fig. 3.39.) served as validation, showing that in 
this adaptation of the Wayne model, the cells survived in hypoxia. This 
drug showed no effect against Mtb grown under aerobic conditions but 
had a bactericidal effect against Mtb grown under severe hypoxia (Wayne 
and Sramek 1994).
The results obtained through microscopy confirmed that notable 
morphological differences are visible between aerobic grown Mtb and
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Mtb grown under severe oxygen limitation (Gillespie et al. 1986). Mtb 
cells enlarged (Fig. 3.58.B and Fig. 3.59.A-D) and their cell walls 
thickened, as previously reported (Wayne and Sohaskey 2001), since 
when submitted to high levels of stress bacteria become more 
heterogeneous in morphology (Kolter et al. 1993).
There are still no standardised methods for Mtb drug susceptible tests. 
However suggestions and recommendations have been made in order to 
establish a comparable standard between laboratories (Mitchison 2005).
The choice of using IC50S throughout this thesis was made since a 
comparison was meant to be established between the inhibitory effects of 
anti-TB compounds against the whole organism (values obtained in this 
chapter) and the inhibitory effects of these compounds using a kinetic 
enzymatic assay. The effect of phenothiazines against different enzymes 
of the Mtb ETC would ideally be made and a correlation would be 
obtained in terms of IC5os comparisons. With this purpose, using a MIC 
or a MBC would not be as precise, since MIC and MBC rely on visual 
identification of growth and on a close (or wider) range in which the 
compounds are tested.
In conclusion, the work presented here further validates the respiratory 
chain of Mtb, and more specifically its type II NADH: menaquinone 
oxidoreductase as a viable target for development of anti-tubercular 
compounds. Phenothiazines should be evaluated as promising candidates 
for future TB treatments since they show activity against bacilli grown 
under different conditions.
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Chapter 4. Cloning and expression of 
Mycobacterium tuberculosis ndhA
4.1. Introduction
The ndhA gene is a homologue of the ndh gene of Mtb that encodes a 
type II NADH: menaquinone oxidoreductase (Ndh-2). Instead of the 463 
amino-acids of ndh, ndhA has 470 amino-acids and comparing their 
sequences, they have a similarity of 63%.
Ndh-2 is already a validated drug target against malaria (Biagini et al.
2006) , it is non-proton pumping and it is insensitive to the drug rotenone, 
which inhibits the initial steps in the ETC (Melo et al. 2004; Teh et al.
2007) . Ndh-2 is located in the inner part of the mycobacterial membrane 
and it catalyses the reaction: NADH + Menaquinone —> NAD + 
Menaquinol (Fig. 4.1.).
Fig. 4.1.: Scheme of the location of the enzyme Ndh-2 in the membrane of Mtb and 
representation of the reaction that it catalyses: NADH + MK (menaquinone) -*• 
NAD + MKH2 (menaquinol).
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Gene disruption of ndh is believed to be lethal to Mtb, but the 
inactivation of ndhA is non-lethal (Weinstein et al. 2005). Until recently, 
none of these genes featured in the list of essential genes for the growth 
of Mtb in aerobic, anaerobic or hypoxic conditions (Sassetti et al. 2003; 
Sassetti and Rubin 2003; Rustad et al. 2008). In 2011, Griffin and 
colleagues confirmed the essentiality of ndh for Mtb growth, this gene 
being the sole Mtb NADH dehydrogenase that could not tolerate 
insertional mutations (Griffin et al. 2011).
The ndh gene was studied in terms of functionality, essentiality and drug 
susceptibility (Weinstein et al. 2005; Teh et al. 2007), however, its 
homologue ndhA is poorly studied and it is often only mentioned in these 
studies focusing on ndh but not studied in detail.
4.2. Methods
4.2.1. Considerations regarding the molecular biology methods used 
throughout this thesis
This section gives a description of the molecular biology methods 
employed in order to clone the gene ndhA in a pUC19 vector using the 
sites SphI and Xbal. A detailed description of all the methods used can be 
found in (Sambrook and Russell 2001).
Initially, four inserts of the ndhA gene were prepared, however when the 
sequences were checked by automated sequencing after insertion in the 
cloning vector only one confirmed the presence of the gene. However for 
the methodological purpose the initial four planned inserts are described. 
It is uncertain why the other three planned inserts failed but for the 
purpose of the methodology only one was required to display the inserted 
gene so the work was carried out with this single one.
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4.2.2. Chemicals, reagents, enzymes and buffers used
All restriction enzymes and respective buffers were from New England 
BioLabs, UK and they will be mentioned in the relevant sections , as well 
as all the other reagents.
4.2.3. Vectors
The vectors used during these studies were pET15b (5,708 bp) which 
contained the template ndhA gene, that was kindly supplied by Professor 
H. Rubin (School of Medicine, University of Pennsylvania, USA). The 
cloning vector, TOPO® plasmid vector pCR® 2.1-TOPO® and the 
expression vector, pUC19 vector (2,686 bp) were from Invitrogen™ 
(USA).
4.2.4. Glycerol stocks
Every time a new batch of cells was produced during these experiments, 
they were stored as glycerol stocks as a backup. 500 \i\ of cell suspension 
was added to 200 pi of 50% (v/v) glycerol in dfUO and stored at -80°C.
4.2.5. Preparation of LB Media and plates
The nutrient media required for the growth of E. coli cells was prepared 
using a Luria-Bertani (LB) broth media powder, from Fisher (Fisher 
Scientific, UK). The media was prepared by adding 25 g of powder per 1 
L of dH20. The solution was autoclaved for 15 minutes at 121 °C and 
allowed to cool down to 45-50°C before the addition of antibiotics.
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Sterile agar plates were prepared using a LB agar media powder (Sigma, 
USA), adding 37 g of powder per 1 L of dfLO. The solution was 
autoclaved for 15 minutes at 121°C, allowed to cool down to 45~50°C 
before the addition of antibiotics. 20 ml of media was dispensed into each 
9 cm diameter Petri dish.
4.2.6. Gel electrophoresis
All PCR amplifications and restriction enzyme digestions were verified 
using electrophoresis in agarose gel.
Samples were run in 1% agarose gels (0.5 g of agarose, 50 ml tris-borate- 
EDTA (TBE) buffer and 1.3 pi of ethidium bromide was added after the 
mixture cooled down to avoid aerosol formation).
A molecular weight ladder of 1Kb intervals, Tracklt™ 1Kb DNA ladder 
(Invitrogen , USA) or Hyperladder I™ (Bioline, UK) were used to 
confirm the size of the fragments.
4.2.7. Determination of DNA concentration using a NanoDrop™
The concentration of DNA in the samples were determined using a 
NanoDrop™ 1000 (Thermo Fisher Scientific, USA) fitted with the 
software ND1000 v.3.7.1.
A volume of 1.5 pi of dH20 was tised to blank the instrument, followed 
by the measurement of an equivalent volume of the isolated DNA sample 
to test. A micropipette was used to deposit the samples onto the 
equipment without touching the probe.
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After each measurement, the graph obtained was checked to confirm that 
the DNA peak was at 260 nm and in general, the ratio 260/280 nm should 
be between 1.8 and 2.0 to assure the purity of the sample.
4.2.8. Enzyme digestion of DNA template
In order to confirm that the template DNA was correctly inserted in the 
vector pET15b (5708 bp), two restriction analyses were used. The ApE-A 
Plasmid Editor v2.0.37 software (available at 
http://biologvlabs.utah.edu/iorgensen/wavned/apel was used to check the 
restriction map of the pET15b vector with and without the insert. All the 
sequences of the different vectors were obtained from the lab life website 
(http://www.lablife.org/vectordbl. The map of the vector pET15b is 
shown in Fig. 4.2.
6932 EcoRV (2)
513 Seal (1)
ndhA 5377..6789
pET-15b, 5708 bp + ndhA 
7121 bp
4040 EcoRV (2)
Fig. 4.2.: Restriction map of the pET-15b vector with the ndhA gene inserted using 
restriction enzymes EcoRv and Seal. Position and length of the ndhA gene are 
indicated with the red arrow. Values in brackets indicate the number of restriction 
sites of an enzyme.
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EcoRv would cut the vector in two positions (Fig 4.2.) which would 
produce two fragments, one with 4229 bp and another with 1479 bp if the 
gene is not inserted, and one with 2892 bp would be produced if the gene 
is inserted.
The second test was to use the enzyme Sad that cuts within pET15b 
vector once. This restriction would just open the vector resulting in a 
single fragment of 7112 bp.
The reactions were set up to a final volume of 30 jiil according to Table 
4.1.
Table 4.1.: Quantities of reagents necessary for the enzyme restriction reactions.
Reaction 1 Reaction 2
5 fil DNA template 5 pi DNA template
3 pi BSA (lOOpg/ml) 3 pi BSA (lOOpg/ml)
3 pi buffer 3 3 pi buffer 1
2 pi enzyme EcoRv 2 pi enzyme Sad
17 pi sterile dH20 17 pi sterile dH20
Both reaction vials were incubated at 37°C for 2 hours and loaded on the 
agarose gel (according to section 4.2.6.).
4.2.9. PCR
Polymerase chain reaction (PCR) allows the generation of millions of 
copies of a targeted region of DNA defined by two flanking primers. The 
reaction is performed by a heat-stable DNA polymerase with high 
fidelity, Platinum® Pjx (Invitrogen™, USA), by thermo-cycling (cycles 
of denaturation, primer annealing and DNA extension).
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The reaction was prepared to a final volume of 50 pi, containing 2 pi of 
10 mM deoxynucleoside triphosphates (dNTPs) mix (New England 
BioLabs, UK); 1 pi of 50 mM magnesium sulphate (MgS04); 5 pi of 10x 
Pfa amplification buffer; 1.5 pi of each primer to obtain a final 
concentration of 200 nM; 1 pi of DNA template (ndhA in pET15b); 5 pi 
of 10x PCR enhancer solution; 0.4 pi of Platinum® Pjx DNA polymerase 
and 34.6 pi of sterile dHbO.
Four pairs of primers were used in these reactions and all of them share 
the same reverse primer.
Table 4.2.: Primers used in the PCR reactions.
Primer Direction Sequence Reaction
ndhpFw Forward 5 ’-GGGCATGCCCATCATCATCATCATCACAGC-S ’ 1
AJW22 Forward 5’- GGAGAACTAGTATGGGCAGCAGCC-3’ 3
AJW27 Forward 5 ’-GGTGCCGCGCGGC ACTAGTATGACGCTCTC-35 4
AJW69 Forward 5 ’-GCGCGCATGC AATGACGCTCTCATCTGG-3 ’ 2
AJW70 Reverse 5 ’-CGGCTCTAGACTAACCCGCTGCCTCTTGC-3 ’ 1,2, 3, 4
The annealing temperature was determined by the lowest melting 
temperature (Tm) of both primers that covered the optimum temperature 
for each primer. The extension time used was according to the size of the 
fragments to be replicated (typically 1 minute per Kb). PCR conditions 
are reported in Table. 4.3..
Forward primer ndhFw provides a polyhistidine-tag to the ndhA gene by 
annealing with the penta-polyhistidine located in the pET15b vector 33 
bp upstream of the inserted ndhA gene.
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Table 4.3.: Description of the PCR reaction conditions.
Initial denaturation step 94°C for 3 minutes
25 cycles 94°C for 30 seconds Denaturation
56°C for 30 seconds Annealing
72°C for 90 seconds Extension
Final extension step 72°C for 10 minutes
The PCR product was run in an agarose gel (see section 4.2.6.) to confirm 
that the sizes of the fragments obtained matched the expected ones. Then 
the bands were cut under an UV-light transluminator and purified using a 
QIAquick® gel extraction kit (QIAGEN®, Germany).
4.2.10. A-tailing of PCR products
Platinum® Pfic leaves the PCR fragments with blunt ends. In order to 
successfully insert the PCR products into the TOPO® cloning vector 
(Invitrogen™, USA) that has single, overhanging 3’ deoxythymidine (T) 
residues, the PCR product needs to have single deoxyadenosines (A) at 
their 3 ends. Taq polymerase acts as a terminal transferase, adding a 
single A to the end of the strands and thus improving the ligation process.
The A-tailing reaction consisted of the incubation of 15 pi of PCR 
product, 1 pi of Taq polymerase, 2 pi 1 Ox Taq polymerase buffer and 2 pi 
of 10 mM dATPs (New England BioLabs, UK) for 15 minutes at 72°C.
4.2.11. Ligation using TOPO TA Cloning®
The ligations were performed using a TOPO® Cloning reaction. Briefly, 4 
pi of PCR product were mixed with 1 pi of salt solution and 1 pi of a
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TOPO® plasmid vector pCR® 2.1-TOPO® (Invitrogen™, USA). This mix 
was incubated for 45 minutes at room temperature.
4.2.12. Transformation of One Shot®TOP10 chemically competent E. 
coli cells
A vial of One Shot® TOP 10 chemically competent E, coli cells 
(Invitrogen™, USA) was thawed on ice. The cell suspension was 
transformed with the addition of 6 pi of TOPO® cloning reaction, 
followed by an incubation on ice for 30 minutes.
The cells were heat-shocked in a water bath at 42°C for 45 seconds and 
transferred immediately to ice for 2 minutes. 200 pi of super optimal 
broth with glucose (SOC) medium were added to the vial at room 
temperature and shaken horizontally at 200 rpm for 1 hour. 40 pi of X- 
Gal (from a stock of 40 mg/ml in dimethylformamide (DMF) kept at 4°C 
in the dark) were added to the cells, before plating them in selective LB 
agar plates, containing 50 pg/ml ampicillin. The TOPO vector encodes a 
gene that confers ampicillin resistance, allowing only the cells with the 
plasmid to grow. The cells were allowed to grow overnight at 37°C.
The successful plasmid-containing cells appeared white due to the 
disruption of lacZ gene, and a consequential inability to express beta- 
galactosidase. Cells without the insert in the lacZ are able to express the 
gene that converts X-Gal (colourless) into a sugar that oxidises into a 
blue pigment resulting in the formation of blue colonies.
Isolated white colonies were picked and grown in 30 ml universal 
containing 5 ml LB broth supplemented with 50 pg/ml ampicillin for 6-8 
hours at 37°C.
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4.2.13. Mini prep of plasmid DNA
The cells from the white colonies were then harvested and their DNA 
purified using a QIAprep® Spin Miniprep Kit (QIAGEN®, Germany) 
according to the manufacturer’s instructions. This procedure causes the 
lysis of the cells under alkaline conditions and the adsorption of DNA 
onto silica in high salt conditions.
4*2.14. Confirmation of recombinant-plasmid size by enzyme 
restriction analysis
In order to confirm that the plasmid was correctly inserted, restriction 
enzyme analysis was used. The ApE-A Plasmid Editor v2.0.37 software 
was used to obtain the expected restriction lengths of the fragments when 
digested with the enzymes A>w?/and PstI (Fig. 4.3).
4946 Xmnl (2)
ndhA 3999..5411
pCR® 2.1-TORO® +ndhA
3925 PstI (2)
1913 Xmnl (2)
2735 PstI (2)
Fig. 4.3.: Restriction map of the pCR® 2.1-TOPO® vector with the ndhA gene 
inserted using restriction enzymes Xmnl and PstIL Position and length of the ndhA 
gene are indicated with the red arrow. Values in brackets indicate the number of 
restriction sites of an enzyme.
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The enzyme Xmnl would have two recognition sites one within the 
TOPO vector and the second within the ndhA insert (Fig. 4.3.). This 
would create a fragment of 2221 bp that contains the end of the insert and 
a fragment of 3200 bp that would contain the beginning of the ndhA gene. 
If the insert was not present, Xmnl would just open the vector and a 
single band corresponding to its length (3931 bp) would be obtained.
The enzyme PstI recognises two restriction sites within the TOPO vector 
(Fig. 4.3.). This would result in a fragment of 1190 bp that does not 
contain the insert and a second one of 4221 bp that would contain the 
insert. If the insert was not present this second fragment would be of 
2741 bp.
The reactions were set up to a final volume of 30pl according to Table
4.4.
Table 4.4.: Quantities of reagents required for the enzyme restriction reactions.
Reaction 1 Reaction 2
12 (.d sample 12 pi sample
3 pi BSA (lOOpg/ml) 3 pi BSA (lOOpg/ml)
3 pi buffer 4 3 pi buffer 3
2 pi enzyme Xmnl 2 pi enzyme PstI
10 pi sterile dH20 10 pi sterile dH20
Both reaction vials were incubated at 37°C for 2 hours and separated on 
an agarose gel (according to section 4.2.6.).
After a positive confirmation by enzyme restriction analysis of the size of 
the fragments obtained, the samples were sequenced.
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4.2.X5. Capillary sequencing
DNA sequencing by capillary electrophoresis using the dideoxy chain 
termination technique was performed externally by Cogenics™ 
(Beckman Coulter Genomics, UK).
The DNA supplied to the sequencing company had a concentration that 
was always higher than 100 ng/pl.
The primers used for the sequencing reaction (Table 4.5.) were the 
universal primers for the TOPO vector Ml 3 Forward and Ml 3 Reverse 
while ndhAFwd and ndhARev were internal primers that anneal within 
the ndhA gene designed in the laboratory.
After retrieving the sequences from the company, they were aligned 
against the published reference sequence for the gene using ClustalW in 
the BioEdit software (Hall 1999), to confirm their presence in the clone.
Table 4.5.: Primers used to sequence the ndhA gene inserted in the TOPO vector.
Primer Direction Sequence
M13Fwd Forward 5 ’-GTA AA ACGACGGCC AG-3 ’
M13Rev Reverse 5 ’-C AGGA AACAGCTATGAC-3 ’
ndhaFwd Forward 5 ’-GCCGATGGGTCCAAAGCTG-3 ’
ndhaRev Reverse 5’-GATGCCTTTGTAGTCGACCG-3 ’
4.2.16. ndhA cloning in a pUC19 vector
pUC19 vector and the ndhA TOPO clone were double digested with the 
restriction enzymes SphI and XbaL The reactions were set up to a final 
volume of 50 pi according to Table 4.6. The restriction sites within the 
TOPO vector were set up in the primers of the initial PCR reactions 
(seeTable 4.2.) this way flanking the ndhA gene. Accordingly, both
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PUC19 vector and ndhA clone extracted from the TOPO vector have 
cohesive extremities.
Table 4.6.: Quantities of reagents required for the enzyme restriction reactions.
Reaction 1 Reaction 2
pUC19 vector TOPO ndhA clone
4 buffer 2 4 pi buffer 2
4 pi BSA (lOOpg/ml) 4 pi BSA (lOOpg/ml)
3 pi enzyme Xbal 3 pi enzyme Xbal
3 pi enzyme SphI 3 pi enzyme SphI
36 pi pUC19 10 pi ndhA clone
- 26 pi sterile dH20
Both reaction vials were incubated at 37°C for 2 hours. A restriction map 
of the TOPO vector containing ndhA using enzymes Xbal and SphI was 
designed using the ApE-A Plasmid Editor v2.0.37 software (Fig. 4.4.).
1 Xbal (2)
ndhA 3999..5411
pCR® 2.1-TOPO® +ndhA
5411 bp
3944 SphI (3)
2383 SphI (3)
Fig. 4.4.: Restriction map of the pCR® 2.1-TOPO® vector with the ndhA gene 
inserted using restriction enzymes Xbal and SphI. Position and length of the ndhA 
gene are indicated with the red arrow. Values in brackets indicate the number of 
restriction sites of an enzyme.
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pUC19 will generate a band of 2668 bp corresponding to virtually the 
original length of the vector (losing only 18 bp).
The double digestion of the TOPO vector (containing the ndhA gene) 
generates 5 fragments with sizes 2382, 1502, 1468, 52 and 7 bp. The 
1468 bp fragment contains the ndhA gene and it is the one to transfer to 
the pUC19 vector.
To improve the likelihood of a successful ligation and to prevent the 
relegation of the plasmid, the 5’-phosphates were removed from pUC19. 
3 pi of Antarctic phosphatase buffer and 1 pi of Antarctic phosphatase 
were added to the pUC19 digest, incubated for 30 minutes at 37°C and 
heat deactivated at 65°C for 10 minutes.
Two processes were used to isolate the DNA from the digests.
The ndhA clone digest was loaded in a low melting point 1.5% agarose 
gel (0.7 5g of AquaPor LE (National Diagnosis, UK) melted in 50 ml of 
THE buffer. 1.3 pi of ethidium bromide was added to the gel when cooled 
down but before it solidified). The band corresponding to the cloned gene 
was cut from the gel under an UV-light transluminator and the DNA 
purified using a QIAquick® gel extraction kit (QIAGEN®, Germany). The 
DNA concentration was determined in a NanoDrop (see section 4.2.7.).
The pUC19 digest DNA was at a much lower concentration in the gel and 
a more efficient method of purification was used. It was purified using 
Agencourt AMPure beads (Beckman Coulter Genomics, UK) due to the 
higher efficiency of this method to recover amplicons than the procedure 
referred to above. 50 pi of the digested pUC19 product was mixed with 
90 pi AMPure beads and placed in a Agencourt SPRIPlate Magnet plate 
(Beckman Coulter Genomics, UK). This results in the pUC19 DNA 
binding to the magnetic beads. After 10 minutes the supernatant, 
containing the contaminants is discarded and the pUC19 DNA and beads
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are washed twice with 70% (v/v) ethanol in dH20. After being dried out, 
50 fxl of dH20 was added, allowing the elution of DNA from the 
magnetic particles. The DNA was collected in a new tube and its 
concentration checked by aNanoDrop (see section 4.2.7.)
4.2.17. Ligation
To infer the ideal concentrations used in the ligation procedure, a 
ligation calculator” was used, freely available at http://www.insilico.uni- 
duesseldorf.de/Lig Input.html. According to the recommended quantities 
based on the size and concentration of fragments, 1 pi of T4 DNA Ligase 
and 1 pi of T4 DNA Ligase buffer (New England BioLabs, UK) were 
added to 2 pi of pUC19 DNA, 1.5 pi of ndhA clone and 4.5 pi of dH20. 
The reaction was incubated in the thermocycler at 25°C for 6 hours.
The ligations (10 pi) were transformed to One Shot® TOP 10 chemically 
competent E. coli cells using the standard method. Briefly the DNA was 
directly incubated with the cells on ice for 30 minutes. Then the samples 
were heat-shocked at 42°C for 45 seconds and incubated with 200 pi of 
SOC medium for 1 hour at 37°C on a rotary shaking incubator.
200 pi of SOC medium was added to the vial and shaken horizontally at 
200 rpm for 1 hour at room temperature. The sample was plated in 
selective LB agar plates, containing 50 pg/ml ampicillin, which is 
selective for the cells that incorporated the plasmid (that contains a gene 
conferring resistance to ampicillin).
The cells were allowed to grow overnight at 37°C.
Thereafter, isolated white colonies were picked (as explained in section 
4.2.12.) and grown for 6-8 hours at 37°C, in 30 ml universals containing 5 
ml LB broth supplemented with 50 pg/ml ampicillin.
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DNA extraction was performed on the grown cells with CompactPrep 
plasmid maxi unit Kit (QIAGEN®, Germany), which is a fast spin 
column-based large-scale plasmid purification system.
4.2.18. Confirmation of clone size by enzyme restriction analysis
In order to confirm that the cloning process was successful, restriction 
enzyme analysis with enzymes Seal, EcoRI and PvuII was used. A 
restriction map of the pUC19 vector incorporating the ndhA gene was 
designed with the ApE-A Plasmid Editor v2.0.37 software (Fig. 4.5.).
28 EcoRI (2)
118 PvuII (2)
ndhA 2724..4136
933 Seal (1)
pUC19+ndhA 
4136 bp
3111 EcoRI (2)
2482 PvuII (2)
Fig. 4.5.: Restriction map of the pUC19 vector with the ndhA gene inserted using 
restriction enzymes Seal, EcoRI and PvuII. Position and length of the ndhA gene 
are indicated with the red arrow. Values in brackets indicate the number of 
restriction sites of an enzyme.
The enzyme Seal would create a single fragment of 4136 bp if ndhA is 
incorporated since it only cuts once within the vector. The enzyme EcoRI
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cuts once within the vector and once within the insertion producing 
fragments of 1053 and 3083 bp. The enzyme PvuII recognizes two sites 
in the vector flanking the place of the insertion, creating fragments of 
1772 and 2364 bp, the first containing the full ndhA sequence.
The reactions were set up to a final volume of 15 pi according to Table 
4.7.
Table 4.7.: Quantities of reagents required for the enzyme restriction reactions.
Reaction 1 Reaction 2 Reaction 3
2 (il sample 2 pi sample 2 pi sample
1.5 pi EcoRI buffer 1.5 pi buffer 3 1.5 pi buffer 2
1 pi enzyme EcoRI 1 pi enzyme Seal 1 pi enzyme PvuII
10.5 pi sterile dH20 10.5 pi sterile dH20 10.5 pi sterile dH20
Reaction vials were incubated at 37°C for 2 hours and loaded in an 
agarose gel (according to section 4.2.6.).
4.2.19. Preparation of ANN0222 E. coli competent cells using calcium 
chloride
ANN0222 cells are E. coli NADH dehydrogenase knockout strain 
(nuoB::nptI-sacRB, ndh::tet) with no associated NADH: quinone 
oxidoreductase (Fisher et al. 2009).
Cells from an ANN0222 cell stock were streaked onto a LB Agar plate 
supplemented with 30 pg/ml kanamycin and 12.5 pg/ml tetracycline and 
incubated overnight at 37°C. ANN0222 are kanamycin and tetracycline 
resistant. Single colonies were picked and grown in 5 ml LB broth (same 
antibiotic concentrations) until dense.
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100 (Xl of cells were inoculated with 100 ml of LB supplemented with 30 
pg/ml kanamycin and 12.5 jxg/ml tetracycline and grown until OD<5oo= 
0.4. The cells were poured into two ice cold 50 ml Falcon tubes and left 
on ice for 10 minutes. The suspensions were centrifuged at 4000 rpm at 
4°C for 10 minutes and the supernatant discarded.
Treatment with calcium chloride makes the cell competent, enhancing the 
permeability of the cell membrane to allow the incorporation of the 
plasmid DNA. The cells were resuspended in 15 ml of ice cold solution 
of magnesium chloride (MgC^) at 80 mM and calcium chloride (CaCL) 
at 20 mM before being centrifuged at 4000 rpm at 4°C for 10 minutes and 
the supernatant discarded.
The cell pellet was resuspended in 2 ml of 100 mM ice cold CaCl2. Then, 
200 pi of glycerol was added to the cells, mixed gently, aliquoted into 20 
cold eppendorfs and stored at -80°C, constituting a ready to use cell 
stock.
4.2.20. Transformation into ANN0222 competent^, coli cells
The cloned DNA was transformed to ANN0222 competent E. coli cells. 
The DNA was directly incubated with the cells on ice for 30 minutes, 
heat-shocked at 42°C for 90 seconds and incubated with 200 pi of SOC 
medium for 1 hour at 37° C on a rotary shaking incubator.
200 pi of SOC medium was added to the vial and shaken horizontally at 
200 rpm for 1 hour at room temperature. The cells were then plated in 
selective LB agar plates, containing 100 pg/ml ampicillin, 30 pg/ml 
kanamycin and 12.5 pg/ml tetracycline. Ampicillin resistance is 
conferred by the incorporation of the pUC19 vector, ensuring that only 
the cells that incorporated the clone will grow.
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The cells were allowed to grow overnight at 37°C. Isolated white 
colonies were picked and grown in 30 ml universals containing 5 ml LB 
broth supplemented with 100 pg/ml ampicillin, 30 pg/ml kanamycin and 
12.5 pg/ml tetracycline. When dense, the 5 ml of cell suspension was 
transferred to 500 ml of broth supplemented with the same drugs.
The cells were induced at an OD6oo= 0.4 with 1 mM IPTG (from a 1 M 
stock solution, diluted in dH^O). If successful, ndhA would replace the 
gene lacZ of the lac operon and IPTG would switch on this inserted gene 
consequentially leading to the production of the protein of interest.
The cells were grown for a minimum of 32 hours before being harvested 
by centrifugation at 4000 rpm for 5 minutes at 4°C.
4.2.21. Preparation of membranes for kinetic studies
For the preparation of cell membranes, the transformed cells were 
harvested by centrifugation at 4000 g for 20 minutes. The supernatant 
was discarded and the resultant pellet resuspended in 50 mM potassium 
phosphate buffer pH 7.4 (50 ml of buffer was added for every 1 L of cell 
culture) and centrifuged at 4000 g for 20 minutes. Once again the 
supernatant was discarded and the pellet re-suspended in the same buffer 
(20 ml of buffer were added for every 1 L of cell culture). Cells were 
maintained on ice for 30 minutes following the addition of hen-egg 
lysozyme to a final concentration of 0.2 mg-mf1.
A One Shot Constant (Constant Systems Ltd, UK) cell disruptor was used 
to break the cells. Cells were maintained on ice to avoid denaturation of 
proteins due to generation of heat and submitted to 1 shot at 20,000psi. 
An anti-foam cup was used in order to minimise foam produced during 
the process and 6 ml of cell culture was used per shot.
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The suspension was centrifuged at 10,000 g for 30 minutes at 4°C before 
the supernatant was collected and centrifuged at 100,000 g for 1 hour, at 
4°C. The resultant pellet was homogenized with a hand homogeniser in 2 
ml of 50 mM potassium phosphate buffer, 2 mM 
ethylenediaminetetraacetic acid (EDTA) pH 7.4 containing 20% (v/v) 
glycerol. The isolated membrane preparation was stored at -80°C until 
required.
4.2.22. Preparation of the quinone electron acceptor and of the 
NADH stock solution
Decylubiquinone (dQ) and NADH are commercially available (Sigma, 
UK). To prepare dQ stock approximately Img was dissolved in 1ml of 
96% ethanol. NADH stock was prepared by dissolving approximately 
70mg in 1ml of 50nM potassium phosphate, 2mM EDTA (pH 7.5). The 
precise concentration of the dQ and NADH stocks were measured in a 
Cary-UV 4000 UV-VIS spectrophotometer (Varian, UK) using extinction 
coefficients of 8.1 and 6.22 mM^cm"1 respectively.
4.2.23. Enzyme activity of isolated membranes
In order to confirm the enzyme activity of the prepared membrane 
fraction, steady-state activity of the ndhA encoded enzyme was measured 
spectrophotometrically at room temperature, in a Cary-UV 4000 UV-VIS 
spectrophotometer (Varian, UK), and quartz cuvette of pathlength 1 cm.
The total volume of the assay was 700 pi. The crude membrane 
(approximately ISpg.ml!) was mixed with 50 mM potassium phosphate 
(pH 7.5), 2 mM EDTA, pH 7.4 containing 10 mM potassium cyanide (pH
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7.5) and variable concentrations of NADH. Potassium cyanide was used 
to inhibit endogenous E. coli quinol oxidases. The reaction was initiated 
by the addition of 50 [xM decylubiquinone (dQ), a synthetic analogue of 
ubiquinone and was monitored spectrophotometrically by following the 
absorbance changes at 283 nm (quinone reduction) and 340 nm (NADH 
oxidation) at room temperature, according to Fisher et al. 2009.
4.3. Results
4.3.1. Cloning and expression the Mtb ndhA gene
The restriction analyses confirmed that the provided template contained 
the ndhA gene (Fig. 4.6.).
The restriction analysis with EcoRv demonstrated that the enzyme cut 
the vector in two places, generating a fragment of 2883 bp that was 
present whether the gene was inserted or not, and a second fragment of 
4229 bp that had the size of the remaining vector plus an insertion of the 
ndhA gene (Fig. 4.6., lane B).
In the second restriction analysis, Sad cuts only once producing a single 
band of the total vector plus gene, at 7112 bp (Fig. 4.6., lane C).
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Fig. 4.6.: Electrophoretic gel showing the restriction analysis with EcoRv and Sad 
in the vector pET15b with the ndhA insertion. Lanes correspond to (A) Tracklt™ 
1Kb DNA ladder, (B) EcoRv restriction and (C) Sad restriction.
Amplification of the ndhA gene from the pET15b vector using four pairs 
of primers (Table 4.2.) was confirmed by gel electrophoresis. As 
expected, all the pairs of primers produced a PCR fragment of about 1450 
bp (Fig. 4.7., lanes B, C, D,E).
Fig. 4.7.: Electrophoretic gel displaying the four amplified products of the ndhA 
gene using the four pairs of primers described in the text. Lanes correspond to (A) 
Tracklt™ 1Kb DNA ladder, (B) PCR reaction 1, (C) PCR reaction 2, (D) PCR 
reaction 3 and (E) PCR reaction 4.
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Fig. 4.6.: Electrophoretic gel showing the restriction analysis with EcoRv and Sad 
in the vector pET15b with the ndhA insertion. Lanes correspond to (A) Tracklt™ 
1Kb DNA ladder, (B) EcoRv restriction and (C) Sad restriction.
Amplification of the ndhA gene from the pET15b vector using four pairs 
of primers (Table 4.2.) was confirmed by gel electrophoresis. As 
expected, all the pairs of primers produced a PCR fragment of about 1450 
bp (Fig. 4.7., lanes B, C, D,E).
Fig. 4.7.: Electrophoretic gel displaying the four amplified products of the ndhA 
gene using the four pairs of primers described in the text. Lanes correspond to (A) 
Tracklt™ 1Kb DNA ladder, (B) PCR reaction 1, (C) PCR reaction 2, (D) PCR 
reaction 3 and (E) PCR reaction 4.
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The restriction analyses with enzymes XmnI and Pstl revealed that the 
ndhA gene was inserted in the TOPO vector.
The restriction with XmnI produced two fragments of 3200 and 2221 bp 
(Fig. 4.8., lane B). These two fragments were produced due to the 
presence of one restriction site in the TOPO vector and another one 
within the ndhA gene (Fig. 4.3.).
Pstl recognizes two restriction sites within the TOPO vector and it 
generates a band of 1190 bp independent of the insertion being present or 
not (Fig. 4.8., lane C). The second band has 4221 bp which corresponds 
to the remaining TOPO vector with the inserted ndhA (Fig. 4.3.).
Fig. 4.8.: Electrophoretic gel showing the restriction analyses with XmnI (left) and 
Pstl (right). The lanes correspond to (A) Tracklt™ 1Kb DNA ladder, (B) XmnI 
restriction in duplicate and (C) Pstl restriction in duplicate.
After the restriction analyses with XmnI and Pstl, the samples were 
sequenced to verify if the insertion had occurred and if the gene was 
inserted in the right direction. The sequencing was done with four
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primers (Table 4.5.). The M13F and M13R are universal primers located 
in TOPO vector flanking the location of the insertion. The two other 
primers used were located within the ndhA gene to check the complete 
sequence of the gene.
The sequencing with M13F revealed the sequence of the TOPO vector 
followed by an insertion in the expected location of the sequence (Fig 
4.9.). This insertion contains the ndhPFw primer, a small portion of the 
pET-15b that linked the polyhistidine to the ndhA sequence in that vector 
and the beginning of the ndhA sequence.
A
B
A
B
A
B
GGCGAATTGG GCCCTCTAGA TGCATGCTCG AGCGGCCGCC AGTGTGATGG
pCR 2.1-TOPO vector
pET-15b vector portion
ATATCTGCAG AATTCGCCCT T
ndhpFw
primer Recognition site Sphl
_ -YT GACGCTCTCA TCTGGTGAAC
g^GCGGCCTG GTGCCGCGCG GCAGCCAT YT GACGCTCTCA TCTGGTGAAC
ndhA gene
A CCTCGGCCGT CGGCGGGCGC CATCGCGTGG TCATCATCGG TAGTGGATTC
B CCTCGGCCGT CGGCGGGCGC CATCGCGTGG TCATCATCGG TAGTGGATTC
Fig. 4.9.: Alignment of the sequence of the pCR2.1-TOPO vector with the ndhA 
gene obtained with the universal M13F primer.
The sequencing using the M13R primer revealed the TOPO vector 
sequence following an insertion in the expected place (Fig. 4.10.). The 
inserted sequence corresponded to the AJW70 primer sequence the ndhA 
sequence that in this case overlaps with the primer sequence since this 
was designed partially on top of the termination of the gene.
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A TGGCCATCAC CAGCCAGATG ATCTACGCCA GGTTAGTGAT GACCTTGATG
B TGGCCATCAC CAGCCAGATG ATCTACGCCA GGTTAGTGAT GACCTTGATG
ndhA gene
A GAACAGCAGG CACAAGGAGC GCTGGCAGCC GCCGAACAGG CCGAGCACGC
B GAACAGCAGG CACAAGGAGC GCTGGCAGCC GCCGAACAGG CCGAGCACGC
pCR 2.1-TORO vector
B TGGCGGCCGT TACTAGTGGA TCCGAGCTCG GTACCAAGCT TGATGCATAG
Fig. 4.10.: Alignment of the sequence of the pCR2.1-TOPO vector obtained with 
the universal M13R primer and the ndhA gene. Sequence shown is the reversed 
complement of the obtained sequence in order to show the 5’-3’ direction of the 
ndhA gene.
The two internal primers, ndhpFw and AJW70, did not reveal any 
abnormality within the ndhA gene sequence.
The pUC19 vector and the TOPO vector with the inserted ndhA gene 
were double digested by the enzymes Xbal and SphI, whose recognition 
sites in the TOPO vector are shown in Fig. 4.9. and 4.10.. The restriction 
cleavages within the pUC19 vector resulting in only one band, of 2686 
bp, of the entire vector in the gel (Fig. 4.11, lane B). A second band exists 
but since it is less than 20 bp, it would not appear in the electrophoretic 
gel.
In the case of the TOPO vector the restriction sites for these enzymes 
were introduced in the primers of the original amplification of the ndhA 
gene and so the sites are flanking the gene. A fragment of 1468 bp 
containing almost exclusively the gene was generated. A second fragment 
of 2382 bp was easily separated in the electrophoretic gel, however a 
third band of 1502 bp was also generated (see Fig. 4.4.). This band is 
proximal to the band of interest in the gel and it could also be extracted 
when the band of 1468 bp was taken from the gel (Fig. 4.11., lane C). 
The tips of this fragment were also generated through the restriction by
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Xbal and SphI so the fragment could be incorporated into the pUC19 
vector.
This is a flaw in the design of the experiment which could have been 
avoided, for example by the digestion of the TOPO vector//?^ gene 
with a further restriction enzyme that would cut halfway the 1502 bp 
fragment (e.g. Psi'I) leaving the 1468 bp band of interest alone in the gel 
or the gel should have run for longer using a high resolution agarose gel. 
This issue was just detected in the writing up of this thesis. However 
although it should decrease the efficiency of the designed experiment it 
should not make it unviable or the results discarded.
Fig. 4.11.: Electrophoretic gel of the restriction analyses with Xba/ and Sp/i/. The 
lanes correspond to (A) Tracklt™ 1Kb DNA ladder, (B) pUC vector and (C) ndhA 
gene incorporated in the TOPO vector.
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The pUC19 with the insertion was checked by using three restriction 
enzymes, Seal, EcoRI and PvuII. In order to interpret the gel 
electrophoresis results, a restriction map of the possible second type of 
insertion (part of the TOPO vector) was constructed (Fig. 4.12.), using 
the ApE-A Plasmid Editor v2.0.37 software.
28 EcoRI (1)
118 PvuII (5)4043 PvuII (5)
Insert 2669..4170 
3326 PvuII (5)
933 Seal (1)
pUC19+insert 
4170 bp
2966 PvuII (5)
2482 PvuII (5)
Fig. 4.12.: Restriction map of the pUC19 vector with the possible insert originated 
from the pCR2.1TOPO vector using restriction enzymes Seal, EcoRI and PvuII. 
Position and length of the insert is indicated with the blue arrow. Values in 
brackets indicate the number of restriction sites of an enzyme.
The Seal restriction analysis revealed the presence of an insertion since a 
band of more than 4000 bp was present (Fig 4.13., lane C). However this 
restriction does not distinguish between the ndhA gene and the other 
possible insert.
The EcoRI enzyme cuts twice, one within the ndhA gene and the other in 
the pUC19 vector (Fig. 4.5.) generating two bands. Gel electrophoresis 
revealed the presence of the ndhA insert in the pUC19 vector since two
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bands were present, one of about 3000 bp and one of about 1000 bp (Fig. 
4.13., lane B). However, in some cases the restriction with EcoRI showed 
both these two bands but also a band of the size of the overall vector, 
similar to the restriction with Seal (Fig 4.13., lane D). This means that 
either the digestion was not complete or that some of the molecules in 
those samples contained an insert that does not present a restriction site 
for EcoRI. If the restriction was not complete, some of the pUC19 are 
circular and the migration rate is different from the one obtained with the 
Seal. This suggests that some of the vectors just cut once with EcoRI, as 
expected for the abnormal insertion, considering that one of the bands 
had a molecular weight of the full vector with the inserted portion (Fig. 
4.12.). In future work, the experiment will need to be designed so that 
this abnormal insert is not selected during the extraction of the ndhA band 
in the gel, by maximising the separation of the bands in the gel.
4136 bp 
3083 bp
1053 bp
|
Fig. 4.13.: Electrophoretic gel of the restriction analyses of the recombinant pUC19 
vector with EcoRI and Seal. The lanes correspond to (A) Tracklt™ 1Kb DNA 
ladder, (B) and (D) restriction with EcoRI and (C) restriction with Seal.
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The restriction with enzyme PvuII revealed two bands of 1772 and 2364 
bp, indicating that the ndhA gene was inserted in the pUC19 (Fig. 4.14., 
lanes B and C). However, the sample loaded in lane C displayed some 
extra bands that at the time of the experiment were interpreted as over­
digestion by the restriction enzyme, since PvuII is known to exhibit star 
activity (non-specific cutting). Analysing the pUC19 vector with the 
abnormal insert, PvuII cuts in three places in that sequence (Fig. 4.12.). 
This restriction generates several fragments, one of 2634 bp but also, a 
greater number of smaller fragments with 717, 484, 360 and 245 bp (Fig. 
4.14., lane C).
Fig. 4.14.: Electrophoretic gel of the restriction analyses of the recombinant pUC19 
vector with PvuII. The lanes correspond to (A) Hyperladder I™ DNA ladder and 
(B) and (C) restriction with PvuII.
Mainly visible on lane C (Fig. 4.14.) is a set of bands whose comparison 
with the ladder (Fig. 4.14., lane A) fits the expected pattern of the
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insertion with a portion of the TOPO vector, the possible abnormal 
insertion mentioned above. The band with lower weight (245 bp) is 
missing in the gel because it might have just run out of the gel.
Overall it seems that it is quite probable that the abnormal insertion, 
corresponding to a portion of the TOPO vector, is being incorporated in 
some pUC19 vectors. Considering that the pattern observed in lane B 
(Fig. 4.14.) was the prevailing one, it is quite probable that there is a 
higher tendency for the ndhA insert to be incorporated. ndhA is slightly 
smaller than the other possible insert and the conditions in the “ligation 
calculator” were optimized for the ndhA gene which could have 
generated this preponderance.
4.3.2. Kinetic profile of the ndhA gene
After the transformation of the gene ndhA in the E. coli cells and its 
probable expression, the cells were disrupted and the enzyme activity of 
the resultant membranes was investigated spectrophotometrically by 
following the absorbance changes at 283 nm (quinone reduction) and 340 
nm (NADH oxidation) that result upon the addition of decylubiquinone to 
the isolated membrane proteic complexes (See Section 4.2.23.). However 
upon analysis of the recombinant ndhA, no NADH: quinone reductase 
activity was measurable (Fig. 4.15.). Similar to its homologue Ndh-2, 
encoded by ndh, ndhA crude membranes should catalise the oxidation of 
NADH with concomitant reduction of quinone visible 
spectrophotometrically at 340 and 283 nm.
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Fig. 4.15.: Graphical representation of the steady state kinetic data of ndhA 
encoded enzyme activity (NADH: menaquinone oxidoreductase). The data were 
monitored at 283 nm (quinone reduction, blue line) and 340 nm (NADH oxidation, 
red line) and it is evidence of the inexistence of enzyme activity. The reaction 
started with the addition of decylubiquinone at t= 35 seconds.
In order to confirm the validity of the assay, in parallel, using the same 
conditions, the activity of the enzyme encoded by ndh {ndhA analogue) 
was assessed using membranes with the ndh gene cloned (provided by 
Doctor Ashley Warman, from this laboratory and whose methodology is 
reported in (Fisher et al. 2009)). The activity of the enzyme encoded by 
the ndh gene was confirmed (Fig. 4.16.).
NADH dehydrogenase catalyses the reaction NADH + Q (quinone) -► 
NAD + KH2 (quinol).
Absorbance changes at 283 nm measure quinone reduction and 
absorbance changes at 340 nm measure NADH oxidation. Before the 
addition of decylubiquinone, the changes in both absorbances were 
negligible. After the addition of decylubiquinone (noticible by the peak 
measured at 283nm), both absorbances (measured at 283 and 340nm) 
decreased (Fig. 4.16.). This indicates that quinone is reduced to quinol 
and NADH is being oxidised (according to the reaction above) and this is 
an indication of electron transport to an alternative acceptor, most 
probably oxygen.
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Fig. 4.16.: Graphical representation of the steady state kinetic data of ndh encoded 
enzyme activity (NADH: menaquinone oxidoreductase). The data were monitored 
at 283 nm (quinone reduction, blue line) and 340 nm (NADH oxidation, red line) 
and it is evidence of the enzyme activity. The reaction started with the addition of 
decylubiquinone at t= 20 seconds.
For the validation of an enzyme to be used in future drug assays, it would 
be important to do a characterisation of its kinetic parameters, Km and 
vmax* Data would be analysed using the Michaelis-Menten equation in 
order to determine these values. Vmax is the rate at which a substrate will 
be converted to a product once bound to the enzyme and the Km is how 
effectively the enzyme would bind the substrate, hence affinity. If the 
assay was to be developed further, different substrates could have been 
tried (different analogues of quinone) and also different coenzymes 
(NADH/NADPH) before moving to drug screening.
4.4. Discussion
The objective of this chapter was to transform E. coli cells with their own 
ndh gene knocked out and express the Mtb ndh A gene.
ndh is an already identified Mtb drug target, whose expression was 
already studied (Weinstein et al. 2005; Teh et al. 2007). In this context, it 
is essential to know if this known ndh homologue is functional and if it 
shows susceptibility to the same drugs.
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Bacteria have plasticity and this means that they can use different 
pathways to achieve the same outcome, in different scenarios, which can 
be difficult to assess in the lab. This factor creates doubt in studies 
focusing on the up-regulation and down-regulation of genes when 
submitting bacteria to different conditions. Similar issues arise with the 
notion of essentiality or non-essentiality since these concepts can easily 
shift depending on a great multitude of conditions. In the case of Mtb, 
plasticity is particularly important due to the fact that this organism is 
extremely successful, not only infecting and surviving inside the human 
host, but being able to persist in a latent state and re-emerge long after the 
initial infection.
The pET15b vector containing the ndhA gene, was inserted in a pCR® 
2.1-TOPO®, which was followed by insertion of the gene into a pUC19 
vector and the transformation of the «<#L4-encoding plasmid into 
ANN0222 competent E. coli cells. The efficiency of intermediate steps 
was evaluated using restriction enzymes and direct sequencing in order to 
assure that the gene was always correctly cut and inserted. After 
expression of the gene in the ANNO0222 competent E. coli cells, the 
cells were disrupted, the membranes isolated and the activity of the 
enzymes checked. However, no enzyme activity was detected. A number 
of factors may be responsible for the lack of observable enzyme activity: 
one is the possibility that the ndhA gene is not a functional type II 
NADH: menaquinone oxidoreductase and the second is that some 
undetected irregularity in the protocol did not allow for the expression of 
the enzyme.
The observations are in conflict with published results reporting the ndhA 
gene expression and enzymatic activity (Weinstein et al. 2005). Also, the 
genes ndh and ndhA show a considerable degree of similarity and as 
shown in the next chapter, their rate of evolution indicates similar 
evolutionary constraints, probably indicating that both are equally
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functional. Taking this into account, it seems unlikely that ndhA does not 
possess enzymatic activity. However the possibility that ndhA may be 
less favourably expressed and translated needs to be considered. ndhA 
could also be toxic to the host cell or may not fold correctly in the cell 
environment of the host E. coli cell.
Regarding the protocol irregularity, it has been recently noted in our 
laboratory (at a time after termination of my laboratory work) that 
expression of active recombinant protein is very much reliant on 
sustained drug pressure in order for the host E. coli cells to retain the 
gene-encoding plasmid. Indeed, it has been observed that expression of 
ndh, which has previously been seen to be highly active, can be lost if 
ampicillin concentrations fall. It has been seen that upon scale up from 
small (e.g. 10 ml) to large volumes (e.g. 500 ml) that failure to maintain 
the drug (in this case ampicillin) at a sufficiently high concentration over 
the longer growth period required for expression, the plasmid will be lost 
and no expression will occur (personal communication by Doctor Ashley 
Warman). This can be mitigated by the use of freshly prepared drug 
stocks and the mantainence of a high concentration of ampicillin 
(typically lOOpg/ml) in all solid and liquid media. This recent 
observation may well account for the apparent lack of ndhA activity seen 
during my expression trials.
In summary, the ndhA gene was successfully isolated and cloned from 
Mtb and transfected into an E. coli expression system (suitable for high- 
throughput screening) (Fisher et al. 2009). The final scale-up and 
enrichment of recombinant ndhA was not possible, but it is envisaged that 
this is due to a technical problem which could not be resolved at the time 
that this study was conducted. Nevertheless this work represents a 
considerable step forward towards the characterisation of ndhA and 
provides a platform for further studies aimed at understanding the role of 
this protein in the ETC of Mtb.
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Chapter 5. Phylogenetic analysis of type IINADH: 
menaquinone oxidoreductase in the 
Actinomycetales group
5.1. Introduction
Mtb possesses two types of NADH: menaquinone oxidoreductase, the 
type I encoded by 14 genes {nuoABCDEFGHIJKLMN) and type II with 
two known copies coded by the genes ndh and ndhA. These are single 
subunit enzymes and catalyze the first step in the respiratory chain, 
transferring electrons from NAD(P)H to the quinone pool (Kerscher 
2000; Yagi and Matsuno-Yagi 2003).
Unlike type I NADH: menaquinone oxidoreductases, type II enzymes are 
believed to be essential for Mtb survival and they are the only NADH: 
menaquinone oxidoreductase used during hypoxia (Rao et al. 2001). Due 
to this fact and since no homologue exists in the human host this enzyme 
is a promising drug target.
There is very little biochemical information on the structure and function 
of type II NADH: menaquinone oxidoreductases since there are no 
crystal structures described. In addition, very little information exists on 
the evolution of this enzyme and its phylogenetics across species. In this 
Chapter, a molecular phylogenetics and bioinformatics study was 
undertaken to address some of the gaps in knowledge with respect to this 
enzyme.
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Melo and collaborators phylogenetically grouped the type II NADH: 
menaquinone oxidoreductases into three groups, A, B and C, or more 
precisely two considering that group B is a sub-group of A, present in 
eukaryotic organisms (Melo et al. 2004). From the 61 prokaryotic species 
analysed in that study nearly 75% had type II NADH: menaquinone 
oxidoreductases and in about 15%, this was the only type of NADH: 
menaquinone oxidoreductase detected in the organism. In the prokaryotic 
organisms that contained type II NADH: menaquinone oxidoreductases 
nearly 90% of the analysed sequences belonged to group A, including in 
Mtb. The group C sequences were typical of hyperthermophilic 
prokaryotes and were quite divergent from the group A sequences (Melo 
et al. 2004).
Specifically this Chapter addresses:
► Detection of all of the type II NADH: menaquinone 
oxidoreductase homologues within the Actinomycetales groups 
and also hypothetical homologues.
► Phylogenetical characterisation of the different type II NADH: 
menaquinone oxidoreductase homologues to better understand the 
relationships between different Actinomycetales, including 
mycobacteria, in terms of ndh genes with the view of 
understanding their use as models for wd/z-targeting drug 
susceptibility tests.
► Characterisation of ndh homologues in mycobacteria in terms of 
patterns of substitution to try to understand the evolutionary 
forces acting on them, specifically on the ndhA gene of Mtb.
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5.2. Methods
5.2.1. Database
In the genome section of NCBI website 
(http://www.ncbi.nlm.nih.gOv/genome/I a search was performed that 
aimed to detect all the available complete genomes of Actinomycetales. 
Only genomes that had an available complete draft with annotated genes 
were used in the following analyses. A total of 98 complete genomes of 
the Actinomycetales group were retrieved. Additionally, 11 genomes of 
Actinobacteria that are not from the Actinomycetales group were 
included for comparison. The latter ones correspond to one genome of 
each of the different genus in the NCBI database.
In order to locate probable ndh genes or its closest homologues (a set of 
protein sequences sharing a common ancestor) the proteomes of the 
previously indicated genomes were searched. These proteomes include 
predicted sequences using software tools and many have unknown 
functions. A pBLAST (basic local alignment search tool for proteins) 
search in NCBI using the ndh sequence of other organisms outside the 
Actinobacteria group was carried out. The software performs a search in 
the defined database of search (in this case each of the individual 
genomes) and retrieves sequences with similarities providing a 
statistically significant match helping to identify families of genes. It is 
important to use sequences outside the Actinobacteria group so that the 
significance of the sequences detected in the search can be compared in 
the same way for all the groups. For example, if a sequence of the ndh of 
Mycobacterium tuberculosis was used in the query, the obtained score 
could expectedly be higher for the genus Mycobacterium, lower for the 
sequences in the remaining Corynebacterineae group and even lower for 
the remaining Actinobacteria. More problematic would be the possibility 
that an organism acquired an ndh sequence from other bacteria outside
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the Actinobacteria group by horizontal transmission. Using a standard 
significance obtained from analysing Actinobacteria, this sequence could 
be dismissed in the analysis.
The BLAST search was performed using several homologues of ndh to 
increase the confidence of the detection. The query sequences were the 
following:
► ZP 07101259 from the well-studied model organism Escherichia 
coli (Taxonomy: Bacteria/ Proteobacteria/ Gammaproteobacteria/ 
Enterobacteriales/ Enterobacteriaceae/ Escherichia) and 
NP_389111 of Bacillus subtilis subsp. subtilis str. 168 
(Taxonomy: Bacteria/ Firmicutes/ Bacillales/ Bacillaceae/ 
Bacillus) were used as representatives of other Bacteria (non- 
Actinobacteria).
► Sequences NP_213539 and NP_214500 from the Aquifex aeolicus 
VF5 (Taxonomy: Bacteria/ Aquificae/ Aquificales/ Aquificaceae/ 
Aquifex) were included because they represented the further apart 
group C of type II NADH: menaquinone oxidoreductase as 
defined by (Melo et al. 2004). Some preliminary BLAST queries 
with the other sequences defined here presented low scores for 
these sequences.
► YP_001581346 of the Archaea Nitrosopumilus maritimus SCM1 
(Taxonomy: Archaea/ Thaumarchaeota/ marine archaeal group 1/ 
Nitrosopumilales/ Nitrosopumilaceae/ Nitrosopumilus) in order to 
use a sequence probably further apart from the first two groups in 
relation to the Actinomycetales group;
► Sequences CAB52797 and CAB52796 from the plant Solarium 
tuberosum (Taxonomy: Eukaryota/ Viridiplantae/ Streptophyta/ 
Embryophyta/ Tracheophyta/ Spermatophyta/ Magnoliophyta/ 
eudicotyledons/ core eudicotyledons/ asterids/ lamiids/ Solanales/ 
Solanaceae/ Solanoideae/ Solaneae) were included in the query to
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represent an even further apart organism from the 
Actinomycetales, a Eukaryotic organism.
BLAST searches with the query sequences above were performed in the 
annotated genome of the organisms that included in their proteomes both 
experimentally-defined and predicted proteins.
Sequences queries retrieved sequences with BLAST scores between 200 
and 40. Results were compared between the retrieved sequences with the 
different queries and a criterion was stipulated to probabilistically define 
which sequences were ndh homologues.
Usually sequences that displayed scores higher than 50 in all the queries 
and usually more than 100 in one of them were hypothesized to be type II 
NADH dehydrogenases. Sequences that were not so clearly placed 
(scores lower than 50 in some of the queries) were further investigated by 
checking the functional motifs classified by NCBI usually by performing 
a BLAST search in the entire NCBI database and looking for the closest 
homologues to that sequence. The placement of a score of 50 as the line 
of investigation was not random. It is around that point that the BLAST 
search also indicates mainly ferredoxin reductases and nitrite reductases 
as possible homologues.
5.2.2. Alignment
Both annotated and hypothetical NADH dehydrogenases were aligned 
using the software “PROMALS3D multiple sequence and structure 
alignment server” (Pei et al. 2008). One of the advantages of this multiple 
alignment software is that it allows the input of secondary structures, 
taking into account secondary structure prediction as well as the primary
198
structure. The three-dimensional structure of type II-NADH menaquinone 
oxidoreductase in E. coli was used (Schmid and Gerloff 2004).
Additionally a few sequences outside the Actinobacteria were included in 
the alignment to better root the Actinobacteria sequences or to better 
place them in the overall tree (described in Melo et al. 2004) in the 
Phylogenetic reconstruction. These sequences corresponded to the 
sequences used in the queries for the BLAST described before as well as 
the sequences:
► AJ489504 from the Archaea Acidianus ambivalens that 
represents a further group C sequence as described previously 
(Melo et al. 2004). Another sequence (YP 919639- ThpenH) 
from Archaea Thermqfilum pendens Hrk 5 was used to better 
phylogenetically establish group C.
► Apart from the sequence NP_389111 of Bacillus subtilis subsp. 
subtilis str. 168 that was used in the BLAST search, three further 
homologue sequences were present in this organism 
(NP 391090, ZP 03592999 and NP_391100).
► Sequence NP_279851 of Archaea Halobacterium sp. NRC-1 
was included because it was in the root of the group A (Melo et 
al. 2004).
It is not feasible to show the multiple alignments of more than 300 
proteins. Instead, the regions of major conservation of the protein using 
the WebLogos website (http://weblogo.berkelev.edu/logo.cgri (Crooks et 
al. 2004) are shown. Logos are graphic representations of the 
conservation of a sequence. Alignments are represented by stacks of 
symbols (amino-acids in this case) whose height is higher or lower 
depending on how conserved the position is. Additionally within each 
stack two or more amino-acids can be present with relative height
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indicating their frequency within that position (Schneider and Stephens 
1990).
5.2.3. Phylogenetic reconstruction
The aligned sequences were run in MrBayes v3.2.1. This software 
estimates a phylogeny using Bayesian inference (Huelsenbeck and 
Ronquist 2001). MrBayes uses a Markov Chain Monte Carlo (MCMC) 
method algorithm. The software performs a number of iterations with the 
calculated data moving from one state to the other in each step of the 
chain. The algorithm uses the state of the chain after a large number of 
iterations to calculate a posterior probability distribution. The confidence 
in the calculated probability distribution will be higher, the larger the 
number of iterations. The number of iterations was set to 1,000,000 
iterations (or generations in the terms used by the software) however this 
value can be extended if convergence of the data was not obtained, but 
this was not the case. The value indicating convergence in the run is the 
standard deviation of split frequencies. The authors suggest a value below 
0.10 to indicate convergence, although the software was run until this 
value was below 0.05, for better confidence.
The obtained tree with posterior probability of each node in the tree was 
displayed using FigTree v 1.3.1 ditto://tree,bio.ed.ac,uk/software/figtreeT
5.2.4. Calculation of Ka/Ks using maximum likelihood
Nucleotide sequences encoding proteins are limited by natural selection 
in the kind of mutations that can occur. In protein coding genes, 
mutations can be either non-synonymous or synonymous. Synonymous
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mutations (Ks or dS) not changing the protein sequence are far more 
neutral than non-synonymous (Ka or dN) mutations (there are still issues 
involving codon-usage where one of the codons that code for the same 
amino acid is preferred in relation to another by the organism). Non- 
synonymous mutations will alter the protein sequence and the seriousness 
of mutations will depend on the region of sequence and the differences in 
properties between the original residue and the new amino acid. Some 
non-synonymous mutations can be neutral.
Given the outcomes described above, a sequence that is not functional or 
essential will allow a much more random number of non-synonymous 
mutations to occur at a much faster rate than in a gene that is functional 
and essential since natural selection will eliminate the organism where 
the mutation occurred if this mutation impaired its survival. However the 
number of mutations observed is dependent on the mutation rate that 
depends on the organism and region of the genome (Yang 2007). 
Synonymous mutations on the other hand accumulate almost neutrally 
and the number of synonymous mutations observed will also depend on 
the mutation rate. This way, synonymous mutations can be used to scale 
the number of non-synonymous mutations in the branches and allow 
comparison using a ratio of non-synonymous to synonymous mutation 
(Ka/Ks or dN/dS ratio) (Yang 2007). If this value is high when compared 
to other closely related homologous sequence, it could mean that the gene 
is accumulating a larger number of non-synonymous mutations than the 
other. This could mean either that it is possible evidence that the gene 
might not be essential and natural selection is allowing it to accumulate 
mutations randomly (Yang 2007). On the other hand, if that value is 
substantially higher than what would be obtained randomly, it could 
mean that a series of non-synonymous mutations were selected to persist 
during evolution and it could be a sign of positive selection. However, 
instances of positive selection are rare. A low value suggests that
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mutations are probably occurring randomly in the gene but damaging 
non-synonymous mutations were continuously eliminated. For example 
the Ka/Ks average value per homologous genes between Human and 
Chimpanzee is 0.23 (Chimpanzee sequencing and analysis consortium 
2005).
The software PAML 4 (Yang 2007) was used to calculate dS/dN ratios 
across clades of the ndh tree. This software uses maximum likelihood in 
the calculations and allows testing for significant differences across this 
ratio in the tree. Sub-trees of interest from the main tree were selected. 
One of these sub-trees was the sub-branch containing the Mtb ndh and 
ndhA genes to check for differences in their selective pressure.
5.3. Results
5.3.1. Retrieved sequences
A total of 299 sequences were retrieved using the BLAST queries 
described above. Almost all the retrieved sequences were classified as 
either “NADH dehydrogenases”, “dehydrogenase”,” oxidoreductase” and 
“FAD-dependent pyridine nucleotide-disulfide oxidoreductase”. Some 
were just classified as “Hypothetical protein”. All the retrieved sequences 
within the Actinomycetales group are displayed in Table 5.1.
NCBI also displays probable functional motifs in the description of the 
protein sequences. From the hypothetical 299 retrieved sequences within 
the Actinomycetales group 266 (89%) contained the multi-domain motif 
ndh (code: COG1252) defined as “NADH dehydrogenase, FAD- 
containing subunit: Energy production and conversion” (Marchler-Bauer 
et al. 2011). 33 (11%) contained the motif HcaD (code: COG0446)
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defined as “Uncharacterized NAD(FAD)-dependent dehydrogenases: 
General function prediction only” (Marchler-Bauer et al. 2011).
As mentioned before a sequence representative of each genus within 
Actinobacteria outside the Actinomycetales group that is available in 
NCBI was incorporated for the phylogenetic analysis. The species were 
the following:
► Acidimicrobium ferrooxidans DSM 10331 retrieved sequences
YP_003110137, YP_003108805, YP_003108722,
YP_003110002) as hypothetical ndh homologues;
► Bifidobacterium animalis subsp. lactis DSM 10140 and 
Gardnerella vaginalis 409-05 are from the Actinobacteridae group 
but Bifidobacteriales subgroup did not have any type II NADH 
dehydrogenase detected;
► Atopobium parvulum DSM 20469, Coriobacterium glomerans
PW2, Cryptobacterium curtum DSM 15641, Eggerthella lenta 
DSM 2243, Olsenella uli DSM 7084 and Slackia
heliotrinireducens DSM 20476 from the Coriobacteridae group 
also did not display any retrievable sequence;
► Rubrobacter xylanophilus DSM 9941 from the Rubrobacteridae
group displayed sequences YP_643995, YP_643877, YP,_643890 
and YP_643877 and Conexibacter woesei DSM 14684 from that 
same group had the sequences YP_003394640 and
YP_003396921 detected in the BLAST queries.
The number of the hypothetical ndh homologues is not similar across all 
the Actinomycetales (see Table 5.1.). One thing to take into account is 
that several bacteria evolved with reduction of the genome as is the case 
of Mycobacterium leprae (Gomez-Valero et al. 2007). It is expected that 
these smaller genomes will have a lower number of hypothetical ndh 
homologues. In order to obtain a clear picture of the relationship between
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genome size of the different Actinomycetales and the number of 
hypothetical ndh homologues, a dispersion graph was drawn (Fig. 5.1.) 
and a linear regression was calculated.
y = 6E-07x +0.2915
= 0.3979
2,000,000 4,000,000 6,000,000 8,000,000
Genome size (bp)
10,000,000
Fig. 5.1.: Relation between the sizes of the genome of the analysed Actinomycetales 
and the number of hypothetical type II NADH dehydrogenases detected. A 
regression curve was calculated in order to illustrate the general trend. Data points 
for the five Mtb strains are shown in red. The lower red dot refers to the 
overlapping of 4 of the Mtb strains.
The distance between the line and the observed number of hypothetical 
ndh homologues allows one to visualise the ones with the most abnormal 
number of sequences. A graph of the distance between observed and 
expected hypothetical number of ndh homologues is shown in Fig. 5.2. 
The expected number of hypothetical ndh genes was obtained from the 
correlation shown in Fig. 5.1. Values above the line (positive) indicate 
that those species have more hypothetical ndh homologues than it was 
expected from its genome size, and negative values indicate that the 
strain has lower number of hypothetical ndh homologue genes than it was 
expected from its genome size.
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The organism that presents the most abnormal number of possible ndh 
homologues in this study is Rhodococcus jostii RHA1 that was described 
as a catabolic powerhouse in an 02-rich environment (McLeod et al. 
2006), followed by the strains of Mycobacterium sp. However, not all the 
genes necessarily code NADH dehydrogenases or are functional. For 
example, the hypothetical proteins YP_704495 and YP_704496 of 
Rhodococcus jostii RHA1 (Table 5.1.) are a single typical ndh sequence 
that has been separated by a mutation generating a STOP codon halfway, 
possibly suggesting that it was not an essential copy. In this study, 
Amycolatopsis mediterranei U32 is the organism with the lowest number 
of ndh homologues considering its genome size , mainly because it 
presents one of the larger bacterial genomes sequenced so far (Zhao et al. 
2010).
Mtb strains contained four hypothetical ndh homologues, not only the 
ndh and the ndhA genes, but also two other sequences that differ greatly 
from these but showed some significant degree of homology to the 
sequences used in the queries. Mtb strain H37Ra actually has two exact 
copies of the ndh gene according to the BLAST search (YP_001283183 
and YP_001281620 in Table 5.1.), which could represent a very recent 
duplication, possibly even in its laboratory life since it is not present in 
the other four strains. M. smegmatis that is sometimes used as a model 
organism for the study of Mtb (Chapter 2) contained 5 hypothetical ndh 
homologues (Table 5.1. and Fig. 5.1.).
5.3.2. Alignment
The Logo (Crooks et al. 2004) representing the obtained alignment is 
shown in Fig. 5.3. It can be seen that some regions contained a much 
higher level of conserved residues partly corresponding to the multi-
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domain motif ndh (code: COG1252) (Marchler-Bauer et al. 2011). The 
red and blue lines below each of the lines of the Logo correspond to the 
regions of the general alignment that contains the Mtb ndh and ndhA 
respectively.
Fig. 5.3.: Logo of the alignment of proteins encoded by the different hypothetical 
ndh genes. Red and blue line below each section represented the common region 
with the ndh and ndhA protein products, respectively. Each lane represents 100 
amino-acids of the overall alignment.
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All the ndh proteins contain a motif GXGXXG for NAD(P)H binding. 
This is displayed in positions 24 to 29 of the alignment. A second one is 
present in most of the ndh protein sequences and is displayed in positions 
187 to 192 of the alignment. Other highly conserved residues are 
observed in the alignment. The region of the alignment 120-130 presents 
a series of highly conserved amino-acids. Another important feature is 
the total conservation of the amino-acids Glycine-Aspartic Acid in 
positions 332-333 of the alignment (Fig. 5.3.).
5.3.3. Phylogenetic reconstruction
Phylogenetic reconstruction was performed using the part of the molecule 
that was alignable between all the available sequences. In order not to 
lose a portion of the sequence in the analysis a few sequences were 
excluded:
► NP_821985 (SavMAe) from Streptomyces avermitilis MA-4680 
does not contain about 25 residues of the homologue sequence in 
the beginning of the alignment. A pBLAST search indicated that 
the most similar sequences in the alignment were YP_003340434 
(SroDSc) from Streptosporangium roseum DSM 43021 and 
YP_956125 (MvaPyc) from Mycobacterium vanbaalenii PYR-1 
and both contain this homologous region.
► YP_001507876 (FspEAd) from Frankia sp, EANlpec is the 
smaller protein sequence in the alignment (299 residues). 
Although it shows homology to the remaining sequences in the 
beginning and end of the sequence, it lacks a great portion of the 
alignable region in the middle of the alignment (about 100 aa). A 
BLAST search indicates that it is more similar to the sequence
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YP_003112856 (CacDSa) of Catenulispora acidiphila DSM 
44928.
v YP_002765779 (RerPRd) from Rhodococcus erythropolis PR4 
lacks about 50 residues of the homologous sequence. A BLAST 
search indicates that the sequence is similar to the sequence 
YP_001852747 (MmaMc) in Mycobacterium marinum M and 
sequence YP 908065 (MulAgb) of Mycobacterium ulcerans 
Agy99.
The obtained phylogenetic tree is displayed in two formats in Figs. 5.4. 
and 5.5. showing the two groups described by Melo et al. 2004 as well as 
two other possible sub-branches. Showing all the information in a single 
tree is difficult considering the number of stains involved, so in Fig. 5.4. 
the posterior distribution of each node was displayed and in Fig. 5.5. the 
code for each of the ndh homologues in the strains was shown. Also 
although Fig. 5.5. allows a clearer visualization of the phylogeny, Fig 5.4. 
shows a more traditional format. Fig. 5.6. displays the same tree format 
as in Fig. 5.5. but focusing on the taxonomy of the strains from which the 
ndh genes were extracted.
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Fig. 5.5.: Phylogenetic tree of the hypothetical type II NADH dehydrogenase 
homologues in Actinomycetales. Red branch corresponds to group A described by 
Melo and colleagues (Melo et al. 2004), Blue branch to group C and orange and 
green branches correspond to new possible sub-branches. Codes of the proteins 
according to Table 5.1. are indicated in the tips of the branches.
The phylogenetic analysis divided the data into four main groups: one in 
red in Figs. 5.4 and 5.5 and by far the largest one corresponds to group A 
of Melo et al. 2004. Species in Actinomycetales mainly possess ndh 
homologues from group A. The group C defined by the authors is typical 
of hyper-thermophilic prokaryotes and only contains the first GXGXXG 
NAD(P)H binding motif. It is only present in 3 sequences in all the 299 
hypothetical sequences (YP 003719267 of Mobiluncus curtisii ATCC 
43063, YP_906742 of Mycobacterium ulcerans Agy99, YP 001851031 
of Mycobacterium marinum M).
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Non-actinobacteria 
Actinobacteria non-actinomycetales
Actinomycetales non-Cory nobacteria 
Corynobacteria non-Mycobacteria 
Mycobacteria (non- Mycobacterium tuberculosis/bovis) 
Mycobacterium tuberculosis/bovis
Fig. 5.6.: Phylogenetic tree of the hypothetical type II NADH dehydrogenase 
homologues in Actinomycetales. Mycobacterium tuberculosis/bovis, other 
mycobacteria, other corynebacteria, Actinomycetales non-corynebacteria, 
remaining Actinobacteria and other organisms are indicated in the tree in different 
colours.
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5.3.4. Group D
In relation to the tree by Melo et al. 2004, two other groups show up as 
sister groups to A and C. For the purpose of making things easier 
throughout the results and discussion the sister group to group C is 
labelled as group D (in orange in Fig. 5.5 and 5.6). This group contains 
an intertwining of genes or predicted genes that either contain the motif 
COG1252 “NADH dehydrogenase, FAD-containing subunit: Energy 
production and conversion” (Marchler-Bauer et al. 2011) or the retrieved 
genes with the motif COG0446: “Uncharacterized NAD(FAD)-dependent 
dehydrogenases: General function prediction only” (Marchler-Bauer et al. 
2011). This shows that sequences with the motifs COG1252 and 
COG0446 are indistinguishable when analysed evolutionarily.
Most of the Mycobacterium sp. strains possess two possible homologues 
within this group and corynebacteria (including mycobacteria) are not 
well represented here. Mycobacterium tuberculosis/bovis however 
possess a hypothetical homologue (Fig. 5.6.). None of the mycobacteria 
or corynebacteria strains that showed proximity in group A (see below) 
present a similar copy of this homologue. It could mean that the other 
mycobacteria lost the gene during evolution or that the gene was acquired 
by the common ancestor of the Mtb complex. The analysis of Becq and 
colleagues actually indicated that this is a probable Mycobacterium 
tuberculosis complex-specific genomic island acquired by horizontal 
transfer (Becq et al. 2007).
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5.3.4. Group E
The most common group A presented a sister group in the analysis that is 
labelled as group E (in green in Fig. 5.4. and 5.5.). Contrarily to the new 
hypothetical group D described previously almost all the mycobacteria 
have a homologue in this clade with nearly all of them clustering 
together. However Mtb has a homologue quite divergent from the ones 
presented in the other mycobacteria, with the exception of 
Mycobacterium marinum and Mycobacterium ulcerans that present two 
homologues in this group E. One clusters with the gene from the 
remaining mycobacteria and another closely related with the homologue 
present in Mtb.
5.3.5. Group A
This group defined by Melo et al. 2004 is the most common one and it is 
found in almost all Prokaryotic and in some Eukaryotic organisms.
Apart from a couple of exceptions, all the sequences outside of the 
Actinomycetales that were placed in the analysis in order to contextualize 
the Actinomycetales sequences (described in section 5.2.2) present a 
more basal position in the tree (sequences in red and orange in Fig. 5.6. 
and 5.7.). The Actinomycetales mostly cluster together (Fig. 5.7). The 
Actinomycetales variation further divides into two well-defined major 
subclades (group A and B in Fig. 5.7). One, group A in Fig. 5.7. mainly 
contains Actinomycetales that are not corynebacteria (more than 90% of 
the sequences of the sequences in this sub-group) while the other (group 
B) mainly contains corynebacteria (around 86% of the sequences), 
suggesting that the separation between corynebacteria and the other 
Actinomycetales might represent the first or one of the first major 
evolutionary splits within the Actinomycetales group. Caution should be
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exercised about general inferences regarding separation of groups since 
this corresponds to the analysis of a type of gene and not the overall 
genome of the strains.
Fig. 5.7.: Phylogenetic tree of the group A (Melo et al 2004) of type II NADH 
dehydrogenase in Actinomycetales. Mycobacterium tuberculosis/bovis specifically, 
other mycobacteria, other corynebacteria, Actinomycetales non-corynebacteria, 
remaining Actinobacteria and other organisms are indicated in the tree and the 
colour code is the same as in the tree in Fig. 5.6. from which this sub-tree is an 
extracted part. Two groups are indicated (A and B) representing the two groups 
that contain Actinomycetales.
The analysis also shows mycobacteria almost confined to specific sub­
codes. The largest one of these contains the ndh gene of Mtb. This gene 
is evolutionarily closer to its equivalent in M. avium, M. marinum and M. 
ulcer arts followed by M. leprae. The ndh gene of M. smegmatis and other 
mycobacteria are contained in this clade but evolutionarily more distant 
than the previous ones. A second clade represented by homologues in 
mycobacteria contains the Mtb ndhA gene. M avium and M. marinum
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also possess close homologues to the Mtb ndhA. This is the only instance 
in the tree where the M. marinum gene is not closely accompanied by an 
equivalent in M ulcerans. It happens in the other four analysed genes of 
M marinum suggesting that most probably it was recently lost from its 
genome. M leprae does not contain a corresponding copy but genome 
reduction is the rule in the evolution of this species (Gomez-Valero et al. 
2007). These species (Mtb, M avium, M. leprae, M. ulcerans, M. 
marinum) appear together in the common ndh homologue and although 
they use different hosts they are all pathogenic to some extent, suggesting 
that this ndh clade might represent an evolutionary clade where 
acquisition of pathogenicity occurred.
ndhA is a closely related copy of the common ndh. Phylogenetically it is 
closer to the regular ndh gene of all mycobacteria suggesting it was the 
result of a gene copy in an ancestor. The fact that it is not present in all 
mycobacteria is most probably due to gene loss during their evolution. 
The fact that some corynebacteria (and even one Actinomycetales non- 
corynebacteria) also appear intertwined in the mycobacteria ndhindhA 
clade (Fig. 5.6 and 5.7) might suggest that this duplication actually 
occurred in an ancestor corynebacteria, but their presence in the 
ndhindhA clade might be caused by horizontal transfer, incorrect 
taxonomy of the species or erroneous phylogenetic reconstruction 
(although the overall clade has a probability of 100% in the analysis (Fig. 
5.5 and 5.6)). Horizontal gene transfer in bacteria is known to be a 
common process involving plasmid exchange and this occurs even 
between evolutionary distinct strains (Barlow 2009).
The M. smegmatis used as a model organism for Mtb studies (Chapter 2) 
showed 5 hypothetical ndh homologues (Table 5.1) and usually 
evolutionarily very distant from the Mtb clades (the ndh homologue 
described in this section is the closest relative) (Fig 5.5 and 5.6), again 
suggesting that it is a bad model organism when dealing with ETC.
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5.3.6. Similarities between the 4 hypothetical ndh homologues in Mtb
After performing the search with the queries, four hypothetical ndh 
homologues arose in Mtb. Two were the known ndh and ndh A, while two 
others are unidentified genes with predicted function only. In the UniProt 
database (http://www.uniprot.org/) they are both classified as “FAD- 
dependent pyridine nucleotide-disulphide oxidoreductase” (IPRO13027) 
and “Pyridine nucleotide-disulphide oxidoreductase, FAD/NAD(P)- 
binding domain” (IPR023753), similar to the ndh and ndhA genes. The 
overall similarities of the 4 ndh Mtb homologueswere checked to see if 
they were in the range of the observed in other type II NADH: 
menaquinone oxidoreductase genes, when compared with the known E. 
coli gene and also with a sequence from group C, Acidianus ambivalens. 
The percentage of identity of the different type II NADH: menaquinone 
oxidoreductase described by Melo et al 2004 when compared with the E. 
coli homologue varied between 12 and 54% (Melo et al. 2004). The four 
hypothetical ndh homologues in Mtb had percentage of identities in 
relation to E. coli varying between 15 and 24% (Table 5.2.). ndh and 
ndhA have the highest percentage of similarity to E. coli since they are 
from group A, followed by the ndh homologue from the clade E that it 
was presented as a sister clade of group A in the phylogenetic analysis 
(Fig. 5.4 and 5.5). The ndh homologue in clade D, a sister clade of clade 
C in the phylogeny (Fig. 5.4 and 5.5), had a level of similarity 
comparable to the representative of group C included (A. ambivalens). 
The level of similarity supports the obtained phylogeny and indicates that 
the levels of similarity are within the perceived for an ndh homologue.
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Table 5.2.: Percentage of identity between the ndh gene of E. coli, A. atnbivalens 
and the four hypothetical ndh homologues of Mtb {ndh, ndhA, ndh-E and ndh-D).
E. coli ndh ndhA ndh-E ndh-D A. ambivalens
E. coli 100 24 24 19 15 15
ndh 100 63 20 18 10
ndhA 100 19 16 16
ndh-E 100 21 16
ndh-D 100 20
A. ambivalens 100
A protein distance matrix (ProtDist) that takes into account the distance 
between the different amino-acids in a position was also calculated using 
the Bioedit Software (Hall 1999). The results are displayed in Table 5.3.
Table 5.3.: Protein distances between the ndh gene oi E. coli, A. ambivalens and the 
four hypothetical ndh homologues of Mtb {ndh, ndhA, ndh-E and ndh-D).
E. coli ndh ndhA ndh-E ndh-D A. ambivalens
E. coli 0.0000 2.7820 2.7366 3.4730 3.9874 4.3692
ndh 0.0000 0.7940 3.3216 3.8134 4.5462
ndhA 0.0000 3.2657 3.9119 4.7834
ndh-E 0.0000 3.8402 4.0378
ndh-D 0.0000 3.3614
A. ambivalens 0.0000
The results are very similar to the ones obtained with the percentage of 
similarity, ndh and ndhA of Mtb are more similar to the ndh of E. coli 
followed by ndh-E. ndh-D appears more similar to the ndh of Mtb and E. 
coli genes than the group C sequence included (A. ambivalens).
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5.3.7. Rates of non-synonymous vs. synonymous mutations
As mentioned in the methodology the Ka/Ks ratio or dN/dS ratio allows 
one to detect selection on genes. The basic idea is that a low non- 
synonymous to synonymous ratio would mean that purifying selection is 
acting on the genes eliminating many of the new originated non- 
synonymous mutations. A higher ratio could either mean that the gene is 
under positive selection or that the purifying selection is relaxed or 
inexistent, a scenario that could happen if the gene is not necessary or it 
is an unused copy.Usually a dN/dS ratio of one or close to that value is 
usually considered a signal of relaxed negative selection probably 
indicating that the gene is non-functional.
Running the entire tree in a Maximum Likelihood analysis, including the 
alternative analysis required, would take several months for each of the 
analyses. For that reason a few representative branches of interest were 
selected. These include the branches where Mtb ndh hypothetical 
homologues are present. Also a major branch that contains the only copy 
of ndh homologues in some of the Actinomycetales studied and that are 
undoubtedly ndh homologues (Group A) was included as a control to 
obtain an independent dN/dS ratio.
The selected clades are indicated in Fig. 5.8. The green section is part of 
the group A and contains the ndh/ndhA clade of Mtb (portion A of Fig. 
5.7). The red section is another part of group A that does not contain 
mycobacteria representatives (portion B of Fig. 5.7). The yellow section 
corresponds to group E. The blue section corresponds to the part of group 
D that contains Mtb representatives.
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Fig. 5.8.: Phylogenetic tree of hypothetical ndh homologues in Actinomycetales 
indicating groups used in the dN/dS analysis in red (Group A control), green 
(Group A - ndh and ndhA), orange (group E) and blue (Group D). Branches in 
black represent groups sequences not used in the dN/dS analysis.
The results for the dN/dS ratio of the four sub-trees are shown on Table 
5.4.. Except for the case of the control the Mtb homologue branches were 
investigated to check if they had a different behaviour from the remaining 
sub-tree (for example recent relaxation of selection meaning higher 
dN/dS). This was done by stipulating that the branch with the Mtb 
homologue has a different dN/dS ratio from the remaining tree. The 
software also allows a comparison between this analysis and the analysis 
considering a single dN/dS ratio using a test named likelihood ratio test 
(Felsenstein 1981) that provides a p-value of significance (Table 5.4).
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This indicates if the Mtb branch in each analysis is significantly different 
from the remaining tree.
Table 5.4.: dN/dS ratios for four separate sub-trees. Trees with Mtb homologues 
were also run stipulating two ratios. A likelihood ratio test (LRT) was used to 
calculate significance values between both analyses.
Single 
dN/dS ratio
Two dN/dS ratios
Clade Overall tree Mtb branch Remaining tree LRT p-value
Group A Control 0.05995 _ .
Group A ndh 0.06463 0.04512 0.06580 0.077
Group A ndhA 0.06819 0.06455 0.853
Group D 0.02188 0.05885 0.02153 0.597
Group E 0.07877 0.06263 0.08054 0.124
Most of the dN/dS estimates indicate a value around 0.06. Group D 
presents overall dN/dS ratio of just above 0.02 and group E presents a 
value close to 0.08. These differences are probably caused by chance. 
Overall the values are very similar and all very far from 1. Values 
between 0.02 and 0.08 indicate a strong effect of purifying selection 
which just acts on genes whose alteration would decrease the probability 
of survival of the organism. It can be seen that all the 4 individual 
branches of possible ndh homologues have even more similar dN/dS 
ratios (0.04512 to 0.06819), suggesting that the four genes are under 
similar levels of selective pressure. Also the dN/dS ratio in the Mtb 
branches was never significantly different from the one in the remaining 
sub-clades.
In order to provide evidence that the methodology would be efficient in 
detecting non-functional genes it was tested in a gene that has been 
suggested to be a pseudogene. One such case is the adenylyl cyclase gene 
that is only present in some of the tuberculosis complex strains. It is
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thought to be a pseudogene in Mtb but actually functional in other 
Mycobacterium species, namely M. avium (Shenoy et al. 2005). A sub-set 
of sequences of this clade were extracted from mycobacteria from NCBI 
(YP_001133357, YPJ)01852602, YP_904378, EG037700, YP_880496, 
YP_641253, NP_215636, NP_854807, ZP_06798993 and
YP 004744585) and submitted the sequences to the same methodology 
described previously (reconstruction with MrBayes and calculations in 
PAML of dN/dS ratios). The overall dN/dS ratio of the tree was 0.10343. 
When calculating the ratio in the Mtb branch against the remaining tree 
the value was of 0.69314 against 0.05096 with the comparison of the 
analyses yielding a significant difference (LTR p=4.213 xiO'14). The 
value for the remaining tree was clearly in the range of what was 
obtained for the hypothetical ndh homologues sub-trees but the value for 
the Mtb branch was about 10 times higher suggesting that the Mtb branch 
was accumulating 10 times more non-synonymous mutations than the 
average analysed mycobacteria genes suggesting lower selective pressure 
in Mtb. Considering that the gene is thought to be functional in M avium 
the individual dN/dS ratio for that branch was calculated and it yielded 
the value of 0.04920 in line with the possible ndh homologues.
5.4. Discussion
While in eukaryotic organisms, specially animals, where horizontal 
transfer does not occur and the history of the genes can provide a good 
approximation to the history of the species, in bacteria a given strain can 
easily acquire the gene of another relatively distant species and it will 
appear phylogenetically proximal when studying that gene (Philippe and 
Douady 2003). Horizontal transfer is known in Mtb genomes (Becq et al. 
2007) and even eukaryotic genes might have been incorporated in the 
Mtb genome (Gamieldien et al. 2002). Recombination between strains 
has also been hypothesized as a force in shaping the Mtb genome (Liu
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and Gutacker 2006). However some possible cases are obtained from the 
evolutionary history of the genes. In this work an extensive search of all 
possible ndh homologues within the available complete genome of 
Actinomycetales as well as on other Actinobacteria was carried out in 
order to establish an evolutionary history of the genes in this group. Melo 
and collaborators performed an evolutionary analysis in a wide group of 
bacteria that contained only three Actinomycetales (Melo et al. 2004). At 
least one ndh homologue is present in most of the Actinomycetales 
species. Here a phylogenetic analysis using Bayesian analysis in 
MrBayes was carried out. This is a character-based method where the 
phylogeny obtained is based on a pattern of shared amino-acid changes 
that is shared between a given group. In the case of distance-based 
methods like the neighbour-joining one used by Melo and collaborators 
(Melo et al. 2004) phytogenies are based on a matrix of genetic distances 
where evolutionary relationships could be totally mixed due to different 
mutation rates of the different species or region of the genome. The two 
main groups described by (Melo et al. 2004), group A (containing B) and 
C are well defined considering the long distance between the two, but for 
more detailed and well-defined relationships between sequences within a 
group, a more powerful phylogenetic analysis is required like the one 
employed here. Almost all the Actinomycetales had an ndh homologue 
from group A. One interesting point is that there is a possible split 
between the corynebacteria group (that includes mycobacteria) and the 
remaining Actinomycetales (Fig. 5.6 and 5.7). There are exceptions in the 
phylogeny for the described group relationships that may be due to the 
occurrence of horizontal transfer, erroneous phylogenetic reconstruction 
and taxonomic misclassification. Hence studies of evolutionary 
relationships between organisms should be performed in overall genomes 
or at least a set of genes, and not on a single gene or family of genes. 
Within the clade containing mainly corynebacteria two ndh of Mtb exist, 
the ndh and the ndhA genes (group B in Fig. 5.7). These homologues are
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closely related but the phylogeny suggests that the duplication occurred 
probably in an ancestor corynebacteria or an early mycobacteria. Most 
probably the ndhA gene was lost in most mycobacteria species during 
evolution. This homologue was kept in the Mtb complex, in M, marinum 
and M. avium (Fig. 5.7). In terms of the ndh gene the species closer to the 
Mtb complex were M. avium, M. leprae, M, ulcerans and M. marinum 
which also have pathogenic potential in different organisms. This 
homologue is present in all mycobacteria and its phylogeny might 
provide the best approximation to the relationship between mycobacteria. 
In this sense this branch could represent a group where some level of 
pathogenicity was acquired. This most probably does not reflect any 
relationship between ndh and virulence, since no report of such 
association was detected in the literature (Triccas and Gicquel 2000; 
Smith 2003). Incidentally one of the genes that codes one of the subunits 
of type I NADH: menaquinone oxidoreductase, nuoG, has been 
suggested to be a virulence gene (Velmurugan et al. 2007).
The search queries also retrieved two types of proteins with unknown but 
predicted functions (Table 5.1). Both types show predicted 
oxidoreductase activity and both possess the NAD binding motif. In 
databases (like UniProt) they are classified in the same groups as other 
ndh homologues. These two abnormal clades are present in Mtb. One was 
labelled as group D. This homologue in Mtb was present in the list of 
non-essential genes in the study of (Sassetti et al. 2003), however it 
showed up-regulation after 24-hours starvation (Betts et al. 2002) and at 
high temperatures (Stewart et al. 2002).This not only shows that this gene 
is expressed (and not only a predicted gene) but also that might be 
important in stress conditions. The group E homologue is also most 
probably expressed since its product was identified in the cell membrane 
fraction of Mtb H37Rv (Mawuenyega et al. 2005). It is possible that these 
proteins could act as type II NADH: menaquinone oxidoreductases.
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Considering that ndh is targeted in drugs against TB it is important to 
characterize these proteins. They could act as alternative NADH 
dehydrogenases not susceptible to the same drugs, as suggested for ndhA 
in chapter 4. Data presented here showed that one of the hypothetical ndh 
homologues in Mtb was more closely related with group A of (Melo et al. 
2004) while the second was more closely related with group C, and the 
latter one was possibly obtained by horizontal transfer (Fig.5.6). Melo 
and collaborators (Melo et al. 2004) did not consider these sequences 
although they used an Mtb genome in the analysis. Percentages of 
similarity and calculated protein distances showed that their similarity 
was within the range of the overall diversity of type II NADH: 
menaquinone oxidoreductases as in that paper, supporting the fact that 
they belonged to this group of enzymes. This is not conclusive and they 
might just be enzymes with similarities but with different functions. 
Further research is necessary to unravel these possibilities.
Independently of the actual function of the hypothetical ndh homologues, 
they presented a very low ratio of non-synonymous mutations when 
compared with synonymous mutations during their evolution (Table 5.4). 
Ratio of non-synonymous to synonymous was used to detect probable 
pseudogenes in the Human Genome (Torrents et al. 2003). Also dN/dS 
ratio has been used to compare essential against non-essential genes in 
bacteria showing that the firsts had a lower rate of change (Jordan et al. 
2002). This is the first characterization of dN/dS ratios in mycobacteria 
genes. The ratio should be close to 1 when mutations are happening 
randomly or when there is a positive selection elevating the number of 
non-synonymous mutations. A low dN/dS ratio indicates that the gene 
has been under purifying selection (Yang 2007), indicating that a 
selective force has been acting against changes in the proteins. This 
observed conservation just makes sense if the gene has a function and if 
its impairment decreases or prevents the survival of the organism (Jordan
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et al. 2002). This could easily be the definition of an essential gene. 
However the four Mtb genes studied here are in the list of non-essential 
genes in the study of Sasseti and colleagues (Sassetti et al. 2003), which 
is contradictory in many ways. One must take into account that these 
essentiality studies test the necessity of a gene under a given condition of 
growth or a limited set of conditions. They do not take into account the 
plasticity of a bacterial genome in adapting to different conditions or the 
changing conditions that bacteria will be under during its evolution. For 
example one gene might not be even expressed under ideal conditions but 
it could be expressed in an extreme condition such as starvation and in 
such a case, that gene may play an important role for the survival of the 
bacteria in that scenario. In a population of a given bacteria there will be 
variation in their genome and if some of that variation includes a harmful 
mutation in that gene, in ideal conditions where that gene is not essential 
that mutation is harmless. In case of environmental changes into an 
extreme condition where that gene is activated, natural selection will 
eliminate the individuals in that population carrying the mutation, making 
the gene essential in that situation. This way the essentiality in 
evolutionary terms is measured in a sequence of conditions taking place 
during thousands and millions of years, where environment and natural 
selection shaped the genome of the bacteria and where genes were 
conserved because of both continuous and episodic conditions.
Comparing for example the reduced genome of M, leprae to hypothesize 
which genes are essential in the genome of Mtb can also be misleading 
because both genomes evolved in separate ways and they adapted to 
different life cycles, conditions and inevitably acquired different 
requirements. Genes that are not considered essential in these essentiality 
studies could play a role in survival in the host or even under the action 
of drugs. This research confined to essential genes can be misdirected. 
Russell and colleagues also point out that knockout studies and search for
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essential genes is a paradigm in drug discovery that should change since 
researchers do not consider the full range of interactions between 
pathways and gene products that occur for the survival of Mtb in the 
different microenvironments of the host (Russell et al. 2010).
The application of the analytical methodology described here 
(phylogenetic reconstruction with calculation of rates of change in 
different clusters) in the genes of the entire genome of Mtb can provide a 
pattern of genes whose evolution suggests that they have been conserved 
during evolution. These patterns could be contrasted with results from 
studies of predicted essentiality, for example those in knockout studies, in 
order to see how they compare. Such a study would require powerful 
bioinformatics5 tools. The patterns of conservation within groups might 
be a useful tool in detecting novel drug targets for therapeutic 
interventions.
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Chapter 6. General discussion
In the course of this work, different methodologies in the study of 
Mycobacterium tuberculosis were undertaken for the first time in the 
laboratories of the School of Tropical Medicine in Liverpool.
TB is currently one of the deadliest diseases worldwide and probably one 
of the most distributed infections worldwide (WHO 2009). There are 
studies revealing the existence of a large number of Mtb carriers, latently 
infected and potentially able to create new episodes of disease and 
infection (WHO 2011). International efforts are now in place in order to 
develop alternative and more efficient anti-TBtreatments.
The first approach to the study of Mtb (Chapter 2) was using the non- 
pathogenic Mycobacterium smegmatis. It was hoped that the use of a 
non-pathogenic organism instead of the highly pathogenic Mtb would 
facilitate the use of all the resources of the lab instead of being contained 
in the category 3 environment which poses limitations on the full use of 
lab resources. Given this, the first objective that was proposed in this 
thesis was the validation of M. smegmatis as a model for Mtb.
This validation was successful in terms of the biochemical 
characterization by spectral analyses of the ETC of M, smegmatis, since it 
was possible to correlate the spectrum profile with growth conditions and 
this enabled further drug testing using this approach. This 
spectrophotometric approach was difficult to implement with Mtb in 
LSTM due to technical limitations (the lack of a gamma-radiation device 
to kill Mtb or of ultra-centrifuges and a cell disrupter machine inside the 
containment level III lab in order to prepare the Mtb crude membranes). 
Using M smegmatis allowed the implementation of microbiology 
techniques that were later needed for the Mtb studies. However, the use
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of this model was abandoned due to the fact that previously reported 
differences between Mtb and M. smegmatis were found during the 
experiments. The more obvious ones were in terms of patterns of growth, 
endurance against stressful conditions and resistance to antimicrobial 
drugs, since the drug susceptibility profile obtained testing DOTS agents 
pointed to high tolerance of these drugs, especially ethambutol and 
isoniazid (Chapter 2). M. smegmatis ETC has significant differences in 
relation to the ETC of Mtb and this invalidates its use as an Mtb model in 
its susceptibility to drugs targeting the ETC, such as the phenothiazines, 
since the phylogenetic study also suggests that there are significant 
differences in terms of the ndh homologues (Chapter 5).
In Chapter 3, drug susceptibility tests were evaluated in Mtb and were 
successful in terms of the possibility of using the Wayne model to screen 
new compounds, using a colorimetric assay. Drug susceptibility was also 
tested comparing drug effects using anaerobic and aerobic organisms and 
using different lengths of exposure to the drugs. All DOTS agents tested 
were active against Mtb in the aerobic assays however with the exception 
of ethambutol they all showed a decrease in efficiency over time. The 
results obtained suggested the existence of different subpopulations of 
bacteria, with different drug tolerance, consistent with the suggestion that 
under stress, bacteria populations will become more heterogeneous 
(Kolter et al. 1993). In terms of the efficiency of DOTS against hypoxic 
organisms, there is a significant decrease in efficacy, apart from 
streptomycin, something that was previously reported (Li and Franzblau 
1999).
The purpose of chemical validation of the phenothiazines group as 
potential anti-TB drugs was achieved.
The results obtained with the phenothiazines serve to confirm the 
potential utility of these drugs as new candidates for anti-TB treatment
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due to their effect against TB, highly accentuated against TB grown 
under severe hypoxia. This shows that phenothiazines have potential 
against growing TB but a greater potential against hypoxia-adapted 
organisms, and definitely phenothiazine compounds should be used as 
promising scaffold compounds for the synthesis of even more effective 
drugs but especially less harmful to the host. They could be useful in 
targeting specific sub-populations of hypoxic Mtb bacilli identified in in 
vivo Mtb infections. Although one contra-indication of the use of 
phenothiazines in anti-TB therapy is the possible antagonistic effect with 
one of the first line anti-TB agents, isoniazid. Despite the reported 
synergistic effect of phenothiazines with DOTS compounds (Amaral and 
Kristiansen 2000; Amaral et al. 2004), no synergism was found in this 
study using isobolographic analysis of drug combination between two of 
the most effective phenothiazines (thioridazine and trifluoperazine) and 
DOTS.
ndh is a recognized anti-TB drug target, phenothiazines being one of its 
specific inhibitors (Weinstein et al. 2005). In this context the objective of 
Chapter 4 was to determine if its homologue ndhA is a viable alternative 
type II NADH: menaquinone oxidoreductase and also if it shows 
susceptibility to the same drugs, namely phenothiazines, as ndh. The 
study of ndhA would allow further insight into the ETC of Mtb. A 
successful attempt was made, in terms of cloning this gene to modified E, 
coli expression cells, but no activity was detected (Chapter 4). This result 
is dubious, since this was achieved by another group (Weinstein et al. 
2005). Some protocol irregularities (the inexistence of sustained drug 
pressure in order for the host cell to retain the gene-encoding plasmid or a 
possible abnormal insert) would need to be corrected in order to achieve a 
reliable conclusion.
Chapter 5 attempted to further characterize the ETC of Mtb in terms of 
the type II NADH: menaquinone dehydrogenase enzymes. There is a lack
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of phylogenetic studies focused in Mtb and the only study focusing on 
these enzymes (Melo et al. 2004) is well cited but is probably out of date. 
Also, a more detailed exploration of the Mtb genome and other 
mycobacteria and Actinomycetales genomes was made (Chapter 5) in 
order to detect potential ndh homologues and to infer an evolutionary 
history was made. In Mtb not only the ndh and the ndhA gene were 
detected but also two other genes with potential NADH reductase 
activity, deserving further investigation. The existence of these 
homologues could be important in terms of drug development targeted at 
ndhA in Chapter 4.
In terms of ndh and ndhA, phylogenetically they share a recent common 
ancestor, their presence meaning that at some point in the past, a 
duplication of an ancestral gene occurred, most probably in an organism 
from which all mycobacteria descend. More importantly, both ndh and 
ndhA genes, as well as the two hypothetical homologues show similar 
rates of changing. This suggests that they have been under strict purifying 
selection, meaning that they should have been functional and important 
genes during the evolution of the organism.
6.1. Critical assessment of the study
This work, namely the drug testing was initially done with M smegmatis. 
As mentioned before this proved to be an unsuitable model for Mtb. 
However even the use of Mtb has its limitation and drawbacks. The 
extracellular model of study was not completely representative of a 
normal infectious Mtb population so it cannot be expected that it 
completely behaves like one. The static model of drug susceptibility test 
that was used is also not an ideal model of study. If possible, a chemostat 
culture could be maintained, with constant monitoring and continuous 
maintenance of the Mtb cultures in the desired conditions. IC50, the
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measure of drug susceptibility used, is considered more exact and it is the 
standard measure employed in enzymatic kinetic studies. One of the 
objectives of this and future work is to allow the comparison between the 
results reported here (Chapter 3) and further studies regarding enzymes of 
the Mtb ETC. So the studies were optimized to calculate IC50S but 
considering published work and the exponential nature of bacterial 
growth, this index should have ideally be complemented with indices 
measuring a more extreme rate of inhibition, for example the 99% 
minimal bactericidal concentration (MBC99). Regarding the expression of 
ndhA in E. coli cells, some faults were already detected and outlined in 
Chapter 4.
6.2. Future work
The results obtained throughout this thesis led to a number of findings 
that demand further investigation.
Regarding phenothiazines, different drug susceptibility tests should be 
performed in order to further understand their mode of action and 
effectiveness. The use of whole blood assays, establishing an infection 
model in macrophages and monitoring the phagocytic process under high 
content imaging, would led to a more clear approximation of the 
behaviour of Mtb to the human infection scenario.
Due to the limitations of the drug assays performed throughout this thesis 
and in light of the new developments, more informative tests could be 
performed. Bioluminescence assays are very useful for screening drug 
susceptibility of mycobacteria either extracellularly or inside 
macrophages. Andreu and colleagues proposed a simple and rapid 96- 
well microplate assay where using auto-luminescent bacteria facilitates 
the determination of growth and inhibition kinetics (Andreu et al. 2012).
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Targeted knockout techniques could be used in order to study the 
function of proteins in Mtb, namely for all the electron transport chain 
proteins, testing their functionality and importance. Particularly 
interesting would be to look at the other ETC components in terms of 
drug targets, such as cytochrome bd, the alternative branch used when the 
bacilli are submitted to anaerobic conditions.
In the last few years, metabolomics emerged as a powerful approach that 
allows an insight into the molecular processes that are the result of all 
cellular activity (Villas-Bdas et al. 2005). This approach uses a great 
variety of analytical procedures in order to analyse all small weight 
molecules in the cell, which directly offers a view of the processes that 
occurred. It is much more informative than looking at the genome and 
proteome. Metabolomics can be used to clearly assess the mode of action 
of a given drug as pointed out previously (Carvalho et al. 2010; Olivier 
and Loots 2011) and it would be a desirable approach in future studies.
In terms of evolutionary studies, it may be helpful to consider the 
complete range of genes that constitute the ETC of Mtb and probably 
even considering the complete genome of Mtb and related species. This 
work would require the designing of new bioinformatic tools.
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